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ISABELLE BOILEAU PREFACE 
PREFACE 
The present dissertation examines the effects of drugs of abuse in 
healthy volunteers using positron emission tomography (PET) and the 
neuroreceptor ligand [l1C]raclopride. 1 have chosen the option provided in 
the "Guidelines for the Thesis Preparation" to present a manuscript 
based-dissertation. In compliance with the regulations provided by McGill 
Faculty of Graduate Studies and Research, the following text is required to 
be sited in full below: 
"As an alternative to the traditional thesis format, the dissertation 
can consist of a collection of papers of which the student is an author or 
co-author. These papers must have a cohesive, unitary character making 
them a report of a single pro gram of research. The structure for the 
manuscript-based thesis must conform to the following: 
Candidates have the option of including, as part of the the sis, the 
text of one or more papers submitted, or to be submitted, for publication, 
or the clearly-duplicated text (not the reprints) of one or more published 
papers. These texts must canfarm ta the "Guidelines for Thesis 
Preparation" with respect to font size, line spacing and margin sizes and 
must be bound together as an integral part of the thesis. (Reprints of 
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published papers can be included in the appendices at the end of the 
thesis.) 
The thesis must be more than a collection of manuscripts. AlI 
components must be integrated into a cohesive unit with a logical 
progression from one chapter to the next. In order to ensure that the thesis 
has continuity, connecting texts that provide logical bridges preceding 
and following each manuscript are mandatory. 
The thesis must conform to aIl other requirements of the 
"Guidelines for Thesis Preparation" in addition to the manuscripts. 
As manuscripts for publication are frequently very concise 
documents, where appropriate, additional material must be provided 
(e.g., in appendices) in sufficient detail to aIlow a clear and precise 
judgment to be made of the importance and originality of the research 
reported in the thesis. 
In general, when co-authored papers are included in a thesis the 
candidate must have made a substantial contribution to aIl papers 
included in the thesis. In addition, the candidate is required to make an 
explicit statement in the thesis as to who contributed to such work and to 
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what extent. This statement should appear in a single section entitled 
IIContributions of Authors ll as a preface to the thesis. The supervisor must 
attest to the accuracy of this statement at the doctoral oral defense. Since 
the task of the examiners is made more difficult in these cases, it is in the 
candidate's interest to clearly specify the responsibilities of aIl the authors 
of the co-authored papers. 
When previously published copyright material is presented in a 
thesis, the candidate must include signed waivers from the publishers and 
submit these to the Graduate and Postdoctoral Studies Office with the 
final deposition, if not submitted previously. The candidate must also 
include signed waivers from any co-authors of unpublished manuscripts." 
This thesis will consist of VII chapters 
1. Chapter 1 
INTRODUCTION 1: Dopamine & Drugs of Abuse: Amphetamine & 
Alcohol. This chapter will provide an overview of the dopamine 
neurotransmission system in mammalian brain, specifically covering 
its anatomical organization. The mechanism of drug action 
(pharmacology) of addictive drugs (amphetamine and alcohol), 
including their similarities and differences will be presented and the 
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existing literature regarding the involvement of the dopamine system 
in drug and natural reward processes will be briefly reviewed. 
2. Chapter II 
INTRODUCTION II: Sensitization to psychostimulants. This chapter 
reviews the experimental data concerning the phenomenon of 
sensitization. Specifically this section provides a brief description of 
the defining features of sensitization to amphetamine, which served in 
building our model of sensitization in humans. 
2. Chapter III 
METHODOLOGICAL OVERVIEW: Positron emission tomography & 
(11C]raclopride. Provides a general, introductory, and technically brief 
description of the methodological procedures involved using positron 
emission tomography research. The focus of this chapter is on the 
methods developed to investigate the dopamine system with 
[Cll]raclopride. 
3. Chapter IV 
RESUL TS 1: Amphetamine-induced increases in extracellular dopamine, 
drug wanting, and novelty seeking: a PETj[l1C]raclopride study in healthy 
men. This chapter presents results presented in manuscript 1, which 
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particularly pertain to the effects of acute amphetamine administration 
on dopamine release in the human brain in vivo. 
4. ChapterV 
RESUL TS II: Alcohol promo tes dopamine release in the human nucleus 
accumbens. This chapter presents results presented in manuscript 2, 
which particularly pertain to the effects of acute alcohol administration 
on dopamine release in the human brain in vivo. 
5. Chapter VI 
RESULTS III: Modeling Sensitization to Stimulants ln Humans: A 
f11C]raclopride / PET Study in Healthy Volunteers. This chapter 
presents results presented in manuscript 3, which particularly pertain 
to the effects of repeated amphetamine administration on dopamine 
release in the human brain in vivo. 
6. Chapter VII 
DISCUSSION: This chapter will briefly discuss the general findings of 
the thesis with relation to previous studies and future direction of 
research is proposed. 
PAGE 8 
ISABELLE BOILEAU STATEMENT OF ORIGINALITY 
STATEMENT OF ORIGINALITY 
The intellectual content of the present thesis, and the research to 
which it refers are the product of my own work supervised and assisted 
by others (see next section on contribution of authors). Any ideas or 
quotations from the work of other people published or otherwise, are fully 
acknowledged in accordance with standard referencing practices. Three 
(3) distinct papers are included in the present thesis, which have been 
publishedj submitted for publication in refereed scientific journals. The 3 
publications included are composed of an abstract, a summary 
presentation of the problem, an outline of the goals, a description of the 
experimental method as weIl as result and discussion sections. 
1. Ley ton M, Boileau l, Benkelfat C, Diksic M, Baker G, Dagher A. 
Amphetamine-induced increases in extracellular dopamine, drug wanting, 
and novelty seeking: a PET/[11C]raclopride study in healthy men. 
Neuropsychopharmacology 2002; 27(6):1027-35. 
2. Boileau l, Assaad JM, Pihl RO, Benkelfat C, Ley ton M, Diksic M, et al. 
Alcohol promotes dopamine release in the human nucleus accumbens. 
Synapse 2003; 49(4): 226-31. 
3. Boileau l, Dagher A, Ley ton M, Gunn R, Baker G, Diksic M, Benkelfat C. 
Modeling Sensitization to Stimulants in Humans: A [11C]raclopride / PET 
Study in Healthy Volunteers. Archives of General Psychiatry 2006; in 
press. 
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ISABELLE BOILEAU CONTRIBUTION OF AUTHORS 
CONTRIBUTION OF AUTHORS 
McGill University requires that in the case where papers in a thesis 
have been published an explicit statement be made regarding the 
contribution of each author 
PUBLICATION 1 describes the effects of amphetamine on the human 
dopamine system in vivo using PET and [l1C]raclopride. The first author 
(M Ley ton) contributed equally with the co-author (A Dagher, C 
Benkelfat) to the overall concept and design of the study. The first author 
(M Ley ton) made the initial experiments, which were continued by the 
author of the thesis (1 Boileau) under the supervision of A Dagher and C 
Benkelfat. The analysis of the data, the methodology related to the 
computation of the statistical maps, and visualization of the results was 
mainly the responsibility of the author of the thesis (1 Boileau) under the 
supervision of A Dagher and C Benkelfat. For publication, the author of 
the thesis (1 Boileau) refined the method. The first author has written the 
publication the input of the author of the thesis (1 Boileau) consisted of 
segments of text. 
Ley ton M, Boileau 1, Benkelfat C, Diksic M, Baker C, Dagher A. Amphetamine-induced 
increases in extracellular dopamine, drug wanting, and novelty seeking: a 
PETf[l1C]radopride study in healthy men. Neuropsychopharmacology 2002; 27(6): 1027-35~ 
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PUBLICATION 2 describes the effects of alcohol on the human dopamine 
system in vivo using PET and [l1C]rac1opride. The work for this 
publication was a joint effort between the departments of Psychology and 
Neurology, Neurosurgery and Psychiatry. During a first testing time, the 
department of Psychology (JM Assaad, RO Pihl, R Tremblay) tested a 
group of subjects drawn from a large cohort of low socio-economic male 
francophone (R Tremblay) twice in an alcohol protocol where 
physiological responses to alcohol consumption were measured. This 
preliminary study enabled to recruit subjects for the PET / [llC]rac1opride 
experiments based on heart rate reactivity to alcohol. AlI co-authors 
participated equally in the conception and design of the overall study as 
well as in drafting and providing critical revision of the manuscript. The 
acquisition, analysis and interpretation of the data were mainly the 
responsibility of the author of the thesis (1 Boileau) under the supervision 
of A Dagher and C Benkelfat. The first author has written the publication. 
Boileau 1, Assaad JM, Pihl RO, Benkelfat C, Ley ton M, Diksic M, Tremblay R, Dagher A. 
Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003; 
49(4): 226-31 
PUBLICATION 3 describes the effects of repeated amphetamine on the 
human dopamine system in vivo using PET and [l1C]rac1opride. AlI co-
authors participated equally with the author of the thesis, in the 
conception and design of the overall study. The acquisition, analysis and 
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interpretation of the data were mainly the responsibility of the author of 
the thesis (1 Boileau) under the supervision of A Dagher and C Benkelfat. 
The first author has written the publication although an co-authors 
participated in drafting and providing critical revision of the manuscript. 
Boileau 1, Dagher A, Ley ton M, Gunn R, Baker G, Diksic M, Benkelfat C. Modeling 
Sensitization to Stimulants in Humans: A [l1C]rac1opride / PET Study in Healthy 
Volunteers. Archives afGeneral Psychiatry 2006; in press. 
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LIST OF FIGURES & TABLES 
CHAPTERI 
Table 1 Pharmacology of drugs of abuse (source, NIDA) 
Figure 1 Receptor subtype distribution in the human brain. 
Figure 2 Schematic of the human (top) and rat brain (bottom) 
illustrating main dopaminergic projections from VTA cell group Al0 
(mesolimbic and mesocortical projections) and from SNc cell group A9 
(nigrostriatal projections). 
Figure 3 The tripartite anatomofunctional subdivisions of the 
striatum (sensorimotor, associative and limbic striata) based on the 
pattern of projections received from motor, limbic, and association 
cortices. 
Figure 4 Schema tic of the dopamine synapse illustrating the sites of 
action of amphetamine. 1) Amphetamine acts directly on the vesicular 
monoamine carriers by a weak base mechanism to exacerbate vesic1e 
depletion. 2) Amphetamine facilitated outward exchange diffusion and 
triggers channel-like dopamine release (10,000 molecules per few 
milliseconds) through the pore of the Na+ / Cl- -dependent plasma 
membrane protein dopamine transporter. 3) Amphetamine is a substrate 
for the dopamine transporter, where it acts to prevent re-uptake. 
CHAPTERII 
Figure 1 Locomotor-activating effects of a challenge dose of 
amphetamine (0.5 mg/kg), measured in hemi-parkinsonian rats, 3 (empty 
squares), 7 (empty triangles), or 28 days after discontinuation from either 
saline (blue) or escalating-doses of amphetamine (red). AnimaIs tested after 
28 days of withdrawal were hypersensitive (sensitized) to the challenge 
dose of amphetamine (Paulson and Robinson 1995) 
Figure 2 Box-and-arrow diagram, representing connections between 
sub-nuc1ei of the basal ganglia, limbic system, cerebral cortex and the 
thalamus. The primary neurotransmitter content and the major projections 
are represented by the colored arrows: blue, GABA; red, glutamate; green, 
dopamine. The changes in neurotransmission associated with the 
expression of behavioral sensitization are represented by the bold lines: 
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continuous lines indieating increases, while dotted lines represent 
decreases in neurotransmission. GPe, external globus pallidus; GPi, 
internaI globus pallidus; SNc, substantia nigra pars compacta; SNr 
substantia nigra pars retieulata; STN, subthalamie nucleus; VT A, ventral 
tegmental area; OFC, orbitofrontal cortex; PPN, pedoculopontine nucleus; 
VL, ventro-Iateral, MD, mediodorsal thalamus; NAS, Nucleus accumbens. 
Figure 3 Course of Schizophrenia. Symptom worsening is 
represented as decreasing on the y-axis. 
CHAPTERIII 
Table 1 List of clinically available ligands for dopamine receptors. 
Table 2 Characteristies of raclopride and dopamine as ligands for 
dopamine receptors. 
Table 3 Changes in [llC]raclopride binding potential induced by 
challenges interfering with dopamine transmission in humans. 
Figure 1 Schematie representation of a Positron Emission 
Tomography scan showing the annihilation event from which gamma 
rays (511 keV each) emerge, and the detection of the signal by scintillation 
detectors located 1800 from each other. 
Figure 2 Compartmental descriptions of a radioactive tracer' s 
concentration, up-take, transport and clearance in brain tissue. Cl blood 
compartment; C2 displaceable compartment composed of free and non-
specifically bound ligand; C3 specifieally-bound. 
Figure 3 From left to right, PET / MRI registration) T1-weighted MRI 
linearly fitted to stereotaxie space (Talairach) using a standard brain 
template (MRITOTAL; MNI 305 average brain) and aligned with a single 
[llC]raclopride PET image of which the 26-frame data (60 minutes line 
graph ) has been collapsed into a single frame (MRITOPET using AIR 
algorithm; Collins et al., 1994). MRI segmentation) T1-weighted MRI in 
Talairach space is corrected for intensity non-uniformity and classified 
into white matter, grey matter and cerebrospinal fluid. After the 
classification, the image is segmented into anatomicallabels (ANIMAL). 
Next, the labelized image is manually reworked into specifie ROI using 
predefined criteria. Parametrie map) Voxel-by-voxel application of the 
SRTM yielding BP map with SDBP maps whieh can be transformed to a 
common space (Talairach) in view of statistical analysis. t-map) Voxel-
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wise t-statistic illustrating differences in radioligand binding between 
baseline and activation scans can be thresholded to statistically significant 
level and overlaid an average MRI. 
CHAPTERIV 
Table 1 Subject characteristics. 
Table 2 Effect of d-amphetamine (0.0, 0.3 mg/kg, p.o.) on Addiction 
Research Center Inventory (ARCI) Scores and Visual Analog Scales (max). 
Effects Assessed with 2-Tailed Repeated Measures t-tests. 
Table 3 [llC]Raclopride binding potential values on test days with 
placebo or d-amphetamine (0.3 mg/kg, p.o.). Newman-Keuls post hoc 
tests. 
Table 4 
potential. 
Pearson correlations with change in [llC]raclopride binding 
Figure 1 One subject' s [llC]raclopride binding potential map (right 
striatum) for the first scan day transformed to Talairach space and 
overlaid on his MRI in Talairach space. Regions of interest drawn on the 
same subject's MRI (left striatum) in Talairach space. Red: Ventral Striatum 
/ Nucleus Accumbens (z: 8 to 4), Blue: Putamen (z: 2 to 10), Green: 
Caudate (z: 2 to 15). 
Figure 2 Statistically generated t-map of d-amphetamine-induced 
changes in [llC]raclopride binding potential superimposed on average 
MRI. Right side on right. 
Figure 3 Correlations between d-amphetamine-induced increases in 
extracellular dopamine and Novelty Seeking and the Novelty Seeking 
subscale, Exploratory-Excitability. [llC]Raclopride BP values were 
extracted from two regions, the manually drawn region of interest in 
ventral striatum and the statistically generated parametric t-map. 
CHAPTERV 
Figure 1 Statistical t-map of the change in [llC]raclopride BP induced 
by an acute oral dose of alcohol (1 ml/kg) in healthy volunteers (n=6). 
Col or clusters superimposed on the average MRI from aIl subjects depict a 
significant change in BP in the ventral striatum. 
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Figure 2 Study design. The vertical arrows indicate the time points of 
blood sampling, subjective mood assessments, and physiological 
measurements. 
Figure 3 Mean [l1C] raclopride BP in the alcohol and control (orange 
juice) conditions. The data are extracted from manually drawn ROI on 
each subject' s MRI. Bonferroni corrected pairwise comparisons; 
Differences between alcohol and control, p<O.OOl. Error bars represent the 
standard error of the mean. 
CHAPTERVI 
Table 1 Experimental design. PET*: no-drug control scan 
performed in a counterbalanced order, either before (day 0, n=5) or after 
(day 22, n=5) the sensitization regimen. PET: amphetamine PET scan. 
Subjects received amphetamine (AMP: d-amphetamine, 0.3 mg/kg, p.o) 
one hour prior to being positioned on the PET couch. Behavioral and 
physiological data were gathered at 15-minute intervals. Sham: Subjects 
received amphetamine one hour prior to being positioned on the PET 
couch; these sessions included aIl aspects of the PET procedure except 
tracer injection. 
Figure 1 Behavioral effects of amphetamine. POMS scores (peak 
change from baseline; mean ± SEM) recorded during the drug-free control 
condition and after 0.3 mg/Kg of oral amphetamine (doses l, 4 and 5). (*) 
Significantly increased compared to dose 1. 
Figure 2 Eye-blink rate (blinks per minute change from baseline; Ô. 
max ± SEM) during control and acute d-amphetamine conditions (doses l, 
4 and 5). (*) Significantly increased compared to dose 1. 
Figure 3 t-Statistical maps of [l1C]raclopride BP change illustrating a 
decrease of [l1C]raclopride BP following dose 1 (A), dose 4 (B) and dose 5 
(C) amphetamine administrations (0.3 mg/kg p.o.), relative to the drug-
free control condition (x: 28; y:2; z: 0). (D) Generallinear model with dose 
as a regressor illustrating the progressive decrease in [l1C]rac1opride BP as 
a factor of repeated amphetamine doses (x: 9; y:7; z: -6). Colored t-maps 
are overlaid on an average Tl MRI of all participants. 
Figure 4 (A) Mean (and SEM) [l1C]raclopride BP in three sub-
compartments of the striatum during the control drug-free scan (ctrl), and 
following amphetamine administration before (dose 1) and after repeated 
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amphetamine (dose 4) (n = 10), and (B) at one-year follow-up (n=7). VS: 
ventral limbic striatum; DC: associative pre-commissural dorsal caudate; 
PDP: post-commissural dorsal putamen. (*) Significantly different from 
dose 1 (p<0.05), (t) significantly different from dose 4 (p<0.05). 
Figure 5 Relationship between novelty seeking personality and 
sensitization. A) Scatter plots and B) voxel-wise regression maps 
illustrating the relationship between Novelty Seeking personality trait and 
sensitization-induced changes in [l1C]raclopride BP (% decreases from 
dose 1) measured during amphetamine doses 4 (x=13, y=15, z=7) and 5 
(x=l1, y=15, z=15) 
CHAPTER VII 
Figure 1 Schematic of the internalization of receptors. Loss of surface 
receptor number through endocytosis which occurs secondary to agonist 
treatment is a mechanism believed to explain changes in [l1C]raclopride 
binding. 
Figure 2 Two-state model of DZ/3 receptors affinity illustrating that 
DZ/3 receptors are divided into two states for agonists (high affinity and 
low affinity sites), with each site contributing to 50% of the population. 
Under baseline conditions (prior to the challenge), 10% of the sites are 
occupied by DOPAMINE, and not available to [l1C]raclopride. Adapted 
from (Laruelle, 2000). 
Figure 3 Schematic of the nonreciprocal striatonigrostriatal 
subcircuits which provides a hypothetical model for the preferential effect 
of amphetamine in the VS and PDP. VTA: ventral tegmental; SNe: 
substantia nigra compacta, SNr: substantia nigra reticulata; Pre DCA: 
anterior dorsal cau date; Pre DPU: anterior dorsal putamen; Post CA: 
posterior dorsal caudate; Post PU: posterior dorsal putamen. The limbic 
loop is in red, the associative loop is in green and the sensorimotor loop is 
in blue. Ascending arrows represent dopamine projections from the 
midbrain descending arrows represent GABA projections from the 
striatum. Adapted from (Martinez, 2003; Haber, 2000). 
Figure 4 a) Scatter plots and b) voxel-wise regression maps 
illustrating the relationship between self-rated positive effects of 
amphetamine (euphoria) during initial dose and changes in 
[l1C]raclopride BP at subsequent exposure (dose 4 and dose 5). 
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Figure 5 t-Map overlaid average MRI illustrating placebo induced 
changes in [l1C]radopride relative to a control condition (no-pill). In this 
experiment, 5 healthy male volunteers received three doses of 
amphetamine (0.3 mg/kg, by mouth) in the same test environment (PET 
unit) on three separate days (every other day). Two weeks later, the 
amphetamine was substituted for a placebo pilI. 
Figure 6 PET [l1C]radopride measurements of dopamine D2/3 
receptor availability obtained in detoxified cocaine users and healthy 
control. The reduction in signal in (BP) in cocaine users is presumed to 
represent a reduced number of D2/3 receptors. Adapted from (Volkow, 
Fowler et al. 2004). 
Figure 7 Scatter plots illustrating the 
exploratory-extraversion personality (NS1) 
measurement of baseline D2/3 receptor density 
striatum (rVS). 
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ABSTRACT 
R adialigand ta 
Tomography (PET) can be used to investigate dopamine (DA) 
receptor binding assessed with Positron Emission 
concentration in vivo. The present dissertation focuses on the use of the 
PET DA D2/3 receptor ligand [l1C]raclopride to study DA release following 
the administration of drugs of abuse: amphetamine and alcohol. 
A number of experimental animal paradigms have indicated that 
DA transmission is generally potently engaged by the acute 
administration of addictive drugs (Di Chiara and Imperato 1988; Weiss, 
Markou et al. 1992), deficient during drug withdrawal (Markou and Koob 
1991; Schulteis, Markou et al. 1995; Epping-Jordan, Watkins et al. 1998) 
and facilitated or sensitized when drug use is reinstated after repetitive 
exposure (Kalivas 1993; Pierce and Kalivas 1997). Despite the abundance 
of data establishing the role of mesolimbic DA in the acute reinforcing 
effects of drugs the exact nature of DA' s contribution to reward or 
addiction is still a subject of debate. 
Studies l and II present direct evidence in humans that 
amphetamine and alcohol promote DA release (decreased [l1C]raclopride 
binding) preferentially in the limbic striatum when given acutely by 
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mouth. Changes in binding correlated with self-reported drug-wanting and 
he art rate but not with drug liking or euphoria and were positively related 
to the personality trait of novelty seeking a known vulnerability factor in 
alcohol and drug dependence (Howard, Kivlahan et al. 1997). 
Study III is primarily concerned with alterations in psychological 
function and in brain response (DA release) resulting from repeated drug 
exposure. In healthy human subjects, re-exposure to amphetamine 14 and 
365 days after 3 repeated doses had greater psychomotor effects and a 
concomitant reduction of [l1C]raclopride binding compared to an initial 
dose. This result is interpreted as sensitization. We found that trait novelty 
seeking was a predictor of subsequent drug-induced DA release and of 
neurochemical sensitization. 
Together our studies indicated that drugs abused by humans 
increase DA release in the striatum, and when given repeatedly their 
administration may lead to sensitization, expressed in the form of 
persistent changes in brain DA neurochemistry. Acute and sensitized DA 
responses were related to trait novelty seeking and to the psychomotor 
effects of drugs but not to its pleasurable effects; however enjoyment of 
the drug-experience seems to alter DA response at subsequent drug-use. 
The model provides a framework for analyzing the neurochemical 
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alterations associated with repeated drug-use and also provides useful 
information regarding the development and triggering of chronic 
relapsing disorders su ch as drug addiction and psychosis. 
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RÉSUMÉ 
La tomography par émission de positons (TEP) et le radioligand 
[llC]raclopride permettent de mesurer les propriétés des récepteurs 
centraux de la dopamine (DA). De cette façon, l'union compétitive entre ce 
radioligand et la DA endogène sert à évaluer in vivo, dans l'espace 
synaptique, les variations de concentration de la DA secondaire à une 
intervention pharmacologique ou suite à une tâche mentale (cognitive). La 
présente dissertation est principalement centrée sur l'investigation de la 
libration de DA suite à l'administration aigue et à la prise répétée de 
drogues d'abus. 
Un ensemble de données de la neurobiologie ont permis de montrer 
que la transmission de la DA est amplifiée par les drogues qui déclenchent 
une dépendance chez l'homme (Di Chiara and Imperato 1988; Weiss, 
Markou et al. 1992) et que celle-ci est déficiente, après l'arrêt de la 
consommation, pendant la période de sevrage (Markou and Koob 1991; 
Schulteis, Markou et Al. 1995; Epping-Jordan, Watkins et Al. 1998). De 
plus, la re-administration de ces substances résulte en une augmentation 
progressive de la réponse dopaminergique communément appelé 
sensibilisation (Kalivas 1993; Pierce and Kalivas 1997). En dépit du grand 
nombre de données corroborant le rôle crucial de la DA mesolimbique 
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dans le renforcement positif et l'addiction aux drogues, la nature exacte de 
ce rôle n'a pas encore été entièrement élucidée. 
Les études 1 et 2 de cette dissertation présentent des évidences 
directes chez l'humain démontrant que l'administration aigue 
d'amphétamine et d'alcool entraîne une augmentation transitoire de DA 
dans le striatum limbique. Cette augmentation (déplacement du 
radioligand) est corrélée au désir pour la drogue (drug-wanting) et à 
l'augmentation du rythme cardiaque, et non à la réponse aux propriétés 
euphorisantes de la drogue (drug liking / euphoria). Aussi l'augmentation 
de DA est corrélée à un trait de personnalité marqué par la recherche de 
nouveauté (novelty seeking). Ce trait a été associé au développement des 
addictions (Howard, Kivlahan et al. 1997). 
Etude 3 de cette dissertation est principalement centrée sur la 
réponse à un régime répétée d'amphétamines. Chez le sujet sain, la re-
administration d'amphétamine 14 et 365 jours après 3 doses 
d'amphétamine, augmente l'activité psychomotrice et le taux de 
déplacement du [llC]rac1opride dans le striatum. Ce résultat suggère une 
sensibilisation aux effets des amphétamines. Aussi le trait de personnalité 
novelty-seeking prédit l'apparition de la sensibilisation. 
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Nos données suggèrent que l'administration de drogues d'abus 
augmente la DA dans le striatum. Avec une administration répétée, l'effet 
des amphétamines se traduit en sensibilisation psychomotrice et 
dopaminergique. La réponse aux amphétamines, en aigue et après 
sensibilisation est corrélée au trait de personnalité novelty seeking et aux 
effets psychomoteurs de la drogue et non au plaisir associé à la 
consommation aigue. Par contre, ce dernier modifie la réponse 
dopaminergique au cours d'administrations subséquentes. Ce model 
représente un paradigme par lequel nous pouvons étudier le 
développement des addictions. 
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CHAPTER 1: Introduction 1 
Dopamine & Drugs of Abuse: Amphetamine & Alcohol 
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1.0. OVBRVIBW 
S ince it has been postulated as a chemieal neurotransmitter (Von Euler and 
Lishajko 1957; Carlsson, Lindqvist et al. 1958), dopamine (DA)'s role in 
brain and peripheral functions has been extensively studied. Perturbation of DA 
neurotransmission can result in profound neurologie al, psychiatrie, or 
physiological signs and symptoms. Therapeutic modulation of DA receptor 
function provides the most eHicacious therapy for many disorders, including 
schizophrenia and Parkinson's disease. DA research spans nearly a half-century, 
spurred by the discovery of chlorpromazine in the early 1950's (Delay, Deniker et 
al. 1952; Carlsson and Lindqvist 1963). DA continues to be of great interest in 
present day research, and remains a critical component in the therapy of many of 
the most serious psychiatrie and neurological disorders. In this regard, positron 
emission tomography (PET; see chapter 3) has lead to a renewal of interest on the 
nature and involvement of DA neurotransmission in number of functions, in 
particular, in reward processing, in drug-reinforcement and in disorders such as 
addiction and psychosis. 
The DA system is a major target of drugs of abuse and it is considered to 
convey the affect-related effects of pharmacologically distinct drug classes. 
Although drugs produce their in vivo effects on DA nerve terminaIs primarily 
via different mechanisms, the resulting increase in synaptic levels of DA may 
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ultimately result in the same regulatory changes, which might make way to the 
complex signs of addiction (craving, sensitization). After describing anatomical 
aspects of the dopaminergic system, this chapter will briefly review the 
involvement of this neurotransmitter system in natural and drug reward 
processing and focus on the mechanism of action of addictive drugs investigated 
in this thesis (amphetamine and alcohol). A brief description of theories of 
addiction will be provided. 
1.1. OVERVIBW O' TBE DOPAMINE SYSTEM 
1.1.1 THE NEUROTRANSMITTER DOPAMINE 
DA is classified chemically as a catecholamine. DA synthesis occurs in 
both the cytosol as well as in the presynaptic terminaIs of DA neurons though a 
two-step biosynthetic pathway. The first step is hydroxylation of the essential 
amino acid tyrosine, catalyzed by the enzyme tyrosine hydroxylase. Tyrosine is 
converted to L-dihydroxyphenylalanine (L-dopa) by the enzyme tyrosine 
hydroxylase, a reaction that also requires the tyrosine hydroxylase cofactor 6-
tetrahydrobiopterin. This slower step is generally considered to be rate limiting 
for DA synthesis. The second step is the conversion of L-dopa to DA via the 
enzymatic action of aromatic amino acid decarboxylase. DA is sequestered into 
storage vesicles by vesicular monoamine transporter II (Liu, Peter et al. 1992). 
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Pulse-evoked DA release in the synaptic cleft diffuses in the extracellular space; 
the clearance rate, and thus the extracellular lifetime of DA is regulated by 
transporters located in the plasma membrane via a Na+ /Cl- dependent process 
(Kuhar, Vaughan et al. 1998; Cragg and Rice 2004). Alternately DA in the 
extracellular space can be catabolized by mono amine oxidase (to 3,4,-
dihydroxyphenylacetic acid) or catechol-O-methyltransferase (to 3-
methoxytyramine). These enzymes are major mechanisms for inactivation of 
catecholamines. Action by both enzymes results in the formation of homovanillic 
acid (3-methoxy-4-hydroxy-phenylacetic acid). 
1.1.2 DOPAMINE RECEPTORS 
The diverse physiological actions of the neurotransmitter DA are 
mediated by the products of five genes, which are seven transmembrane G 
protein-coupled DA receptors (Missale, Nash et al. 1998). The receptors are 
categorized into two families, Dl-like and D2-like, according to their ability to 
increase or inhibit the activity of the enzyme adeny1cyclase, which generates the 
intracellular second messenger cyclic AMP (cAMP) (Kebabian and Greengard 
1971). The D2-like family receptors (D2, D3, and D4) originate from three genes. 
They are prototypic G protein-coupled receptors, primarily coupled to Gi / Go 
proteins, they inhibit adenylate cyclase, activate K+ channels and they have both 
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hetero and auto receptor functions. Alternative splicing gives rise to variants of 
D2 and D3 receptors in certain tissues. D2 receptors can be subject to post-
transcriptional processing, such that the final product can be expressed in a 
complete form (D2-long), or after cleavage, in a short form (D2-short) 
(Guiramand, Montmayeur et al. 1995). The Dl-like family (Dior DiA and Ds or 
DSB) comes from intron-Iess genes (albeit Ds pseudogenes exist), and the 
receptors generally couple to GOLF and Gs protein to activate adenylate cyclase. 
1998). G-protein-coupled DA receptors, can occur in different conformations 
states that express different affinities for DA and other agonists. The high-affinity 
sites (D2 high sites) are G-protein-coupled, whereas the low-affinity sites (D2low 
sites) are those uncoupled with G-proteins. DA receptors can convert between 
states with high or a low affinity for agonists, while retaining the same affinity 
for antagonists (Sibley, Leff et al. 1982). It has been proposed that receptor 
affinity might explain why PET competition studies with radiolabeled 
antagonists such as (11C]raclopride have been unable to show a reduction in 
radiotracer binding greater than 40% i.e.: a ceiling effect (Laruelle 2000). 
Specifically, whereas the antagonist [l1C]raclopride can bind to receptors in both 
high and low affinity states, DA bind selectively to the high affinity receptors; 
therefore due to the fact that some proportion of the binding sites are entirely 
insensitive to DA, complete displacement of antagonist radioligands by DA 
cannot be detected in vivo (Hwang, Narendran et al. 2004; Narendran, Hwang et 
al. 2004). 
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Receptor localization in the central nervous system also differentiates one 
receptor subtype from another (Figure 1). The expression territories of the Dl 
receptor subtype spread over telencephalic area, localized to many, but not aIl, 
brain regions receiving dopaminergic innervation. The highest amount of Dl 
receptor mRNA has been found in the caudate-putamen, the olfactory tubercle, 
the piriform and entorhinal cortices and in limbic related regions including, 
nucleus accumbens, amygdala, medial prefrontal, infralimbic, prelimbic, anterior 
cingulate and in the insula. Dl receptors in substantia nigra pars compacta or 
pars reticulata are present but sparsely distributed on non-DA containing ceIls 
(interneurons) and on afferent nerve terminaIs from other brain regions 
(Mansour, Meador-Woodruff et al. 1991). D2 receptor mRNAs in the rat brain, as 
determined by in situ hybridization, has been found in DA containing neurons 
(as auto receptors) and in aIl associated projection areas: subsantia nigra, VTA, 
caudate, putamen, globus pallidus, nucleus accumbens, prefrontal cortex, 
cingulate cortex, entorhinal cortex, piriform cortex, septum, amygdala, zona 
incerta, hypothalalamus, olfactory bulb (Meador-Woodruff, Mansour et al. 1991). 
Within the D2 -like receptor class, the D2 receptor is the most highly expressed. 
The D4 type overlaps with the D2 type however with a more moderate level of 
expression in the nucleus accumbens and caudate-putamen (Rivera, CueIlar et al. 
2002), whereas the D3 type is found in a more restricted manner, in are as of lower 
D2 concentration such as the island of Calleja, the nucleus accumbens and the 
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bed nucleus of stria terminalis (Bouthenet, Souil et al. 1991; Sokoloff, Giros et al. 
1992). 
Figure 1 Receptor subtype distribution in the human brain. 
1.1.3. ANATOMICAL ORGANIZATION 
1.1.3.1. THE MESENCEPHALON DOPAMINE CELLS 
Central nervous system DA neurons are for the most part gathered as a 
single continuous group of cells in the midbrain. In both rodents and primates 
(Figure 2) these mesencephalic DA cells have been compartmentally organized 
into three distinct cytoarchitectonic subdivisions: the A8 cell group roughly 
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corresponds to the reticulata retrorubral area; the A9 cells (the nigrostriatal 
dopaminergic system) are primarily gathered within the SNc with sorne cells 
found in the substantia nigra pars reticulata (SNr) and the AI0 cell group (the 
mesolimbic and mesocortical dopaminergic systems) lies medial to the SNc in the 
VTA (Dahlstrom and Fuxe 1964). Retrograde tracing techniques have enabled 
neuroanatomists to identify the output topography of these cells, thus leading to 
their delineation into a dorsal and a ventral tier. The dorsal (and mediodorsal) 
part of the VTA and SNc(A 10) represents the dorsal tier (calcium-binding protein 
or calbindin-positive cells) and topographically innervates the ventrally located 
structures of the limbic striatum (matrix compartment) including the nucleus 
accumbens (NAS) (shell), septum, olfactory tubercle, piriform cortex and 
amygdala as well as the medial prefrontal, cingulate, perirhinal, and entorhinal 
cortices, whereas the ventral part of the VTA and SNc (A 9) composes the ventral 
tier (calbindin-negative cells) which primarily directs axons to the more dorsal 
neostriatum (lateral SNc to motor striatum and medial SNe and VTA to 
associative striatum; patch compartment) (Gerfen, Baimbridge et al. 1987). 
However, sorne neurons occupying the medial densocellular zone of the ventral 
tier have been recognized to have projections to the ventral striatum. The A8 cell 
group or retrorubral field innervates all striatal sub-compartments (for review 
see Fallon and Laughlin 1995). 85% of the VTA NAS projections contain DA 
(Swanson 1982). The non-dopaminergic part of the projection from the VTA to 
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the NAS and striatum is GABAergic and appears to terminate on cholinergie 
interneurons which in turn input to medium-size spiny neurons. 
1'.9: NIGFIOSTRIAT,"oJ 
Al0: MESOLIMBIC 
/ MESOCORTICAL 
Figure 2 Schema tic of the human (top) and rat brain (bottom) illustrating 
main dopaminergic projections from VTA ceIl group AIO (mesolimbic and 
mesocortical projections) and from SNc ceIl group A9 (nigrostriatal projections). 
1.1.3.2. THE CORPUS STRIATUM 
The striatum is a nuc1ear complex within the basal ganglia and a major 
recipient of DA input. Understanding the organization of the connections 
between the DA mesencephalic ceIls and the striatum is essential for unraveling 
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the role of DA in normal and pathological states such as schizophrenia, drug 
abuse and Parkinson' s disease. The striatum is divided into three components. It 
includes the caudate nucleus, the putamen and the globus pallidus. The caudate 
and putamen together comprise the neostriatum which has a stripy appearance 
due to bands of white matter and is sometimes simply abbreviated dorsal striatum 
(Figure 3). The ventral (limbic) striatum (rostroventral caudate / putamen and 
nucleus accumbens) together with the ventral part of the pallidum (globus 
pallidus ventral to the anterior commissure) are recognized as forming part of a 
functional circuit distinct from the dorsal striatum. This classification is based on 
inputs received from the amygdala and cortical are as mediating emotion and 
motivation (cingulate, orbital, and superior temporal cortices) (Haber and 
McF arland 1999). 
Limbic strialum 
Figure 3 The tripartite anatomofunctional subdivisions of the striatum 
(sensorimotor, associative and limbic striata) based on the pattern of projections 
received from motor, limbic, and association cortices. 
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Most (90%) of the neurons composing the striatum have spiny dendrites 
and have a receptivej outflow (projection) function. They contain the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA). Other neurons have 
dendrites that lack spines and serve an associative or interneuronal function. 
They use the transmitter acetylcholine (Ach) and are excitatory. AlI neurons also 
contain various neuropeptides (enkephalin, substance P, neuropeptide Y) that 
are co-released with the neurotransmitters. 
1.1.3.3. STRIATAL CONNECTIONS 
Afferent connections to the striatum form the basis for its function. The 
major source of input to the striatum emerges from the cortex, particularly the 
frontal lobes projections (minor projections also arise from the intralaminar 
nuclei of the thalamus and from the pedoculopontine nucleus). Projections from 
the cortex to the striatum are excitatory, mediated by the neurotransmitter 
glutamate. The primary motor, premotor, supplementary motor and 
somatosensory areas of cortex project mainly to the putamen whereas the 
association cortex of the prefrontal and parietal lobes project to the caudate 
preferentially. These pathways contribute to control of movement speed and 
posture as weIl as to regulation and the organization of higher motor behavior 
and cognitive processes. The ventral striatum including the nucleus accumbens 
PAGE 37 
ISABELLE BOILEAU CHAPTER 1: DOPAMINE AND DRUGS OF ABUSE 
receives input from are as that do not project to the dorsal striatum (motor and 
sensory areas of the frontal and parietal lobes), notably temporal cortex including 
the hippocampal formation, limbic, and orbitofrontal cortical areas as weIl as the 
basolateral amygdala (Figure 3). Its location at the interface of descending limbie 
projections from the amygdala, the hippocampus and the prefrontal cortex and 
of ascending DA fibers arising from the midbrain confers an important role for 
this region in integrating emotional (limbie) and motor information ("limbie-
motor interface"). The striatum receives important dopaminergic (Figure 2) 
afferent projections from the SNe. The nigrostriatal tract are involved in the fine-
tuning of movement. The breakdown of neurons in this pathway is associated 
with the tremors, rigidity, and slowness of movement characteristic of 
Parkinson's disease. 
The major outflow from the striatum originates from the globus pallidus 
internaI segment (GPi). Efferents from the GPi use GABA as a transmitter and 
are inhibitory and project to specifie thalamic nuclei, which in turn outputs on 
and probably excite the primary motor, premotor and supplementary motor 
are as of the frontal lobe cortex. Conversely, the ventral striatum conveys 
information to the cingulate, orbitofrontal and prefrontal cortex and to the 
ventral tegmental are a of the brainstem via projections through the ventral 
pallidum to dorsomedial and ventral anterior nuc1ei of the thalamus. 
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1.2. WBAT 18 THE B.OLE OP DOPAMINE? 
1.2.1. DOPAMINE AND REWARD MOTIVATED BEHAVIOR 
Olds and Milner incidental finding that in rats, electrical stimulation of 
DA fibers (medial forebrain bundle extending from the lateral hypothalamus to 
the VTA) reinforce arbitrary selected operant responses despite the absence of 
biological needs (Olds and Milner 1954). This finding has lead to the suggestion 
that meso-corticolimbic DA is a center for appetitive motivation and reward 
processes. Elucidating the role of DA in reward can provide insight into a 
number of psychopathologies, inc1uding depression, drug addiction, obsessive-
compulsive and eating disorders. Presently, several lines of evidence from 
electrophysiological, microdialysis, or voltammetric studies in animaIs and 
recently PET studies in humans support the involvement of DA in a wide variety 
of adaptive (appetitive) behavioral actions inc1uding goal-directed locomotor 
activity, feeding (Mark, Smith et al. 1994; Kiyatkin 1995; Richardson and Gratton 
1996; Small, Jones-Gotman et al. 2003), drinking (Young, Joseph et al. 1992), 
sexual (Pfaus, Damsma et al. 1995) and maternaI behaviors (Stern and Lonstein 
2001; Silva, Bernardi et al. 2003) as well as non-adaptive behaviors such as drug 
reinforcement (Di Chiara and Imperato 1988) (see 1.2), and brain-stimulation 
reward (Yokel and Wise 1976). However, precisely what role DA plays in sensing 
and responding to reward, both natural and drug-related, is still a matter of 
investigation (Berridge and Robinson 1998). 
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Wise initially introduced the anhedonia hypothesis to explain the reduction 
of reward-directed actions after pharmacological blockade of DA receptors (Wise 
and Bozarth 1982). Today, the idea that DA carries the pleasure or hedonic signal 
associated with reward has been replaced by views suggesting an anticipatory, 
attentional, learning, appetitive role for DA (Le.: approach behavior as opposed 
to the consummatory behavior). In this regard, a series of recording studies in 
higher non-human primates (Schultz 1998) revealed that DA neurons within 
both the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) 
respond with burst firing to unexpected primary rewards (drops of juice) and to 
stimuli predictive of reward but not to primary rewards whose delivery is 
expected, due to being signaled by prior cues (Mirenowicz and Schultz 1994). 
These findings form the basis of the prediction error theory. This theory suggests 
that activity changes in DA neurons encode an error in the prediction of the time 
and amount of immediate and future rewards - thus contributing to learning 
(Schultz 1998). Increased dopaminergic activity is hypothesized to indicate that 
immediate or future reward is expected, while decreased dopaminergic activity 
signaIs the converse (Montague, Dayan et al. 1996). This formulation has been 
refined in a number of influential computational models (such as the temporal 
difference learning algorithm) believed to correspond to DA neurotransmission 
(Suttan and Barta 1981; Egelman, Persan et al. 1998; Schultz 1998; McClure, Daw 
et al. 2003; Montague, Hyman et al. 2004). 
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In their formulation of the incentive salience hypothesis of dopaminergic 
function, Robinson and Berridge have proposed that DA release assigns 
incentive, or motivational, value (salience) to otherwise neutral objects or 
behavioral acts. In other words their hypothesis suggests that DA mediates the 
motivational rather than affective component of reward, i.e.: the wanting but not 
the liking (Robinson and Berridge 1993). In line with this, blockade of DA 
receptor function has been shown to inhibit the ability to use actions aimed at 
acquiring rewards, i.e.: instrumental responding to drug-associated eues, 
without influencing the behavioral measures of affective reactions to rewards 
(Robinson and Berridge 1993; Salamone, Cousins et al. 1997; Ikemoto and 
Panksepp 1999; Wyvell and Berridge 2001; Salamone, Corre a et al. 2003). The 
latter has been proposed to involve opioid neurotransmission onto GABAergic 
spiny neurons within the shell region of the nucleus accumbens, since 
microinjections of opioid agonists into this region increase affective or hedonic 
facial responses to rewarding food (highly palatable su gars and fats) (Kelley, 
Bakshi et al. 2002). 
1.2.2. SELF-ADMINISTERED DRUGS 
Experimental disruption of DA transmission by discrete lesions and local 
intracerebral infusion of DA antagonists (especially in the shell region of the 
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nucleus accumbens) reduces approach towards biologically meaningful - and 
rewarding - stimuli or events. The general hypothesis that DA is involved in 
sorne aspect of reward and reinforcement has also built on the fact that a number 
of addictive drugs (e.g. amphetamine, alcohol, cocaine, morphine) seem to exert 
their primary action on the DA system through sorne combination of promoting 
release, preventing the transmitter'sreuptake or mimicking its action in the brain 
(Di Chiara and Imperato 1988; Koob 1992). There is an overwhelming amount of 
data supporting the involvement of DA in psychostimulant reinforcement (Koob, 
Sanna et al. 1998). DA receptor blockers given during pairing of the drug with a 
specifie environment impair conditioned place-preference, elicit an extinction-
like increase of responding in trained animaIs and prevent acquisition of 
instrumental responding in untrained animaIs (Di Chiara 1995). The knock-out 
(KO) mice technology, although limited by a number of caveats (i.e.: phenotypic 
alterations due to adaptive changes) as also reinforced existing hypothesis 
regarding the role of DA in drug-induced reward and reward-related behaviors. 
Consistent with the effects of DA antagonist treatment on response to reward 
(Wise and Rompre 1989), deletion of DA receptors (Dl, D2/3) either eliminates or 
markedly attenuates the voluntary consumption of drugs and conditioned place 
preference and operant responding for drugs (for review see (Holmes, 
Lachowicz et al. 2004). Neuroimaging techniques have provided clinical data, 
which favors the role of DA in the reinforcing effects of psychostimulants. For 
example, amphetamine-induced euphoria measurements in healthy humans 
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correlate with the reduced-binding (in the ventral striatum) of the DA receptor 
PET ligand [Cll]raclopride (Drevets, Gautier et al. 2001) (see chapter 3). In 
another PET study, DA transporter occupancy or blockade provoked by a single 
dose administration of cocaine in cocaine users was significantly associated with 
the magnitude of self-reported high (Volkow, Wang et al. 1997). Functional 
magnetic resonance imaging (fMRI) studies have also shown that the 
administration of cocaine to cocaine-addicted subjects increased drug-related 
rush together with regional cerebral activity in the VTA (BOLD signal). 
1.S. PBARMACOLGY OP DaUGS OP ABUSB 
The different molecular targets for almost every major drug of abuse have 
been identified (see table 1). Although drugs have a widely different repertoire of 
effects, which undoubtedly have different mechanisms and caU into play 
different neurotransmitter systems, aH drug targets identified are proteins that 
are involved in synaptic transmission and have a direct or indirect action on DA. 
This thesis is partly concerned with visualizing DA release foHowing the acute 
administration of two of the most widely used and abused psychoactive 
substances: amphetamine and alcohol. The next sections will review the 
neuropharmacolgy of those drugs with regards to their acute mechanism of 
action on the DA system. 
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DRUG 
Alcohol 
Amphetamine and derivatives 
Cocaine 
Opiates 
Nicotine 
Cannabinoids 
Phencyclidine 
Hallucinogens 
Inhalants 
CHAPTER 1: DOPAMINE AND DRUGS OF ABUSE 
INITIAL TARGET 
Facilitates GABAA and inhibits NMDA 
glutamate receptor function 
Dopamine transporters (DAT, VMAT) 
Dopamine transporters 
Agonist at ~, Ô, K opioid peptide receptors 
Agonist at nicotinic acetylcholine receptors 
Agonist at cannabinoid receptors CBI and CB2 
Antagonist at NMDA glutamate receptors 
Partial agonist at 5-HT2A receptors 
Unknown 
Table 1 Pharmacology of drugs of abuse (websource, NIDA) 
1.3.1. ALCOHOL 
A variety of animal taxa consume alcohol on a regular basis through their 
fruit-based diet. In sorne cases drunkenness in wild elephants, primates, 
warthogs, birds and buUerflies has been reported since ethanol content in sweet 
rotting fruits has been shown to be as high as 12% (although this represents an 
environmental extreme) (Dudley 2000; Dudley 2002). In this perspective, one can 
hypothesize that alcohol use or misuse in modern humans probably dates back 
to the nutritional behaviors of ancestral primates. Alcohol is considered to be a 
most reinforcing drug and hold an important dependence liability. Psychiatrie 
epidemiological surveys reveal that alcohol abuse and dependency represent one 
of the most, if not the most, prevalent of psychiatrie problems over onels lifetime. 
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Approximately 30% of young people get drunk regularly (consume more than 5 
drinks of alcohol in a row at least every month) and 5% fit DSM IV criteria for 
alcohol abuse (http://www.niaaa.nih.gov/databasesl). 
Although the net effect of alcohol in humans is to produce sedation, 
anxiolytic and intoxicating effects similar to the effects se en with barbiturates 
and benzodiazepines, acute consumption of alcohol (depending on the dose) 
stimulates locomotor activity and produces a sense of well-being and mild 
euphoria (Charness, Simon et al. 1989). The acute effects of alcohol are subject to 
large inter-individual variability (heart rate, mood), the neurobiochemical basis 
of which has been suggested to reside in the functioning of DA mediated 
appetitive motivational system (Pihl and Peterson 1995). 
1.3.1.1. ALCOHOL-INDUCED DA RELEASE MECHANISM 
Several lines of evidence suggest a prominent role of the mesolimbic DA 
pathway in the acute reinforcing action of alcohol. For example rats self-
administer ethanol in the VTA; a response shown to be modulated by the 
presence of DA agonist and antagonist in a direction that confirms the role of DA 
in ethanol reinforcement (Catto, McBride et al. 1994). In vivo electrochemistry 
and microdialysis studies in un-anesthetized rats have indicated that acute 
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ethanol administration increases in a dose-dependent manner the dialysate level 
of striatal-DA. Furthermore, consistent with the topographie specificity of DA 
release observed during psychostimulants-induced reward, alcohol-induced DA 
release is preferential in the nucleus accumbens and the bed nucleus of the stria 
terminalis (Di Chiara and Imperato 1988; Carboni, Silvagni et al. 2000). 
Many mechanisms are known to interact in alcohol-induced excitation of 
the mesolimbic reward system. On the one hand ethanol influences DA cell firing 
rate directly through its action on ion channels on membranes, particularly 
calcium and chloride (Brodie, Pesold et al. 1999). In partieular, it inhibits calcium 
entry through voltage gated-channels thus inhibiting transmitter release. 
(Tabakoff and Hoffman 1996). On the other hand ethanol acts on DA 
neurotransmission through the indirect action of multiple neurotransmitter 
systems: opiatergic (K & lA- receptors), serotonergic (5-HT3) and glutamatergie, 
acethylcholinergic (Nevo and Hamon 1995). In general, alcohol inhibits receptors 
for excitatory neurotransmitters and augments activity at receptors for inhibitory 
neurotransmitters. For example, similar to the action of benzodiazepine, alcohol 
is believed to affect brain function primarily by enhancing the function of GABA 
(GABAA receptors) (Koob 1992). Furthermore alcohol acts on NMDA receptors, 
inhibiting their functions and thereby diminishing glutamate-mediated 
neurotransmission (Rossetti, Hmaidan et al. 1992). A large body of studies has 
demonstrated that alcohol potentiates GA BA inhibitory interneurons at synapses 
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leading to downstream release from tonie inhibition of DA containing neurons. 
Specifically, it reduces the firing rate of neurons in the substantia nigra pars 
reticulata which in turn is believed to causes a net increase in DA cell firing, and 
increased DA release in the striatum and nucleus accumbens (Mereu and Cessa 
1985; Di Chiara and Imperato 1988). This action stimulates glutamatergic 
neurons that further excite DA cells burst firing (Cessa, Muntoni et al. 1985; 
Crace 2000). 
1.3.2. AMPHETAMINE 
Stimulant drugs such as the amphetamines are among the most widely 
used and abused of the many psychoactive compounds available. This class of 
drug is also referred to as sympathomimetic to indicate their potency to innervate 
the sympathetic nervous system. Their use to decrease fatigue and to heighten 
physical and mental abilities dates back to ancient China where people use to 
drink tea made with plants containing ephedrine (Ephedra sinica) called Ma 
huang which translates into "looking for trouble" (Sulzer, Sonders et al. 2005). Its 
medical use in Canada is restricted to the management of attention deficit 
hyperactivity disorder (ADHD), sleep-disorder (narcolepsy) and weight control. 
Nevertheless, illicit amphetamine is still widely available and extensively used 
for its stimulant and euphorigenic effects. Worldwide statistics indicate that 24 
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million people use amphetamine-type-stimulants for recreational use and the 
expansion of the amphetamine market is continuing 
(http://www.unodc.org/unodc/global illicit drag trends.html). 
Experimental models in animaIs have typically investigated the neural 
substrates that mediate the behavioral expression of stimulant action through 
measurements of locomotor activity. In humans, the main effects of 
amphetamine have been measured in locomotor and stereotyped activity, self-
reported euphoria and excitements, appetite and mental function. Briefly, in 
animaIs and humans amphetamine initial produces hyperactivity, which at 
higher doses expresses itself as intense stereotyped behavior. Most often this 
period (of binge) is followed by a period of inactivity or crash. Continuous 
amphetamine treatment (at least 3 days in rats) at higher doses (48 mg/kg in 
rats) has been shown to be neurotoxic (Ricaurte, Seiden et al. 1984) and 
accompanied by hallucinatory-like behavior. This amphetamine neurotoxicity 
syndrome is believed to be different than amphetamine-induced psychosis 
(Ellis on and Eison 1983). In this regard, amphetamine is known to be a potent 
psychotomimetic. This is based on the observation that their use in sorne patients 
with schizophrenia can intensif y or precipitate psychotic symptoms (see chapter 
2 and discussion). 
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1.3.2.1. AMPHETAMINE-INDUCED DA RELEASE MECHANISM 
Amphetamine is a highly addictive psychostimulant, which promotes the 
release of DA, norepinephrine and serotonin. This drug crosses plasma 
membranes via lipophilic diffusion (Mack and Bonisch 1979). Once inside the 
cells, it can displace DA from secretory vesicles into the neuronal cytoplasm 
(Sulzer and Rayport 1990) and induce DA overflow into the synaptic cleft by 
facilitating outward exchange diffusion and triggering channel-like DA release 
(10,000 molecules per few milliseconds) through the pore of the Na+ / CI- -
dependent plasma membrane protein DAT (Staal, Mosharov et al. 2004). 
Although both synaptic vesicle and cytosolic DA pools contribute to the amount 
of DA released following amphetamine, the DA previously residing in the 
synaptic vesicles (vs DA in the cytosolic pool) represents the larger portion of 
amphetamine-mediated release (Jones, Gainetdinov et al. 1998). Like cocaine, 
amphetamine is also a substrate for the DA transporter (DAT) where it acts to 
inhibit DA up-take (Liang and Rutledge 1982) (Figure 4). This reversaI (and 
blocking) of the uptake mechanism increases extracellular DA concentration 
thereby promoting D2/3 autoreceptors activation which, through feedback 
mechanisms decreases DA cell firing (Bunney, Walters et al. 1973; Shi, Pun et al. 
2000). For example decreased excitability of DA neurons has been recorded 
following the systemic intravenous administration of amphetamine at doses 
ranging from 0.25 to 5.0 mg/kg, (Groves, Fenster et al. 1981). In presence of D2/3 
autoreceptors blockers the amphetamine-induced inhibition of DA cell firing is 
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replaced by an excitation mediated in part through adrenergic al receptors (Shi, 
Pun et al. 2000). Amphetamine mediated DA neuron excitation is also believed to 
occur through the inhibition of metabotropic glutamate receptor-mediated IPSPs 
(Paladini, Fiorillo et al. 2001). However, under normal conditions DA release 
after amphetamine is impulse-independent and relies only to a small extend on 
calcium (Hurd and Ungerstedt 1989). DA-mediated feedback inhibition has been 
shown to be altered after chronic treatment and might play an important role in 
the development of behaviors associated with the abuse of these drugs (Wolf, 
White et al. 1993). Amphetamine derivatives are competitive inhibitors of MAO. 
Their inhibitory action on this enzyme increases DA available for release (Sulzer, 
Sonders et al. 2005). Amphetamine has also been noted to have an effect on 
tyrosine hydroxylase activity enhancing DA synthe sis (Costa, Groppetti et al. 
1972). 
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Figure 4 Schematic of the DA 
synapse illustrating the sites of action 
of amphetamine. 1) Amphetamine acts 
directly on the vesicular monoamine 
carriers by a weak base mechanism to 
exacerbate vesicle depletion. 2) 
Amphetamine facilitated outward 
exchange diffusion and triggers 
channel-like DA release (10,000 
molecules per few ms) through the 
pore of the Na+ / Cl- -dependent 
plasma membrane protein D AT. 3) 
Amphetamine is a substrate for the 
DAT, where it acts to prevent re-
uptake. 
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1.4. DOPAMINB BYPOTBBSBS O' ADDICTION 
Although drugs of abuse typically activate DA neural networks and 
neuroadaptations (including tolerance, withdrawal and sensitization: see chapter 
2) induced by chronic administration, have been shown to occur downstream of 
DA receptors, it is unclear what neurophysiologic processes are critical for the 
transition from casual to addictive drug use. Addiction can be defined as 
overwhelming involvement with the use of a drug (compulsive use) and the loss 
of control over drug taking, despite adverse medical, relational or social 
consequences (APA 1994). A number of hypotheses have been formulated to 
describe how drugs of abuse, through their action on DA, might lead to 
addiction; most account for only sorne specific aspects of the whole process of 
addiction. A large amount of experimental models have been studied with the 
purpose of clarifying the Hnk between DA and addiction, but a detailed account 
of the specific lite rature is beyond the scope of this thesis chapter. The reader is 
referred to the following reviews (Di Chiara 1999; Robbins and Everitt 1999; 
Hyman and Malenka 2001). The next paragraph briefly reviews sorne of the most 
influential theories. 
Abstinence from chronic exposure to addictive drugs reduces in vivo DA 
transmission and induces a state of anhedonia that is expressed by a disinterest 
in normally rewarding stimuli (decreased sucrose consumption, ability to 
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associate rewards with a distinctive environment, and sensitivity to rewarding 
electrical brain stimulation) (Koob and Le Moal 1997). In line with this, early 
theories have suggested that withdrawal-induced anhedonia (physical / 
psychological dependence) fuels drug self-administration and addiction by a 
negative reinforcing mechanism i.e.: people use drugs to avoid the unpleasant 
withdrawal symptoms. This theory has been refined into the idea that the 
development of addiction involves counteradaptive mechanisms which change 
the hedonic set-point (allostasis) for reward (Solomon and Corbit 1973; Koob and 
Le Moal 2001). Others have argued that the excessive drive to take drugs results 
from an aberrant learning process (Tiffany 1990; Di Chiara 1998; Berke and 
Hyman 2000; Hyman and Malenka 2001). This is based on the observation that 
both normallearning and addiction involve sorne of the same mechanisms (long 
term potentiation; (Overton, Richards et al. 1999), molecular events (transcription 
factors such as ~FosB and CREB; (NestIer 2001) and neurotransmitter systems 
(dopamine projections from the VTA and SNc to the nucleus accumbens and 
striatum, as well as glutamate inputs from the prefrontal cortex, amygdala and 
hippocampus). The power of drug-related cu es (environment, priming dose of 
drug or stress) to induce a return to drug (relapse) is an example of the excessive 
strength of association between stimulus and response (and stimulus-reward) 
expressed in addiction (addiction memory)(Di Chiara 1998; Boening 2001). 
Furthermore, as contextual cues bec orne associated and strengthened through 
repeated drug use, the neurocircuitry involved in emotional memory (obsessive 
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thoughts) and executive function (decision making and behavioral inhibition) 
become deficient. Indeed chronic exposure to drugs has been shown to impair 
functions of the prefrontal cortex and decrease frontocortical blood flow, glucose 
utilization and volume (Liu, Matochik et al. 1998)(for review see (Jentsch and 
Taylor 1999; Davidson, Putnam et al. 2000; Volkow 2004). In their incentive 
sensitization view of addiction Robinson and Berridge propose that the 
progression from initial drug use to addiction may evolve as repeated activation 
of the mesocorticolimbic pathway associated with repeated drug use promote an 
abnormal incentive state (abnormal wanting) which remain engaged even in the 
absence of ongoing drug use (Robinson and Berridge 2001). In a model that 
integrates findings from brain imaging and molecular studies, Volkow and her 
colleagues have suggested that in addiction while mesolimbic DA transmission 
is deficient, reducing responding for natural rewards, it is hyper responsive to 
drug-associated stimuli (increased Dl signaling, glutamate on the PFC). This 
effect which would lead to an unmanageable motivation to seek drugs is though 
to result from cellular adaptations in the glutamatergic projection from the PFC 
to the NAS (Kalivas, Volkow et al. 2005). Clearly the entire scope of the 
addiction experience cannot be explained in one theory 
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2.0. SBNSITIZATION OVBRVIBW 
A ltered dopamine (DA) neurotransmission is thought to play a critieal role in the pathophysiology of psychotic states and 
addiction. However, the mechanism responsible for a dysregulated DA 
neurotransmission remain poorly understood. Sensitization is one such 
purported mechanism; by which repeated exposure to stimulants or stress 
would progressively result in heightened behavioural responsiveness, 
following re-exposure to stress or drug. This increased behavioural 
response is possibly related to increased dopaminergic neurotransmission. 
The study of sensitization in humans offers a novel perspective on the 
understanding of the neurobiology of the triggering and relapse of 
psychotic states, as well as the phenomenon of drug craving 1 drug 
seeking behaviour, consistent with several clinical observations: (1) ability 
of psychostimulants to induce psychosis in normal individuals and 
stimulant abusers, (2) ability of psychostimulants or environmental 
stressors to elicit disease exacerbation or relapse in stable patients with 
schizophrenia or bipolar affective disorder, (Lieberman, Sheitman et al. 
1997; Laruelle 2000) (3) ability of environmental stressors to elicit relapse 
in abstinent drug user s, (4) ability of drug-related cues to similarly elicit 
relapse. In the presented thesis we have tested the specifie hypothesis that 
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sensitization, in healthy volunteers, as a result of repeated exposure to 
amphetamine, is associated with an increased DA release in the 
mesolimbic dopaminergic system. The present chapter provides a 
description of the phenomenon of sensitization along with core features 
and presents the theories that suggest that sensitization might play a role 
in chronic-relapsing disorders such as addiction and psychosis. 
2.1. SBNSITIZATION DBPINITION 
Repeated exposure to drug (of abuse) often leads to a decreased 
reaction to their effeds such that a larger dose is eventually required to 
achieve the same effed. This response known as tolerance is believed to 
results from the organism' s effort to oppose the effed of the drug and 
maintain a homeostatic state. In sorne situations, reverse-tolerance or an 
increased sensitivity, i.e.: sensitization to the effects of drugs (or noxious 
stimuli) can occur. Sensitization has been defined as an experience-
dependent type-plasticity, whereby repeated exp os ure to dependence-
producing pharmacological challenge (or to a noxious stimulus) primarily 
functions to increase behavioural output; a simple example of this has 
been derived from the investigation of the gill and siphon withdrawal 
reflex of the Aplysia following repeated electrical stimulation (Kandel and 
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Schwartz 1982). An overwhelming amount of experiments have been 
conducted in animaIs to investigate the conditions that lead to 
behavioural sensitization. Landmark rodent models of stimulant 
sensitization have used intermittent moderate doses of cocaine or 
amphetamine pre-treatment followed by testing with a single dose in a 
(paired or unpaired) testing environment (Ungerstedt, Ljungberg et al. 
1975; Post, Kopanda et al. 1976; Stripling and Ellinwood 1977; Post, Weiss 
et al. 1988; Vezina and Stewart 1989; Stewart and Badiani 1993; Vezina 
1993). These early experiments have shown that behavioral sensitization 
to the locomotor activating and stereotypie effects of repeated stimulant 
administration is a replicable finding. 
2.2. SBNSITIZATION COR.B 'BATUR.BS 
The core features of sensitization are as follows (Robinson and 
Berridge 2000). (1) Sensitization results from the repeated administration 
of DA elevating drugs, though it has also been observed after a single 
dose administration (Grignaschi, Burbassi et al. 2004) and it cannot be 
explained by a change in the disposition of the drug (metabolism, 
accumulation in adipose tissue). Drugs able to induce sensitization 
primarily include psychostimulants, amphetamine and cocaine (Downs 
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and Eddy 1932; Robinson and Becker 1986; Kalivas and Stewart 1991), D2 
dopamine receptor agonists (Hoffman and Wise 1992; Mattingly, Rowlett 
et al. 1993), Il-opioids (Kalivas and Duffy 1987; Vezina, Kalivas et al. 1987; 
Kalivas and Stewart 1991), NMDA receptor antagonists (Wolf and Khansa 
1991) but also nicotine (Johnson, Blomqvist et al. 1995; Cadoni and Di 
Chiara 2000; Miller, Wilkins et al. 2001; Shim, Javaid et al. 2001), cannabis, 
(Cadoni, Pisanu et al. 2001; Lamarque, Taghzouti et al. 2001) alcohol 
(Phillips, Roberts et al. 1997; Lessov and Phillips 1998; Correa, Arizzi et al. 
2003) and caffeine (Cauli, Pinna et al. 2003). 
3S 
24 28 32 36 <40 4<4 
Paulson & Robinson 1995 Time (5 minute intervals) 
Figure 1 Locomotor-activating effects of a challenge dose of 
amphetamine (0.5 mg/kg), measured in hemiparkinsonian rats, 3 (empty 
squares), 7 (empty triangles), or 28 days after discontinuation from either 
saline (blue) or escalating-doses of amphetamine (red). AnimaIs tested 
after 28 days of withdrawal were hypersensitive (sensitized) to the 
challenge dose of amphetamine (Paulson and Robinson 1995) 
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(2) Secondly, sensitization is characterized by an increased 
magnitude of behavioural response to subsequent exposure as weIl as a 
lower threshold for response triggering (ex: the progressive enhancement 
in rotational behaviour in rats). Explicitly the dose-response curve for 
behavioural effects is shifted to the left (Figure 1). 
(3) Thirdly, sensitization is believed to be an enduring 
phenomenon; this defining feature of sensitization is mainly derived from 
the observation that chronic methamphetamine users remain 
hypersensitive to the psychotomimetic effects of amphetamine after years 
of abstinence (Sato, Chen et al. 1983). Behavioural sensitization to 
amphetamine persists undiminished for at least 12 months in rodents 
(Paulson, Camp et al. 1991), 28 months in non-human primates (Castner 
and Goldman-Rakic 1999). Behavioral changes have been associated with 
enduring (3.5 months), though perhaps reversible, structural 
reorganization of dendritic spines on medium spiny neurons of the 
nucleus accumbens and on pyramidal cells of the medial prefrontal cortex 
(Robinson and Kolb 1997; Li, Kolb et al. 2003; Li, Acerbo et al. 2004). 
(4) Fourthly, sensitization is influenced by environmental context 
and conditioning; whereby, the exclusive repeated pairing of drug 
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administration with a novel environment facilita tes the expression of 
sensitization (see section 2.6). 
(5) Fifth, sensitization is dependent on dose and temporal pattern 
of drug treatment. In particular, robust sensitization is achieved by 
repeated intermittent low doses of pharmaceutical agents, rather than 
escalating or continuous doses (Vanderschuren, Tjon et al. 1997). 
(6) Additionally, the phenomenon of sensitization is subject to 
cross-sensitization with stress. It is well established that repeated stress 
(maternaI separation, social defeat stress, foot shock, tail-pinch, restraint) 
can induce heightened sensitivity to low doses of drugs (locomotor 
activation and drug self administration as well as neuroendocrine arousal 
and DA release) and inversely repeated drug exposure modify the stress 
response (Pani, Porcella et al. 2000; Stewart 2000; Barr, Hofmann et al. 
2002; Nikulina, Covington et al. 2004; Kikusui, Faccidomo et al. 2005). The 
neurobiological substrate mediating cross-sensitization between stress and 
psychostimulants is thought to reside in the interaction between 
hypothalamus-pituitary-adrenal stress axis (HP A) and mesencephalic DA 
projections (Marinelli and Piazza 2002). 
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(7) Another characteristic of this phenomenon is the substantial 
inter-individual variability in the vulnerability to sensitize (see section 
2.6). Typically, the magnitude of behavioural sensitization is greater in 
rats identified based on their locomotor responsiveness to a novel 
environment. 
(8) Lastly, withdrawal plays an essential role in its development. 
Specifically, in the rodent the expression of neurochemical sensitization 
does not reach asymptote until at least two-weeks post-treatment (Pauls on 
and Robinson 1995) (See section 2.4.2). 
2.8. BBBAVIORAL CBARACTBRISTICS 
2.3.1. SENSITIZATION IN ANIMALS 
In experimental animaIs, the most commonly studied drug 
responses showing sensitization are different forms of motor activation 
such as stereotyped and rotational behaviour, intra-cranial self-
stimulation, and acoustic startle reflex at subsequent exp os ures to the 
same dose (Post and Kopanda 1976; Wolf and Khansa 1991; Pierce and 
Kalivas 1997; Tzschentke 2001). 
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Using alternate paradigms, a number of investigations have 
attempted to demonstrate sensitization to the reinforcing effeds of drugs 
(and natural rewards) with repeated exposures. Specifically sensitization 
through repeated exposure to stress or psychostimulants, potentiates 
reward seeking behaviour: it increases instrumental responding for food, 
ethanol and sex (Cailhol and Mormede 2000; Wyvell and Berridge 2001), it 
enhances the acquisition of cue-driven (Pavlovian conditioned) 
amphetamine and cocaine self-administration (Woolverton, Cervo et al. 
1984; Piazza, Deminiere et al. 1989; Horger, Shelton et al. 1990; Piazza, 
Deminiere et al. 1990; Horger, Giles et al. 1992; Robinson and Berridge 
1993; Piazza and Le Moa11996), it facilitates learning preference for places 
associated with drug administration (Lett 1989) and increases the 
breakpoint (amount of work an animal is willing to do to obtain reward) 
achieved on a progressive ratio schedule (Mendrek, Blaha et al. 1998; 
Lorrain, Arnold et al. 2000; Vezina, Lorrain et al. 2002). This and other 
evidence form the basis for the incentive-sensitization theory of addiction, 
suggesting that sensitization induced by drugs results in excessive "drug 
wanting" in face of reward eues, hence triggering 1/ compulsive drug pursuit" 
transmission salient and wanted (Robinson and Berridge 1993; Robinson 
and Berridge 2001). 
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Behavioural sensitization has also been noted in nonhuman 
primate models, which might provide insight into the neural substrates of 
both drug-induced and idiopathic psychosis. In monkeys, a sensitizing 
regimen of amphetamine has been shown to enhance many amphetamine-
induced behaviours and progressively induce hyper-vigilance, abnormal 
eye-tracking, grasping, and checking the environment for stimuli that are 
not observable to the experimenter (paranoid-like). Together these 
behaviours have been referred to has psychotomimetic or hallucinatory-
like (Ellinwood, Sudilovsky et al. 1973; Snyder 1973; Ellison, Nielsen et al. 
1981; Castner and Goldman-Rakic 1999; Castner, al-Tikriti et al. 2000; 
Castner, Goldman-Rakic et al. 2003). Thus far, these models have 
supported the role of sensitization in generating psychostimulant-induced 
psychosis. 
2.3.2. SENSITIZATION IN HUMANS 
Experimental evidence supporting the occurrence of sensitization in 
humans is limited (Szechtman, Cleghorn et al. 1988; Strakowski and Sax 
1998). The most compelling is derived from longitudinal observations of 
methamphetamine abus ers; following long periods of abstinence or 
remission from psychostimulants-induced psycho sis, re-exposure to 
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methamphetamine (or stress) induces an increased behavioural response 
inc1uding re-occurrence of psychosis, even in lower doses than initially 
used (Sato, Chen et al. 1983; Yui, Goto et al. 1999). 
There have been very few controlled experimental studies 
investigating the behavioural consequences of repeated psychostimulant 
exposure. Strakowski and colleagues have documented that in healthy 
volunteers, small oral doses of amphetamine (0.25 mg/Kg) repeated two 
or three times elicit a progressive increase in magnitude and duration of 
psychostimulants-induced eye-blink rate, motor activity and mood effects 
(Strakowski, Sax et al. 1996; Strakowski and Sax 1998). The observation of 
sensitization of the mood response to amphetamine was independently 
replicated by the same group in female healthy volunteers (Strakowski, 
Sax et al. 2001). As evidence of sensitization in humans, it was also 
proposed that PET / SPECT derived findings of enhanced DA release 
response to a single-dose of amphetamine reported in patients with 
schizophrenia could, in part, reflect endogenous sensitization (Breier, Su et 
al. 1997; Laruelle, Abi-Dargham et al. 1999). 
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2.'. NEURAL AND PUNCTIONAL CORRELATES 
Although the process of sensitization is believed to inc1ude changes 
occurring over a wide network of brain areas, neuroadaptations of the 
mesoaccumbens DA system most likely underlie the emergence of 
locomotor sensitization following the repeated intermittent systemic 
administration of amphetamine. Sensitization involves an induction (see 
section 2.4.1) phase and an expression (see section 2.4.3) phase separated by 
a period of re-setting or withdrawal (see section 2.4.2) (Kalivas and Duffy 
1993). 
2.4.1. INDUCTION 
Induction requires the stimulation of DA cell bodies in the ventral 
tegmental area (VTA) (A10 and/or A9 DA cell groups). In this regard, 
microinjection studies have shown that direct injections of 
psychostimulants (or opioids) in the VTA induce sensitization upon 
subsequent drug challenges, whereas injections at the level of DA cell 
terminal fields, the striatum or frontal cortex, do not (Kalivas and Stewart 
1991; Hooks, Colvin et al. 1992; Kalivas and Duffy 1993; Kalivas, Sorg et al. 
1993). DA receptor blockers, most consistently Dl antagonists (Vezina and 
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Stewart 1989; Stewart and Druhan 1993) but also D2 antagonists (Meng, 
Feldpaush et al. 1998), NMDA blockade (Karler, Calder et al. 1991; Karler, 
Turkanis et al. 1991; Karler, Finnegan et al. 1993; Stewart and Druhan 
1993; Ranaldi, Munn et al. 2000) basic fibroblast growth factor (bFGF) 
antibody in the ventral tegmental area (VTA) (Flores, Samaha et al. 2000; 
Flores and Stewart 2000), removal of circulating corticosterone (Deroche, 
Marinelli et al. 1995) prevent the induction of sensitization. 
Induction of sensitization is characterized by a post-receptor 
signalling cascade of molecular events, which inc1udes protein 
phosphorylation and turnover, RNA translation and gene transcription. 
This stage, which starts at the site of action of the drug, is believed to 
ultimately result in the phenotype of structural changes associated with 
sensitization. For example, repeated treatment with psychostimulants, 
such as cocaine and amphetamine, are known to change the morphology 
of medium spiny neurons in the NAS, increasing the density and the 
number of branched spines on these neurons (and synaptic efficacy) 
(Robinson and Kolb 1997; Li, Kolb et al. 2003). The activation of several 
intracellular cascades is believed to be an instrumental mechanism of 
sensitization. Specifically, the downstream signalling of the cAMP-PKA 
pathway through G-protein coupled DA receptor stimulation, the Ca2+ 
calmodulin dependent kinase (CaM-K) cascade initiated by activation of 
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NMDA receptors and the Rasjmitogen-activated protein kinase (MAP) 
signal transduction cascade triggered by the transmitter brain derived 
neurotrophic factor (BDNF). In turn, these cascades activate programs of 
gene expression by inducing immediate early genes (IEG), c-Fos for 
example, and by up-regulating several transcription factors including 
cAMP response element binding protein (CREB) and ~FosB (NestIer 
2001). The induction of ~FosB is particularly significant because it 
mediates stimulation of cyclin-dependent kinase-5 (Cdk5), which appears 
to be involved in the increased density of dendritic spines on NAS 
neurons after chronic cocaine exposure (Bibb, Chen et al. 2001). 
2.4.2. WITHDRA W AL 
The expression of sensitization is a delayed phenomenon, oruy 
becoming apparent during re-exposure to the stimulus, after a period of 
discontinuation (Pauls on and Robinson 1995). lndeed, the most 
appropriate period for studying sensitization is long after acute 
withdrawal signs have dissipated. In fact, relative to short-term 
withdrawal, prolonged withdrawal periods are associated with an 
intensified drug reaction (Robinson and Becker 1986; Kalivas and Stewart 
1991; Paulson and Robinson 1995). 
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Withdrawal may be considered as a sequence of phases beginning 
with a period of acute crash upon drug discontinuation and ending with 
long-term withdrawal; together the evolving stages of withdrawal 
encompass residual, transient as weIl as enduring behavioural and 
neurochemical signs. After psychostimulant binge depressive symptoms 
combined with irritability, anxiety and anhedonia have been noted 
(Gawin and Kleber 1986). 
The neurochemical basis of withdrawal involves at least in part, 
mesocorticolimbic DA. A considerable body of evidence indicates that 
acute withdrawal from DA-elevating drugs disturbs compensatory 
processes geared at restoring steady baseline-state of DA (DA tone) (Grace 
2000). Thought the spontaneous activity of VTA DA neurons does not 
seem to be altered during amphetamine withdrawal (Lee and Ellinwood 
1989), a reduction of extracellular DA levels in the NAS as been estimated 
by microdialysis (Rossetti et a!., 1992). In this respect, DA autoreceptor 
sensitivity is known to undergo time dependent changes during 
withdrawal; specifically, after short withdrawal somatodendritic D2 
autoreceptor regulation of impulse generation is believed to be 
desensitized (Kalivas and Stewart 1991). Withdrawal from repeated 
psychostimulant treatment has also been found to induce changes in DAT 
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mRNA and protein levels (Kuhar and Pilotte 1996). Again, these reported 
changes have been inconsistent. Activations of the HP A axis during 
withdrawal has also been shown to a be a key player in the resetting of 
biological parameters, priming the organism to sensitization (Deroche, 
Marinelli et al. 1995; Deroche, Marinelli et al. 1997). 
2.4.3. EXPRESSION 
The anatomical substrates for the expression of sensitization 
consists of changes at multiple sites, occurring over an entire circuit of 
interconnected cortical and sub cortical structures, deemed critical for the 
translation of biologically salient stimuli, into adapted motor and non-
motor outputs (Pierce and Kalivas 1997). DA is a critical player of this 
system, and its projections to NAS and the prefrontal cortex (PFC) have 
been recognized as key neural substrates of behavioural sensitization (Le 
Moal and Simon 1991; Koob 1992; Pierce and Kalivas 1997). One general 
hypothesis is that sensitization is related to a progressively developing 
change in the balance of neurotransmitters within these systems such that 
the magnitude and threshold of a behavioural response is shifted (Pierce 
and Kalivas 1997). Sensitization-related changes in pre and postsynaptic 
neurotransmission include increased excitatory glutamatergic input from 
PFC and reduced GABAergic inhibition from NAS and ventral pallidum 
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to the cells of the VTA, both of which could contribute to increased DA 
release at the level of the NAS and striatum. 
Sensitization Circuit Model 
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VTA 
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.-::::. GABA 
:::::-. DA 
Figure 2 Box-and-arrow diagram, representing connections between 
sub-nuclei of the basal ganglia, limbic system, cerebral cortex and the 
thalamus. The primary neurotransmitter content and the major projections 
are represented by the colored arrows: blue, GABA; red, glutamate; green, 
DA. The changes in neurotransmission associated with the expression of 
behavioral sensitization are represented by the bold lines: continuous lines 
indicating increases, while dotted lines represent decreases in 
neurotransmission. GPe, external globus pallidus; GPi, internaI globus 
pallidus; SNe, substantia nigra pars compacta; SNr substantia nigra pars 
reticulata; STN, subthalamic nucleus; VTA, ventral tegmental area; OFC, 
orbitofrontal cortex; PPN, pedoculopontine nucleus; VL, ventro-Iateral, 
MD, mediodorsal thalamus; NAS, Nucleus accumbens. 
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One of the most common neurochemical correlates of sensitization 
is enhanced DA transmission at the level of the NAS upon re-exposure to 
a depolarizing or pharmacological challenge (for review see: (Pierce and 
Kalivas 1997) (Robinson and Becker 1986; Wolf 1998; Vanderschuren and 
Kalivas 2000) (Post, Weiss et al. 1988; Vezina 2004). Studies reveal that DA 
neurotransmission in the NAS has a time course characterized by reduced 
activity upon drug discontinuation, but hyper responsiveness following 
re-exposure to psychostimulants, after a week of withdrawal (Kolta, 
Shreve et al. 1985). 
Different pre and post-synaptic events are thought to mediate the 
augmented DA transmission during the expression of sensitization. The 
sensitization-induced increase of DA release has, in part, been attributed 
to adaptive changes in DA transporter 1) kinetics and 2) expression 
(Izenwasser and Cox 1990; Benmansour, Tejani-Butt et al. 1992; Giros, 
Jaber et al. 1996) Findings show DAT upregulation upon withdrawal of 
psychostimulants, followed by a selective reduction following a longer 
drug-free period in the shell of the NAS (Kuhar and Pilotte 1996; Pilotte, 
Sharpe et al. 1996). Changes occurring in 3) DA autoreceptor sensitivity 
and 4) DA synthesis have also been reported, though less consistently 
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(Kalivas and Duffy 1988; Gifford and Johnson 1992). Changes in 5) 
calcium conductance involving activation of calcium-calmodulin kinase 
(CAM-KIl) have been reported. Findings suggest that repeated 
amphetamine administration leads to the emergence of a novel calcium-
dependent mechanism for DA release because sensitized, but not acute 
DA responses to amphetamine are abolished when CAM-KIl is blocked 
(Pierce and Kalivas 1997). CAM-KIl-related mechanisms induced by 
amphetamine-sensitization include phosphorylation of synapsin l (Iwata, 
Ito et al. 1999). This mechanism is thought to have a role in augmenting 
the pool of DA-containing vesicles available for exocytosis. 6) Long-term 
potentiation-like mechanisms thought to facilitate DA transmission 
(Overton, Richards et al. 1999), via increases in glutamate efflux on 
midbrain DA neurons, have been invoked. 
Finally, although stimulation of post-synaptic receptors in the NAS 
is necessary for the expression of sensitization, the bulk of evidence 
suggests that neither the development nor expression of sensitization 
entails changes in Dl, D2, DA receptor density (Kleven, Perry et al. 1990; 
Henry and White 1991; Farfel, Kleven et al. 1992; King, Ellinwood et al. 
1994; Bonhomme, Cador et al. 1995; Zhang, Walsh et al. 2000) however D3 
over-expression has been reported (Guillin, Diaz et al. 2001). In addition, 
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affinity changes in sensitization have been reported by sorne (Seeman, 
Tallerico et al. 2002) but not others (Pierce and Kalivas 1997). 
2.5. CONTBXT AND CONDITIONING 
Conditioned stimuli, or secondary reinforcers (CS; discret eues or 
envrironmental / contextual eues) are stimuli with formerly 
motivationally neutral properties that gain incentive properties by their 
predictive association with primary reinforcers. Both human and non-
human primates studies have shown the implication of the DA system in 
conditioning and reward prediction (Schultz, Dayan et al. 1997) (de la 
Fuente-Fernandez, Phillips et al. 2002). When drug administration 
(unconditioned stimuli, US) is paired with a distinct environmental 
context (CS) or a diserete eue the later aequire the ability to elicit 
conditional responses including drug-like psyehomotor effects (Pavlov 
1923; Pavlov 1927). By the same bias, repeated psychomotor stimulant 
treatment, in addition to producing sensitization to the psychomotor-
activating effects of drugs, increases response (neurochemical and 
behavioral/ motivational) to their associated eues (Robinson, Browman et 
al. 1998). Whether sensitization simply reflects the addition of the 
conditioned response to a stable uneonditioned pharmacological response 
has been a subject of debate. There is considerable evidence showing that 
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the context in which drugs are administered largely impact on their ability 
to induce psychomotor sensitization (Badiani, Camp et al. 1997; Crombag, 
Badiani et al. 2000; Crombag, Badiani et al. 2001). Indeed several studies 
have shown that the expression of sensitization can be entirely context-
specific i.e.: absent in an environment previously not paired with drug 
administration, even after treatment that induces robust sensitization 
(Stewart and Vezina 1991; Anagnostaras and Robinson 1996; Battisti, 
Uretsky et al. 2000). However, different paradigms geared at dissociating 
associative vs non-associative (non context-specific) sensitization have 
shown that the CS alone does not promote locomotor sensitization but 
rather other environmental properties would act to facilitate sensitization 
through mechanisms independent of associative learning. In this regard 
studies have shown that a distinct and relatively noveZ environment (not 
the home cage) potentiates sensitization even in specific conditions that 
degrade the ability of contextual stimuli to acquire CS properties i.e.: after 
habituation. The mechanism proposed for this facilitation might reside in 
that exposure to a novel environment activates the HP A axis, increasing 
the release of corticosterone (Badiani, Browman et al. 1995). 
There is sorne evidence that the expression of sensitization depends 
on context, however there is also evidence for non-associative 
sensitization i.e.: an increased in the unconditioned response to the drug. 
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This is based on the findings that sensitization measured as increased DA 
release is observed in vitro from slices preparation (Robinson and Becker 
1982), in rats anesthetized with chloral hydrate during pretreatment and 
in animaIs continuously housed in the test chambers (Segal and Kuczenski 
1997). 
2.6. INDIVIDUAL DIRBRBNCBS 
From a large number of individuals who use psychostimulants 
only a few will ever develop addiction or drug-induced psychosis, hence 
the need to identify reliable predictors of individual response to drug and 
vulnerability to sensitization. There is a great deal of evidence to indicate 
that personality factors play an important part in understanding patterns 
of addiction. A number research has lead to evidence of a relationship 
between personality factors, and alcohol and drug addiction (de Wit and 
Richards 2004). Personality factors that appear to be central to this 
relationship are novelty seeking and impulsivity. 
In animaIs, response to a novel environment is the most used 
experimental paradigm to distinguish high responders to drugs: highly 
reactive rats, as rated by their locomotor behavior when placed in a novel 
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environment, consistently show a greater propensity for drug self-
administration, are more sensitive to reward by food, have a higher level 
of DA activity in the NAS under basal condition and demonstrate an 
increased and prolonged secretion of glucocorticoids (GC) in response to 
stress; unlike low reactive rats, high reactive rats show pronounced 
sensitization to locomotor properties of stimulants (Piazza et al., 1990, 
1991; Dellu et al., 1996; Rouge-Pont et al., 1993, Hooks et al., 1991). Sorne 
of these biobehavioural markers in rats have been compared to Novelty 
Seeking (NS) personality traits in humans, characterized by a "tendency 
toward the activation of behavior" such as exploratory behavior in 
response to novelty and/or "impulsive decision making, extravagance in 
the approach to cues of reward, and quiek loss of temper" (Dellu et al., 
1996). 
In humans, the Cloninger Tridimensional Personality 
Questionnaire (TPQ; Cloninger, 1987, 1988; Cloninger et a1., 1991), the 
Eysenck Extroversion and Psychotism scale (EEP; Eysenck, 1953, 1990), 
and the Zuckerman' s Sensation-Seeking Inventory (55I; Zuckerman, 1994) 
are sorne of the most common psychometrie instruments used to measure 
individual differences in response to novelty. Despite sorne subtle 
terminologieal and conceptual differences [the TPQ uses four novelty 
seeking subscales: [1] Exploratory-Excitability vs. Stoic-Reserve, [2] 
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Impulsiveness VS. Reflection, [3] Extravagance vs. Reserve, and [4] 
Disorderliness vs. Regimentation; the SSI, four axes: [1] Thrill and 
adventure-seeking, [2] Experience-seeking and [3] Disinhibition; the EEP 
three axes: [1] Extraversion, [2] Psychoticism, [2] Neuroticism], an three 
instruments are believed to refer to a common temperament, related to 
investigatory behaviour and sensitivity to novelty (Jaffee and Archer, 
1987). Healthy volunteers scoring high on Novelty Seeking are prone to 
sensitization of the mood response to amphetamine (Sax and Strakowski 
1998); likewise, detoxified alcoholics who score high on novelty seeking 
are more susceptible to relapse (Meszaros et aL, 1999). Conversally, 
novelty seeking, in the absence of other risk factors, does not predict 
response to the reinforcing-effects of amphetamine (Corr and Kumari, 
2000). It has been suggested that novelty seeking [Impulsivity / 
Exploratory-extraversion] might be related, in sorne significant part, to 
DA neurotransrnission (Gerra et al. 2000): differences in novelty seeking 
would reflect interindividual variability in DA neurotransmission, hence a 
distinct disposition to engage in behaviors motivated by positive incentive 
and/ or reward (Depue and Collins, 1999; Koob et al., 1993; Panksepp, 
1986; Stewart et al., 1984, Bardo et al., 1996). 
In vivo brain imaging studies have recently started to investigate 
the association between biological factors and personality traits. These 
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studies have most1y been interested in looking at the association between 
levels of D2 dopamine receptor (and dopamine transporter) and 
personality. The main findings of these studies is that low levels of in vivo 
D2 receptor binding in the striatum is associated with high detachment 
scores (high aloufness, social irritability) (Farde, Gustavsson et al. 1997; 
Laakso, Vilkman et al. 2000) as rated by the Karolinska Scales of 
Personality (Schalling, Asberg et al. 1987). 
In the present studies (study 1, 2, 3), we have used the NS / TPQ 
subscore as a possible predietor of acute and sensitized DA responses to 
amphetamine. Using exploratory analyses, we examined the relationship 
between specifie drug induced D2 binding and personality traits from the 
Tridimensional Personality Questionnaire. 
2.7. RBLBVANCB TO CBRONIC-RBLAPSING 
DISORDBRS 
It has been postulated that pathological forms of behavioral and 
neurochemical plasticity, i.e.: sensitization, might he a factor contrihuting 
to chronic relapsing disorders such as addiction, psychosis, post-traumatic 
stress-disorder - to name a few. Particularly, sensitization is believed to be 
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a vulnerability factor in the development of addictions (Robinson and 
Berridge 2001). In humans, sorne aspects of sensitization may increase 
craving for drugs even if, as a result of tolerance, the actual enjoyment of 
drugs is diminished. Another form of sensitization observed both in 
humans and in non-human primates is a syndrome of amphetamine-
induced paranoia. The involvement of the DA neurotransmitter system in 
both the reinforcing effects of drugs of abuse (see chapter 1) and in 
psychosis and schizophrenia (see 2.7.1) has been demonstrated. 
Dopaminergic transmission sensitization presumably resulting from 
repeated drug (or stress) -induced DA stimulation may therefore underlie 
the development of both these disorders. We have presented the incentive 
sensitization view of addiction in chapter 1. The next section will serve to 
introduce the concept of endogenous sensitization as a model of psychosis 
development by first presenting the DA hypothesis of psychosis. 
2.7.1. THE DA HYPOTHESIS OF PSYCHOSIS 
For many decades the predominant biological the ory has been that 
DA hyperactivity in the brain is the underlying cause of schizophrenia 
(Carlsson and Lindqvist 1963). This idea has been supported by indirect 
pharmacological evidence: the root of the hypothesis residing in the 
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discovery that the DA antagonist chlorpromazine reverses the symptoms 
of schizophrenia (Delay, Deniker et al. 1952). Since then several similar 
antipsychotic compounds have been produced aIl sharing the ability to 
antagonize D2 receptors; in fact the potency of antipsychotic runs parallei 
to activity on D2 receptors (Seeman and Lee 1975). The ability of drugs to 
induce psychosis by increasing dopaminergic tone constitutes a second 
line of evidence supporting the DA hypothesis of schizophrenia. 
Amphetamine, which release DA in the brain, can induce sorne psychosis-
like symptoms in otherwise healthy individuals and trigger positive 
symptoms and relapse in remitting patients with schizophrenia (Angrist, 
Corwin et al. 1987); as well Parkinson's patients treated chronically with 
the precursor of DA L-dopa have been observed to exhibit periods of 
psychotic symptoms (Cummings 1992). Imaging studies have also 
contributed evidence in support of the DA hypothesis of psychosis. For 
one, studies investigating presynaptic DA metabolism with PET have 
shown that schizophrenia (drug-free) is associated with abnormal patterns 
of L-[l1C]dopa utilization in corticostriatal systems (Elkashef, Doudet et al. 
2000; Gefvert, Lindstrom et al. 2003); specifically results indicate that the 
synthesis of DA is elevated within the striatum and parts of medial 
pre frontal cortex in schizophrenia (Lindstrom, Gefvert et al. 1999). PET 
studies using [l1C]raclopride have also shown an exaggerated 
amphetamine-provoked DA release along with positive symptom 
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exacerbation in schizophrenia (Laruelle, Abi-Dargham et al. 1996; Breier, 
Su et al. 1997; Abi-Dargham, Cil et al. 1998; Laruelle, Abi-Dargham et al. 
1999). An extension to the DA hypothesis of schizophrenia has emerged to 
explain the negative symptoms of schizophrenia: hypofrontality lack of 
goal directed behaviors, aloofness, impaired cognitive function (working 
memory). This theory is based on the premise that schizophrenia is 
associated with a deficit in dorsolateral prefrontal cortex (DLPFC) DA 
function, presumably of neurodevelopmental origin (Weinberger 1987; 
Davis, Kahn et al. 1991; Friedman, Temporini et al. 1999). Indirect 
evidence has accumulated to support the involvement of altered 
prefrontal DA function in the pathophysiology of cognitive impairments 
associated with schizophrenia, inc1uding: decreased perfusion in frontal 
regions (Weinberger, Berman et al. 1992; Malaspina, Harkavy-Friedman et 
al. 2004), reduced tyrosine hydroxylase and length of DA transporter 
positive fibers (Akil, Pierri et al. 1999), upregulation of Dl receptors 
correlating with poor working memory (Abi-Dargham, Mawlawi et al. 
2002). In addition to possible contributions to negative symptoms and 
cognitive impairment, a deficit in prefrontal DA innervation in 
schizophrenia has been suggested to contribute to the disinhibition of 
subcortical DA (Laruelle, Abi-Dargham et al. 1996; Breier, Su et al. 1997; 
Abi-Dargham, Cil et al. 1998) through a negative feedback on VT A 
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activity (Pycock, Kerwin et al. 1980; Deutch 1990; Bubser and Koch 1994; 
Thompson and Moss 1995). 
2.7.2. ENDOGENOUS SENSITIZATION 
It has been postulated that one of the etiopathogenic processes 
involved in the emergence of positive symptoms of schizophrenia is a 
pathological form of neural plasticity. This pathophysiological model of 
schizophrenia, defined as endogenous sensitization has been put forth in a 
comprehensive review (Lieberman, Sheitman et al. 1997). This model 
builds upon the neurodevelopmental (genetic and epigenetic) theory of 
schizophrenia, which postulates that the disease is the consequence of a 
pathological process occurring in utero or early in development (perinatal) 
and proposes neurochemical sensitization has a mechanism explaining the 
late onset (early adulthood), the longitudinal course as well as the 
relapsing-remitting expression of the illness. Specifically, the illness would 
unfold in a series of stages. (1) Neuromaturational abnormalities (jetaI 
development) in synaptic connectivity in the cortex are believed to be at the 
origin of the process of endogenous sensitization. These abnormalities 
would translate into cortico-subcortical connectivity deficiency and in a 
failure of the cortex (prefrontal glutamate hyofunction) to regulate DA 
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firing. In turn, this disconnectivity would lead to an excess of subcortical 
DA, which would result in sustained hyper stimulation of D2 receptors 
making the system vulnerable to the development of sensitization. (2) 
Through the repeated failure of normal homeostatic and buffering 
mechanism, a deficient cellular adaptation to physiological events (stress) 
would occur during the prodromal phase. In other words, during this 
phase in adolescence the consequences of the disrupted neuronal system 
and of its repeated failure to inhibit DA release would progress from 
silent vulnerability to overt symptomatology (ie: the emergence of 
psychosis). (3) During the end phase the sensitization process has bec orne 
self-perpetuating leading to the development of a neurotoxic residual 
illness state. 
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Figure 3 Course of Schizophrenia. Symptom worsening is 
represented as decreasing on the y axis. Adapted from Lieberman. 
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CHAPTER III: Methodological overview 
Positron emission tomography & [l1C]raclopride. 
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s.o. POSITRION EMISSION TOMOGRAPBY • 
[l1C]RACLOPRIDE 
Positron Emission Tomography (PET) produces three-dimensional (3D) images of a biochemical process in vivo by 
combining computed tomography with the tracer kinetic assay method 
(Phelps 1991). Essentially, PET allows visualizing the distribution and 
time-course of positron-emitting radioisotopes (tissue activity time 
course); among the most commonly used positron-emitting nuclides in 
PET are llCarbon, 13Nitrogen, 150xygen and 18Fluorine. This technology 
makes use of biologically active compounds (eg.: receptor ligands) bearing 
short-lived positron-emitting isotopes, known as radiotracers and of 
appropriate mathematical models that describe the radiotracer' s kinetics. 
The use of PET radiotracers has provided tremendous promise when 
probing processes such as membrane transport, metabolism, 
neurotransmitter synthe sis and ligand-receptor interactions. PET has 
proven to be a powerful research, drug development and clinical tool, that 
can be used to elucidate the neurochemical underpinning of 
pathophysiological states, to provide diagnostic or prognostic information 
about disorders ranging from dementia and movement disorders to 
schizophrenia and drug abuse and to determine the principle of action 
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(drug kinetic, affinity and occupancy) and the efficacy of new 
pharmacotherapies. 
This chapter will introduce the basic theoretical concepts of 3D PET 
imaging with a primary focus on the use of PET for imaging the dopamine 
(DA) neurotransmitter systems (which has been described in chapter 1) to 
probe the mysteries of how drugs such as stimulants affect the brain. 
S.l. RADIOTRACBR PRODUCTION 
The first step in a PET experiment is the production of a radioactive 
isotope (radioisotope) by means of a particle accelerator known as a 
cyclotron. This machine creates radioactivity by disturbing the natural 
balance between neutrons and protons in the atomic nucleus. For 
example, the overall effect of bombarding carbon atoms with deuterons 
(ions of the stable hydrogen isotope, 2H) in the cyclotron is to transform a 
stable isotope to a neutron-deficient element, which undergoes nuclear 
decay by spontaneously emitting a positron (a particle of equal mass and 
opposite charge to that of the electron: or anti-electron). Essentially the 
energy emitted from the nuclear decay is the signal that is recorded by the 
PET camera. The radioisotope is synthetically introduced into a 
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biologically relevant precursor molecule by means of a biosynthesizer; this 
operation produces what is called a radiopharmaceuticals. 
Radiopharmaceuticals with high selectivity for a specifie class of 
neuroreceptors are conventionally called radioligands. 
3.2. PROPBRTIBS O' AN IN VIVO RADIOLIGAND 
A certain number of considerations need to be addressed before 
initiating research with a new radioligand. The standard in defining the 
suitability of a new radioligand resides not only in its selectivity for a 
receptor protein (pharmacologieal specificity) but also in a number of 
other requirements whieh, when appropriately combined insures that the 
specifie physiologie al or pharmacologieal process of interest is adequately 
and safely measured. First amongst desirable properties is the tracer' s 
brain penetrance. A radioligand must have a low molecular weigh (less 
then 400-600 Dalton) and a high degree of lipophilicity in order to pass the 
blood-brain-barrier. However excessive lipopilicity increases binding to 
plasma protein therefore reducing both brain up-take and the intra-
cerebral ratio of tracer specifically bound to the receptor pool versus that 
whieh is bound to non-specifie proteins. Thirdly, the affinity of the ligand 
should combine tight specifie binding with fast clearance from the 
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receptor compartment. In other words, optimal affinity should allow 
equilibrium between the rate of association (Kon) and the rate of 
dissociation (Koff) from receptors during the physical half-life of the 
radio isotope (Innis 2002). Fourthly, a PET ligand must have good specifie 
activity: high radioactive yield and small mass (usually < 0.01 J.lg/kg). 
Typically, but without clear consensus, the mass dose of a radioligand 
should occupancy no less then 5%, (ideally around 1 %) of the receptor 
pool to be considered an appropriate tracer, meaning one which does not 
have pharmacologie al effects. Lastly a good PET ligand should have a 
high chemical purity. Table 1 lists examples of DA-related radioligands 
that have presently reached the clinical state; this list is not an exhaustive 
list. 
Table 1 List of clinically available ligands for DA receptors 
Isotope Ligand Receptor Pharmacological 
effect 
11C N-propyl-norapomorphine D2/3 Agonist 
11C Raclopride D2/3 Antagonist 
11C / 18F Fallypride D2/3 Antagonist 
11Cj18F Spiperon Methyl-spiperone D2/3 Antagonist 
11C Pimozide D2/3 Antagonist 
11C SKF 82957 Dl Agonist 
11C SCH23390 Dl Antagonist 
11C NNC1129756 Dl Antagonist 
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3.3. RBCORDING POSITRON BMISSION 
In clinical applications, PET radioligand studies require that a very 
small amount, or a tracer dose of a radiopharmaceutical be introduced 
into the subject, usually by intravenous injection. As mentioned, 
radioisotopes are unstable and decay by a process involving positron 
emission. Briefly, positrons emitted from a decaying nucleus travels a 
short distance in the surrounding tissue before encountering a free 
electron, The two particles combine in a matter-antimatter annihilation 
from which gamma rays (511 keV each) of opposite directions emerge. 
The tomograph' s highly sensitive scintillation detectors made of dense 
crystalline materials (bismuth germanium oxide, BGO) captures the 
source of annihilation based on the external detection of coincidence rays 
between two detectors on opposite sides of the scanner. The angular and 
linear positions of the coincidence events are measured and stored into a 
sinogram (or matrix). Sophisticated algorithms are then used to 
reconstruct the sinogram data to an image that depicts the localization and 
concentration of the positron-emitting radioisotope. Only a fraction of 
gamma rays actually reach the external detectors; sorne are absorbed as 
they interact with head tissues of different density. Therefore, a 
transmission scan is performed to accurately compensate for attenuated 
photons. This static scan yields a map of the density that is then used to 
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correct the emission recording for attenuation. Figure 1 is a schematic of a 
PET experiment. 
AlI experiments that compose this thesis were performed on a 
CTI/Siemens ECAT HR + PET (Knoxville, TN) camera with lead septa 
removed to alIow for 3D acquisition. This high-resolution tomography 
with intrinsic resolution 4.8 X 4.8 X 5.6 mm FWHM provides 47 
contiguous trans-axial slices. For aIl studies data acquisition is started at 
tracer injection after a 10-minute transmission scan. Images are 
reconstructed using a 128 X 128 matrix by applying a Hanning filter with 
eut off frequency of 0.4 cycles per pixel. 
Figure 1 Schema tic representation of a Positron Emission Tomography scan 
showing the annihilation event from which gamma rays (511 keV each) emerge, and the 
detection of the signal by scintillation detectors located 1800 from each other. 
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Ultimately a full determination of the quantitative information 
available from the PET image requires a bio-mathematical kinetic model, 
which de scribes the different components in which the 
radiopharmaceutical participates and that contribute to the externally 
detected total signal. The analysis of a ligand' s kinetics is understood 
under the theoretical framework of tissue compartments. A tissue 
compartment is a physiological space in which the tracer concentration is 
assumed to be homogeneous at all times. For instance, a three-
compartment configuration has been described for brain-tissue: a blood 
compartment (Cl), an intracerebral compartment in which the tracer is 
free or nonspecifically bound (C2), and a specifically bound compartment 
(C3). The tracer's transport between compartments is described as a series 
of rate constants (K1-K4) (Figure 2). 
Figure 2 Compartmental descriptions of a radioactive tracer's concentration, up-
take, transport and clearance in brain tissue. Ca blood compartment; C2 displaceable 
compartment composed of free and non-specifically bound ligand; C3 specifically-bound 
compartment. KI rate constant from blood to tissue; K2 rate constants; KJ bimolecular 
association rate constants (Kon);"K4 dissociation rate constants (Koff). 
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Analysis of reversible radioligand binding is based on a simple 
model, called the law of mass action. The later assumes a theoretical 
relationship between occupancy and ligand concentration where the rate 
of binding is proportional to the product of the concentration of receptors 
and ligand. The change in tracer concentration in any given compartment 
can be expressed in mathematical terms as the amount of tracer entering 
and leaving per unit time. For reversible ligands i.e.: that do not form a 
covalent bounds with the receptor (like the antagonist raclopride), the 
relationship between the specifically bound and the free and non-
specifically bound tracer satisfies the Michaelis-Menten equation. Transfer 
between the bound and free compartments are expressed by the rate 
constants of association (ken) and dissociation (keff). The plot of the 
Michaelis-Menten equation illustrates that at receptor saturation the 
bound ligand is equal to the maximum number of available receptor (Bmax) 
and the receptor dissociation constant (Kd) is equal to the free ligand 
concentration at 50% of maximal binding. It is therefore assumed that 
tissue tracer concentration is related to the number of receptors to which 
the radiotracer ligand binds selectively. However, methods are required to 
di still from images of radioactivity the parameter which reflects purely the 
Process under study ie.: the binding potential of the ligand to the receptor. 
The term "binding potential" (defined as the ratio between Bmax and Kci) 
was introduced as a PET outcome measure of the capacity of a given 
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tissue for ligand-binding site interaction, since Bmax and Ki are inseparable 
in a single PET experiment (Mintun, Raichle et al. 1984). 
3.4.1. SIMPLIFIED REFERENCE TISSUE MODEL 
For experiments performed at tracer doses (high specific activity), 
the binding potential (BP) or equilibrium volume of distribution in the 
bound compartment (C3) equals the product of receptor density and 
affinity (Bmax/KD). This can be expressed as: 
Where Bmax is the total concentration of D2 binding sites, /2 the free 
fraction of radioligand in tissue, Kb the equilibrium dissociation constant 
of the radioligand, Nf the concentration of free dopamine in tissue, and 
K~ the equilibrium dissociation constant of dopamine at the D2 receptor 
(Lammertsma and Hume 1996; Gunn, Lammertsma et al. 1997). As 
mentioned above (see section 3.4) quantification of receptor kinetics have 
to be derived from the total tissue equilibrium volume of distribution (Ct 
= C2 + C3; free + bound) and requires information from an input function. 
The input from arterial blood (arterial function) can be used, however one 
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robust approach, which circumvents arterial cannulation, relies on the use 
of a reference region with a negligible presence of binding sites. This 
reference-tissue model makes the assumption that the volume distribution 
in the free compartment (C2) is constant across the brain therefore 
allowing the reduction of parameter (rate constants). Given this, the 
outcome measures (C3) can be computed indirectly by subtracting Ct of a 
reference region from Ct in regions of interest. The simplified reference 
tissue method (SRTM), frequently referred to as the Lammertsma method, 
is well documented as a robust and stable reference tissue method for the 
estimation of (11 C]radopride' s binding to D2/3 receptors after a bolus 
injection (Lammertsma and Hume 1996). In contrast to the original 
reference tissue model Lammertsma' sone-tissue compartment method 
allows additional parameter reduction (3 parameters rather than 4). 
3.5. PARAMBTBIC MAPPING 
One way to retain spatial information in the data is to apply the 
pharmacokinetic model (such as the SRTM described above) at the finest 
spatial scale, determined by the image digitization matrix - the pixel. By 
estimating a parameter at each pixel a map of the parameter spatial 
distribution, or parametric map can be made (Gunn, Lammertsma et al. 
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1997). The parametric image then contains the most complete yet succinct 
summary of the data. Parametric images can be investigated with 
statistical techniques to test the spatial difference in parameter 
distribution between conditions. A vox el-wise statistical mapping method 
using the SRTM model has been developed for dual scan subtraction 
studies (activation vs baseline). This method applies nonlinear least-
squares the ory on the scan' s dynamic information to estimate the 
parameters of the kinetic model (SRTM) and utilizes the residuals to 
calculate their associated variance; thereby increasing the number of 
degrees of freedom and providing a better estimate of the (voxel-wise) 
standard deviation (Aston, Gunn et al. 2000) (figure 3). 
8.6. ANATOMICAL DBPINITION 
Anatomical areas cannot readily be identified on PET images. In 
order to make PET-derived data (parametric BP map) anatomically 
relevant, a structural (MRI) scan from individual subjects is used and 
aligned with each subject functional PET study using computer-assisted 
image co-registration techniques such as the one developed by Collins et 
aL, (1994) (Collins, Neelin et al. 1994). Each subject participating in the 
studies that compose this thesis underwent a whole brain high-resolution 
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Tl-weighted MRI using a gradient echo pulse sequence (TR 9.7 ms, TE 4 
ms, flip angle 12°, FOV 250, matrix 256 X 256). MR images were 
corrected for image intensity non-uniformity this adjustment eliminates 
anatomy-dependent field inhomogeneity or what is called the shading 
artifact (SIed, Zijdenbos et al. 1998). Images where then linearly and non-
linearly resampled to an average MRI template (MNI average 305) in 
stereotactic space a process called spatial normalization. Images are 
automatically classified into labels of tissue type (gray matter, white 
matter, CSF, or background) and segmented into labels representing 
structural and functional anatomy (Collins DL 1995; Collins, Zijdenbos et 
al. 1999). These binary representations of anatomical and functional 
structures can then be matched to PET data. 
3.7. PARTIAL VOLUMB BnBCT 
The degree of spatial diffusion of imaged radioactivity is such that 
each point source appears spread-out, distributed over a Gaussian curve. 
In the center of the Field of View (FOV), the spatial resolution of a multi-
ring (16 rings of bismuth germanate oxide detectors) commercial PET 
scanner such as the HR + camera (Siemens / CTI, Knoxville, TN) is 4mm 
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Figure 3 From left to right, PET / MRI registration) Tl-weighted MRI 
linearly fitted to stereotaxie space (Talairach) using a standard brain 
template (MRITOTAL; MNI 305 average brain) and aligned with a single 
[llC]raclopride PET image of which the 26-frame data (60 minutes line 
graph ) has been collapsed into a single frame (MRITOPET using AIR 
algorithm; Collins et a1., 1994). MRI segmentation) Tl-weighted MRI in 
Talairach space is corrected for intensity non-uniformity and classified 
into white matter, grey matter and cerebrospinal fluid. After the 
classification, the image is segmented into anatomie al labels (ANIMAL). 
Next, the labelized image is manually reworked into specifie ROI using 
predefined criteria. Parametric map) Voxel-by-voxel application of the 
SRTM yielding BP map with SDBP maps whieh can be transformed to a 
common space (Talairach) in view of statistical analysis. t-map) Vox el-
wise t-statistie illustrating differences in radioligand binding between 
baseline and activation scans can be thresholded to statistically significant 
level and overlaid an average MRI. 
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full-width-at-half-maximum (FWHM) when operating in 3D acquisition 
mode; where FWHM indicates the distance at which two discrete point 
sources begin to be distinguishable (at half peak activity). Due to the 
limited resolution of the tomograph the measured voxel intensity in the 
PET image is the sum of the true activity at that voxel weighted by its 
regional spread function i.e.: by the loss of signal from the structure and 
contamination from adjacent brain regions (spill-over and tissue fraction 
effect). This point-spread artifact, which results in an over or under 
estimation of the true tracer activity, is called partial volume effect (PVE). 
Correction for the effect of partial volume is a crucial step to a better 
estimation of true local tissue concentration of radioactivity. The 
geometric transfer method (GTM) is an efficient and well-validated MRI-
based algorithm, which assumes homogeneous true activity across 
anatomical domains and uses binary representation of anatomical 
structures to correct for the regional spread effect (Rousset, Ma et al. 1998; 
Aston, Cunningham et al. 2002). We used a partial volume correction 
(PVC) model, which can be directly applied to the parametric image 
(Aston, Cunningham et al. 2002). This method uses a more accurate noise 
model that includes correlated and uncorrelated components, as weIl as 
error estimates (obtained from background) used for weighting in the 
subsequent kinetic fitting. 
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8.8. DIRBeT MBASURBMBNT O' DOPAMINB IN 
BUMANS 
The progression from ex vivo receptor binding methods (e.g. 
autoradiography) as me ans of exploring dopaminergic neurotransmission 
(REF), to the in vivo PET approach occurred two decades ago when the 
radiolabeled neuroleptic 3-N-[11C]methylspiperone ([l1C]NMSP) was used 
for the first time to visualize the distribution of dopamine and serotonin 
receptors in brain (Wagner, Burns et al. 1983). The imaging of neuroleptic 
drug binding in vivo therefore presented the interesting possibility of 
measuring competitive binding with endogenous neurotransmitter 
present as ligands (Friedman, DeJesus et al. 1984). Since then this non-
invasive imaging modality has allowed investigating dopaminergic 
transmission at the level of plasma membrane receptors with 1) Dl 
receptor antagonists including SCH-23390 and NNC (112 & 756) (Billard, 
Ruperto et al. 1984; Andersen, Gronvald et al. 1992); with 2) D2/3 receptor 
antagonists such as the butyrophenone (3H]spiperone and its methylated 
analog [l1C]NMSP (Leysen, Gommeren et al. 1978; Wagner, Burns et al. 
1983; Lyon, Titeler et al. 1986), the benzamide [llC]raclopride (Ehrin, 
Farde et aL 1985; Kohler, Hall et aL 1985), the high-affinity antagonist 
ligand (18F]fallypride (Mukherjee, Yang et al. 1997; Mukherjee, Yang et al. 
1999); with 3) the Dl receptor agonist SKF-82957 (Zhou, Katki et al. 1991) 
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and with 4) D2 receptor agonists, N-[llC]propyl-norapomorphine (NPA) 
and apomorphine (Seeman, Watanabe et al. 1985; Zijlstra, van der Worp et 
al. 1993). Sever al tracers also exist to map non-receptor proteins such as 
dopamine up-take sites ([llC]Cocaine, b-[l23I]CIT, FE-[1231]CIT, [1231]/ [lSF]/ 
[llC]FP-CIT, (1SF]/ [l1C]CFT, (1231]/ [llC]Altropane, [1231]/ [1lC]PE2I, and 
[llC]methylphenidate; (Aquilonius, Bergstrom et al. 1987; Kilbourn, 
DaSilva et al. 1993; Stoessl and Ruth 1998; Bergstrom, Tupala et al. 2001) 
and enzymes, (1sF]DOP A (Gjedde, Reith et al. 1991; Cumming and Gjedde 
1998). The development of these DA system ligands have made it possible 
to directly study disorders such as schizophrenia (Wong, Wagner et al. 
1986; Laruelle, Abi-Dargham et al. 1996; Abi-Dargham, Gil et al. 1998; Abi-
Dargham, Rodenhiser et al. 2000), Parkinson' s disease (Brooks 1997), 
Tourette's syndrome (Wong, Ricaurte et al. 1998), drug addiction 
(Lindsey, Gatley et al. 2003), ADHD (Rosa Neto, Lou et al. 2002; Krause, 
Dresel et al. 2003; Jucaite, Fernell et al. 2005). It has allowed to investigate 
the response to pain (Pertovaara, Martikainen et al. 2004; Martikainen, 
Hagelberg et al. 2005), the neurochemical basis of personality (Breier, 
Kestler et al. 1998; Laakso, Vilkman et al. 2000) and the role of DA in 
behaviors such as feeding (Small, Jones-Gotman et al. 2003; Volkow, Wang 
et al. 2003) gambling (Zald, Boileau et al. 2004) and playing a video game 
(Koepp, Gunn et al. 1998). Table 3 provides a list of findings that have 
emerged from using radiotracers of the DA system in human. 
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Of particular interest to the focus of this thesis is the suitability of 
the substituted benzamide neuroleptic [l1C]rac1opride to measure 
pharmacological and behavioral modulation of dopamine release in the 
intrasynaptic c1eft (for review see (Laruelle 2000). 
This agent is a D2/3-like DA receptor antagonist, which has high 
affinity and selectivity for those receptors, in low and high receptor 
affinity states. In high receptor density regions (the striatum) 
[11C]rac1opride has been shown to provide an accurate and reliable 
estimate of the D2/3 receptor density. Due to its low nanomolar receptor 
affinity and fast dissociation rate, [l1C]rac1opride is highly sensitive to 
competition from endogenous DA within the synapse (KD = 1.2 nM) 
(Kohler, Hall et al. 1985; Seeman, Guan et al. 1989) Table 2. This antagonist 
ligand competes with endogenous DA for overlapping sites on D2/3 
receptors; specifically the agonist (DA) binds in a pocket composed of the 
receptors transmembrane helices 3, 4, 5, and 6, whereas the antagonist 
binds in the same pocket but with minimal contact with transmembrane 
helix 5 (Javitch, Shi et al. 2000). Because DA shows selectivity for the 
activated receptor state and [l1C]rac1opride does not, the competition 
between the ligand and the endogenous neurotransmitter is measured at 
the level of receptors in high-affinity state (Laruelle 2000). In principle, the 
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competition model assumes that changes in endogenous DA synaptic 
levels are translated into changes in the availability of binding sites or 
binding potential (BP) for the exogenous radioligand [llC]rac1opride. 
Table 2 Characteristics of Raclopride and Dopamine as ligands for DA receptors 
Raclopride Specificity MW Affinity Lipophilicity Reference 
lM () _(Nml (Log P) 
(] ~ ~>p (Kohler, 1 ÎI D2/3 497 Hall et al. 
:"... O"CH) 
Antagonist 1.2 1.3 1985) CI 
Dopamine 
~ (Lidow, Dl and D2/3 133 4 Hydrophilic Goldman--YI Agonist Rakic et al. :"... OH 1989) H 
This model has been supported by a variety of protocols using 
[llC]rac1opride. For example, when a tracer dose of [llC]rac1opride is 
administered conjointly or following an experimental procedure that 
elevates DA, be it a pharmacological challenge with amphetamine 
(Dewey, Smith et al. 1993), cocaine (Schlaepfer, Pearlson et al. 1997), 
methylphenidate (Volkow, Wang et al. 1994), nicotine(Brody, Olmstead et 
al. 2004), ketamine (Vollenweider, Vontobel et al. 2000; Kegeles, Martinez 
et al. 2002), psilocybin (Vollenweider, Vontobel et al. 1999), an 
experimental stress challenge (Pruessner, Champagne et al. 2004)(Trier 
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mathematical challenge test, (Kirschbaum, Pirke et al. 1993) a cognitive 
task (video game) (Koepp, Gunn et al. 1998) or expectation of reward (de 
la Fuente-Fernandez, Ruth et al. 2001; de la Fuente-Fernandez, Phillips et 
al. 2002), measurements of tracer receptor occupancy reveal a reduction in 
receptor BP, relative to baseline. Conversely, depleting endogenous DA 
(a-methyl-para-tyrosine (AMPT), ~-hydroxybutyrate, reserpine, acute 
dietary phenylalanine-tyrosine depletion) leaves more receptors available 
for tracer binding (Ginovart, Farde et al. 1997; Ley ton, Dagher et al. 2003; 
Montgomery, McTavish et al. 2003; Verhoeff, Christensen et al. 2003). 
Stability and reproducibility of [l1C]raclopride have been addressed 
through test retest studies. Both long-term stability of baseline 
[llC]raclopride BP (11 months) (Hietala, Nagren et al. 1999) and within-
subject reproducibility of amphetamine-induced decrease in ligand 
binding (Kegeles, Zea-Ponce et al. 1999) have been reliably found. Table 3 
summarizes finding obtained from competition studies using 
[llC]raclopride in humans. 
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Table 3 Changes in [l1C]raclopride binding potential induced by 
challenges interfering with dopamine transmission in humans 
Subjects ROI Effect on Reference 
(n) SRTM-derived 
Challenge [llC]raclopride 
BP 
Amphetamine 14 Ventral 
-17.8 ± 13.8% (Martinez, Slifstein i.v. 0.3 mg /kg Healthy controls Striatum et al. 2003) 
16 L Ventral (Oswald, Wong et 
Amphetamine Healthy controls Striatum -10.6 ± 5.1 % al. 2005) 
i.v. 0.3 mg /kg R Ventral -9.27 ± 5.6 % 
Striatum 
Amphetamine 7 Ventral 
-14.8 ± 11.5 % (Drevets, Gautier Lv. 0.3 mg /kg Healthy controls Striatum et al. 2001) 
Amphetamine 12 Ventral 
-13%±5% (Cardenas, Houle p.o. 0.3 mg /kg Healthy controls Striatum et al. 2004) 
6 hours post- 12 Ventral (Cardenas, Houle 
Amphetamine Healthy controls Striatum -18%±6% et al. 2004) 
p.o. 0.3 mg /kg 
Methylphenidate 7 Ventral 
-18.4 ± 8.7 % (Wang, Volkow et Lv. 0.5 mg /kg Healthy controls Striatum al. 1999) 
Cocaine 11 Ventral (Schlaepfer, 
i.v48 mg. Cocaine users Striatum N.R. Pearlson et al. 1997) 
Nicotine 20 Ventral 
-25.9% to -36.6% (Brody, Olmstead 1 cigarette/ 1.1 mg Smokers Striatum et al. 2004) 
Nicotine 10 Caudate 
-21.2 to 17% (Barrett, Boileau 3 -6 cigarettes Smokers et al. 2004) 
Psilocybin 7 L Caudate -19.9 ± 5.5% (Vollenweider, Healthy controls R Caudate Vontobel et al. p.o. 0.25 mg/kg -18.6±5.4% 1999) 
Ketamine 9 Ventral (Breier, Adler et 
Lv. bolus 0.12 Healthy controls Striatum al. 1998) 
mg/kg -ll.2±8.9% 
+ 0.65 mg/kg Ih 
constant infusion 
Phenylalanine 8 Ventral (Ley ton, Dagher et 
Tyrosine depletion Healthy controls Striatum 11.8 ± 11.9% al. 2003) 
+ Amphetamine 
0.3 mg kg p.o. 
Alpha-methyl- 6 Ventral (Verhoeff, 
para-tyrosine Healthy controls Striatum 13.3 ± 5.9% Christensen et al. p.o. 5250 mg 2003) 
(29h) 
Experimental 10 Ventral (Pruessner, 
Cognitive Stress Healthy controls / Striatum -0.02 ± 4.4 Champagne et al. 
(30 min.) High and low -16.7 ± 8.6 2004) parental bon ding 
Metabolic Stress 6 Striatum -5.49 % (Adler, Elman et 
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2-deoxy-glucose Healthy controls al. 2000) 
40 mg/kg 
Gambling 10 Lateral 
-8.7 ± 11.1 (Zald, Boileau et 
monetary reward Healthy controls Putamen al. 2004) 
Video Game Healthy controls Striatum N.R. (Koepp, Gunn et 
al. 1998) 
Non-hedonic food 10 food-deprived Dorsal (Wang, Volkow 
+20mg healthy controls Caudate -10 ± 7 % et al. 2002) 
Methylphenidate 
Reward 6 Ventral (de la Fuente-Parkinson' s Striatum Fernandez, Expectancy patient ~-23% Phillips et al. Placebo 
2002) 
Yoga Nidra 8 Ventral (Kjaer, Bertelsen 
meditation Meditation Striatum -7.9 ± 7 % et al. 2002) 
teachers 
Direct measurements of amphetamine-induced DA release in 
primates using in vivo microdialysis have established a quantitative 
relationship between changes in DA release and changes in Dz BP, such 
that, for every 1 % change in BP, there appears to be a corresponding 44% 
change in synaptic DA concentration (Endres, Kolachana et al. 1997; 
Laruelle, Iyer et al. 1997). In humans, endogenous competition studies 
using amphetamine result in observations consistent with the occupancy 
model: an i.v. or oral dose of d-amphetamine (0.3 mg/kg) results in a 
15%and 10% decrease in BP (Drevets, Price et al. 1999; Ley ton, Boileau et 
al. 2002). 
Yet, the mechanisms underlying the changes in BP in response to 
changes in synaptic DA concentrations are not fully elucidated, nor are an 
the data entirely consistent with the occupancy model. It is believed that 
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G-protein-coupled receptor internalization may be invoked in the 
interaction between the radioligand and D2/3 receptors. The activation of 
these receptors by endogenous or artificial agonist ligands promotes 
multistep molecular and cellular events of which inhibition of the second 
messenger system, and desensitization and recycling of the receptors via 
phosphorylation-dephosphorylation processes (Dumartin, Caille et al. 
1998). Rapid internalization of D2/3 receptors in the endosomal 
compartment in the face of amphetamine-induced released dopamine, 
leads to fewer externalized receptors available for [11C]raclopride binding 
(Sun, Ginovart et al. 2003). Hence, the distribution of receptors in the 
external and internaI pool depends on the relative presence of the agonist. 
In vitro studies have demonstrated the occurrence of agonist mediated 
receptor internalization in sever al transfected cell lines for beta-
adrenergic, muscarinic cholinergic, serontonergic, Dl and D2/3 dopamine 
receptors, delta-opiate and 5HT-1A (Barton, Black et al. 1991) Vickery and 
Von Zastrow, 1999)(Riad, Zimmer et al. 2004; Zimmer, Riad et al. 2004). 
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PREFACE CHAPTER IV 
The following section introduces the first manuscript (study 1) included in 
the present thesis. This manuscript entitled "Amphetamine-induced increases 
in extracellular dopamine, drug wanting, and novelty seeking: a 
PETj[l1 C] raclop ride study in healthy men" has been published in 
Neuropsychopharmacology 2002; 27(6):1027-35. 
Changes in DA transmission induced by pathology or by 
pharmacological or cognitive challenges can be measured in vivo by 
recording positron emission following a [l1C]raclopride injection (see 
chapter 3). Study 1 of the present thesis was carried out in an effort to test 
the feasibility as weIl as validate the use of PET and [l1C]raclopride as a 
new tool (in our laboratory) to investigate the DA system in humans in 
vivo. This study was a necessary starting point, which served to launch 
subsequent studies investigating the nature of DA in the subjective effects 
of drugs. 
Over the years, the PET 1 (11C]raclopride technique has le ad to a 
renewal of interest with regards to the nature of DA release in drug-
reinforcement and addiction. Where basic research studying prototypic 
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addictive drugs in animal models faU short, this technical advance has 
opened the possibility to investigate the role of DA in triggering and / or 
maintenance of drug-use with relation to many human factors such as 
personality characteristics, psychological stress, subjective pleasurable 
effects, social factors, self-perceived loss of control. Imaging studies in 
humans have for the most part corroborated the importance of DA release 
in the reinforcing effects of stimulant drugs after acute pharmacological 
challenges (see chapter 1). Specifically, the reinforcing, "euphorigenic" 
effects of cocaine (Volkow, Fowler et al. 1999) and amphetamine during 
acute administration (Drevets, Gautier et al. 2001) have respectively been 
associated with the magnitude of DA transporter blockade and that of 
synaptic DA release (decreased [llC]rac1opride BP). 
In study 1 of this thesis we report that amphetamine-induced DA 
release is related to "drug-wanting" and not to "drug-liking" per se. In 
contrast to existing neuroimaging findings, which for the most have 
supported the view that DA is related to the positive / pleasurable effects 
of drugs, results to study 1 parts from this original view, in that it suggests 
that DA might have a role in driving the motivation to use drugs 
(motivational role). Study 1 of the present thesis also asks the following 
questions: Can DAergic responses to drugs explain individual differences 
in the vulnerability to addiction? Do personality factors interact with brain 
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mechanisms to influence the development of an addiction? Results 
presented in the following manuscript suggest that indeed, differences in 
personality can substantially modulate the neural (DA) response as weIl 
as the desire for stimulant drugs (" drug-wanting"). 
Although the interaction between endogenous DA levels and 
[l1C]raclopride for binding on D2/3 receptors is complex, involving both 
competitive and non-competitive mechanisms, it is believed that the 
observation of decreased [l1C]raclopride binding in the limbic striatum 
after amphetamine reported in study 1 can be interpreted has increased 
synaptic DA. Thus study 1 validates the suitability of this tool (in our 
laboratory) to investigate the effects of acute drugs on human behavior. 
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Amphetamine-Induced Increases in Extracellular Dopamine, 
Drug Wanting, and N ovelty Seeking A PET / [llC]Raclopride 
Study in Healthy Men 
Marco Leyton1, Isabelle Boileaul, Chawki Benkelfat1, 
Mirko Diksic1, Glen Baker2, Alain Dagher1 
From the Departments of Psychiatry, Neurology & Neurosurgeryl, McGill 
University, Montréal, Québec, Canada, and Department of Psychiatry2, 
University of Alberta, Edmonton, Alberta, Canada 
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ABSTRACT 
Animal studies suggest that psycho stimulant drugs preferentially 
increase synaptic dopamine (DA) levels in the ventral striatum. Individual 
variability is substantial, and might be a trait related to both novelty 
seeking and drug seeking. Here, eight healthy men had two PET 
(11C]raclopride studies, once with placebo, once with d-amphetamine (0.30 
mg/kg, p.o.). PET data were analyzed using voxel-by-voxel brain 
parametric maps to identify statistically significant clusters and manually 
drawn regions of interest (ROI). Compared to placebo, d-amphetamine 
decreased [llC]raclopride binding potential (BP) with preferential effects 
in bila ter al ventral striatum. Change in BP in the statistically generated 
cluster correlated with self-reported drug-induced drug wanting (r=0.83, 
p=O.Ol) and the personality trait of Novelty Seeking-Exploratory 
Excitability (r=0.79, p=0.02). The same associations were seen in the 
manually drawn ROI in ventral striatum but not in dorsal putamen or 
caudate. Changes in extracellular DA did not correlate with mood. 
Mesolimbic DA might mediate interest in obtaining reward rather than 
reward, pey se. 
Key words: addiction, reward, reinforcement, nucleus accumbens 
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INTRODUCTION 
Preclinical studies indicate that psychostimulant drugs increase 
extracellular dopamine (DA) levels with preferential effects in ventral 
striatum (Di Chiara and Imperato 1988). The behavioral significance of 
increased DA, though, remains a subject of debate. One influential theory 
suggests that mesolimbic DA mediates rewarding, possibly pleasurable 
effects of addictive drugs (Wise and Bozarth 1982). Other work suggests 
that DA signaIs interest in rewards (Stewart 1984), the expectation that a 
reward is forthcoming (Schultz 1998)or wanting reward as opposed to 
liking it (Robinson and Berridge 1993). 
Significant individual variability in stimulant drug-induced DA 
release is apparent. Sorne evidence suggests that this variability reflects a 
pre-existing trait. Predictors of the variability include elevated exploratory 
behavior in novel environments (Hooks, Jones et al. 1991)high levels of 
sugar feeding (Sills and Crawley 1996) and a predisposition to rapidly 
acquire drug self-administration (Zocchi, Orsini et al. 1998). 
In humans, psychostimulant drugs of abuse elicit a range of 
behavioral effects, including mood elevation and increased drug wanting 
(Uhlenhuth, Johanson et al. 1981; Jaffe, Cascella et al. 1989; Cousins, 
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Stamat et al. 2001). Functional neuroimaging studies with labeled D2/3 
benzamide ligands suggest that relatively high d-amphetamine doses (0.2 
- 0.3 mg/kg, given i.v.) increase extracellular DA levels in human 
striatum (Laruelle, Abi-Dargham et al. 1995; Breier, Su et al. 1997; Drevets, 
Gautier et al. 2001). The magnitude of the drug-induced DA release 
correlates with the self-reported euphoria (Laruelle, Abi-Dargham et al. 
1995; Drevets, Gautier et al. 2001); however, it remains unclear whether 
the mood-elevation is mediated by DA or instead reflects other effects of 
the drug. High amphetamine doses increase both catecholamine and 
serotonin release whereas lower doses primarily increase catecholamines 
(Kuczenski and Segal 1989). Mood-elevating effects of cocaine are 
reported to be reduced by lowering serotonin transmission (Aronson et al 
1995). In comparison, stimulant drug-induced mood elevation is not 
decreased consistently by DA antagonists (Brauer and De Wit 1997). 
The present study addressed three questions. First, could a 
relatively low oral dose of d-amphetamine elicit detectable changes in 
[llC]raclopride binding? Second, would the effect on extracellular DA be 
larger in ventral than dorsal striatum? Third, would amphetamine-
induced increases in extracellular DA be related to drug-induced drug 
wanting, drug-induced mood-elevation, or the personality trait of novelty 
seeking? 
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METHODS 
SUBJECTS 
Eight non-smoking men (Table 1) were recruited using newspaper 
advertisements. AlI were healthy, as determined by a physical exam, 
standard laboratory tests, and an interview with the SCID-NP. None had a 
personal or first-degree relative history of axis 1 psychiatrie disorders. On 
the day of each PET scan, all tested negative on a urine drug sere en 
sensitive to cocaine, opiates, PCP, LSD, THC and amphetamines (Triage 
Panel for Drugs of Abuse). The study was carried out in accordance with 
the Declaration of Helsinki and was approved by the Research Ethics 
Committee of the Montreal Neurological Institute. AlI subjects gave 
informed written consent. 
PET ANDMRI 
AlI subjects were scanned with an ECAT HR+ tomograph 
(CTIjSiemens). 3D dynamie images were blurred to 4.2 mm FWHM in the 
transaxial direction using a Hanning filter. Prior to tracer injection, 
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transmission scans were performed using 68Ga for attenuation correction. 
Sixt Y minutes before tracer injection ([l1C]raclopride, 10mCi, 2-min bolus), 
an intravenous catheter was inserted into the subject' s arm, and an oral 
dose of d-amphetamine was administered (0.0 or 0.3 mg/kg). PET studies 
were conducted between 14:00 and 17:00. 
Each subject underwent a magnetic resonance imaging (MRI) scan 
(160 slices, 1 mm thiek) obtained with a Philips Gyroscan (1.5 Tesla). Each 
MRI was linearly re-sampled, transferred into standard stereotaxie space, 
co-registered to each subject' s PET images (Collins, Neelin et al. 1994), and 
then transferred into Talairach space (Talairach and P 1988). 
Voxelwise [l1C]raclopride binding potential (BP=Bmaxfree/Kd) was 
calculated to generate parametric images (Gunn, Lammertsma et al. 1997). 
t-Maps were then constructed, representing voxel-by-voxel t-tests of 
change in (11C]raclopride BP between the amphetamine vs. placebo scans 
(Aston, Gunn et al. 2000). Clusters of voxels with a t > 4.2 were considered 
statistically significant. BP values for each subject were extracted from the 
region identified by the t-map as well as from a priori identified regions of 
interest (ROI). ROI were drawn manually on aligned transverse slices 
from each subject' s MRI in stereotaxie space on caudate nucleus, dorsal 
putamen, and ventral striatum bilaterally. The boundaries for each ROI 
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were labeled well within the gray matter of the structure to reduce artifact 
due to misalignment or partial volume effects (Figure 1). The rostrocaudal 
extent of the ROI relative to the anterior commissure was approximately 
the same for all subjects, z ::;; 2 to 15 mm for dorsal caudate, z ::;; 2 to 10 mm 
for dorsal putamen, and z ::;; -4 to -8 mm for ventral striatum, 
corresponding approximately to nucleus accumbens (Talairach and P 
1988). Left and right ROI values were combined. ROI drawn on five 
consecutive 1 mm slices in cerebellum served as the reference region. 
SUBJECTIVE EFFECTS OF AMPHETAMINE 
Subjective effects induced by d-amphetamine were measured with 
the Addiction Research Center Inventory (ARCI) Benzedrine scale 
(Haertzen, Hill et al. 1963), and 10 visual analog scales (VAS) labeled 
Want Drug, Like Drug, Euphoria, Mind Racing, Alert, Energetic, Excited, 
Rush, Anxiety, and High (Bond and Lader 1974). The VAS were 
administered at five time points, immediately before drug (or placebo), 
and at 30, 60, 90 and 120 minutes after drug. Changes in VAS measures 
were analyzed as the peak change from pre-drug administration to the 
end of the test session. The ARCI was administered only once each 
session, 120 minutes post-drug. 
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TRIDIMENSIONAL PERSONALITY QUESTIONAIRE 
AlI subjects completed the Tridimensional Personality 
Questionnaire (TPQ; (Cloninger 1987; Cloninger, Przybeck et al. 1991). 
The TPQ measures four dimensions, novelty seeking, harm avoidance, 
reward dependence, and persistence. Cloninger has proposed that TPQ 
traits of novelty seeking, harm avoidance, and reward dependence are 
mediated in significant part by activity in dopamine, serotonin and 
norepinephrine pathways, respectively. 
PLASMA AMPHETAMINE 
Blood samples were drawn immediately before d-amphetamine 
administration and 90 minutes later, which corresponded to the mid-point 
of the 60-min PET scan. Plasma concentrations of amphetamine were 
analyzed with gas chromatography (Paetsch, Baker et al. 1992). 
STATISTICS 
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Plasma d-amphetamine concentrations, self-report questionnaire 
data, and [l1C]raclopride region of interest (ROI) BP values were analyzed 
by within groups ANOVAs and, when appropriate, Newman-Keuls post 
hoc tests. Correlations were assessed with Pearson' s correlation coefficient. 
RESULTS 
On the day that subjects received active drug, plasma levels of d-
amphetamine increased from O.O±O.O ng/ ml before drug administration to 
10.5±8.2ng/mI90 minutes later corresponding to the mid-point of the PET 
scan (p :;;:; 0.001). d-Amphetamine was not detected on the placebo test day. 
ARCI scores were significantly higher on the d-amphetamine test 
day compared to placebo (p :;;:; 0.02). d-Amphetamine, compared to 
placebo, also lead to significantly greater peak changes on V AS labeled 
Alert (p:;;:; 0.002), Mind Racing (p :;;:; 0.003), Energetic (p :;;:; 0.01), and Excited 
(p :;;:; 0.03) (Table 2). 
[l1C]Raclopride BP values varied with both region of interest (ROI) 
and drug administration. A drug x ROI ANOV A yielded significant main 
effects of drug (F(l,7) :;;:; 55.6, P < 0.001) and ROI (F(2,14) :;;:; 31.2, P < 0.0001), 
and a significant drug x ROI interaction (F(2,14):;;:;8.96, p :;;:; 0.003). As seen 
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in post-mortem and previous PET studies (Hall, Sedvall et al. 1994; 
Mawlawi, Martinez et al. 2001), [llC]raclopride BP values were 
significantly lower in ventral striatum, compared to dorsal caudate and 
putamen (p < 0.001) and this was evident on both the placebo and 
amphetamine test days (p < 0.001) (Table 3). 
d-Amphetamine significantly decreased [llC]raclopride BP in 
ventral striatum (p = 0.05) but not in dorsal cau date (p = 0.68) or putamen 
(p = 0.96) (Table 3). The same regional specificity was seen when change 
in BP was calculated as percent change from the placebo test day (F(2,14) 
= 6.01, P = 0.01). The change in BP was significantly greater in ventral 
striatum (-10.7±9.5%) than in dorsal caudate (-1.5±9.3%, p = 0.02) or 
putamen (0.4±9.0, p :;:: 0.02). Parametric mapping analyses yielded the 
same results. Compared to placebo, a significant effect of d-amphetamine 
on [l1C]raclopride BP was restricted to bilateral ventral striatum (Peak 
Effect: x, y, z :;:: 32.1, -3.2, -6.5, t = 7.34) (Figure 2). In this t-map identified 
cluster there was a mean -8.4±19.6% decrease in [llC]raclopride BP. 
Inter-regional correlations suggested that the effect of d-
amphetamine on extracellular DA was qualitatively as well as 
quantitatively different in ventral vs. dorsal striatum. The change in 
[l1C]raclopride BP in dorsal caudate and putamen correlated with each 
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other (r2 = 0.88, P < 0.001) but not with changes in ventral striatum or the 
t-map (p > 0.70). In comparison, there was a significant correlation 
between change in [l1C]radopride BP in the t-map identified dus ter and 
the manually drawn ventral striatum (r2 = 0.67, P = 0.01) supporting the 
proposition that both methods of analysis identified the same changes in 
tracer binding. Finally, there was a non-significant trend for oIder age to 
be associated with reduced d-amphetamine-induced changes in 
[l1C]radopride BP in the ventral striatum (r2 = -0.46, P = 0.06) yet not in 
other regions (p > 0.20). d-Amphetamine-induced changes in 
[l1C]radopride BP in the ventral striatum correlated significantly with two 
TPQ items, overall Novelty Seeking (r2 = 0.56, P = 0.03) and the Novelty 
Seeking subscale, Exploratory Excitability (r2 = 0.55, P = 0.05). Associations 
with changes in BP in the t-map identified region were similar ( 
Table 4 and Table 3). Change in BP in ventral striatum did not 
correlate significantly with any other TPQ scale or subscale (p > 0.10). 
Change in [l1C]radopride BP in dorsal caudate or putamen did not 
correlate with any TPQ scale or subscale (p > 0.10). d-Amphetamine-
induced increases in extracellular DA in the ventral striatum correlated 
significantly with only one reported effect of the drug, V AS Want Drug on 
the d-amphetamine test day (t-Map: r2 = 0.69, p = 0.01; ROI: r2 = 0.38, P = 
0.10) ( 
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Table 4; Figure 4) and Novelty seeking and drug-induced drug 
wanting were significantly correlated with each other. TPQ Exploratory 
Excitability predicted drug wanting on the drug administration test (r2 = 
0.74, P = 0.006), an association not seen on the placebo test (r2 = 0.004, P = 
0.89). 
Drug-induced change in extracellular DA in dorsal caudate and 
putamen correlated negatively with a one reported effect of the drug, V AS 
mind racing (dorsal caudate: r2 = -0.70, P = 0.009; dorsal putamen: r2 = -
0.55, P = 0.03); however, these negative correlations - not expected a priori 
- were driven by a single outlier, and the associations were no longer 
significant when the point was removed (dorsal caudate: p > 0.15; dorsal 
putamen: p > 0.65). Change in BP did not correlate significantly with any 
other self-report variable. 
DISCUSSION 
The present study suggests that (i) a moderately low oral dose of d-
amphetamine (0.3 mg/kg) significantly increases extracellular DA in 
human striatum, (ii) this effect of d-amphetamine occurs preferentially in 
ventral striatum, (iii) d-amphetamine-induced increases in extracellular 
DA are more closely related to drug-induced drug wanting than mood-
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elevation, and (iv) the personality trait of novelty seeking predicts greater 
amphetamine-induced DA release and amphetamine-induced drug 
wanting. A non-significant trend (p = 0.06) suggested that the ability of d-
amphetamine to induce DA release in ventral striatum might decrease 
from age 20 to 30. 
The effed of 0.3 mg/kg, given p.o. on (11C]raclopride BP was 
smaller and more circumscribed than that reported to occur when the 
same dose is given intravenously. d-Amphetamine, 0.3 mg/kg, p.o. 
decreased [l1C]raclopride BP in the ventral striatum by an average of 10%; 
significant changes were not seen in dorsal caudate or putamen. In 
comparison, the same dose of d-amphetamine given i.v. decreases 
[l1C]raclopride BP by 10-20% in striatum as a whole (Breier, Su et al. 1997); 
(Drevets, Gautier et al. 2001). A recent report suggests that 0.3 mg/kg d-
amphetamine given i.v. also has larger effeds on [l1C]raclopride BP in the 
ventral striatum than other subcompartments (anteroventral striatum, -
15.4±10.6%; dorsal putamen, -10.2±10.6%; dorsal caudate, -4.5±8.2%) 
(Drevets, Gautier et al. 2001). The present study with a low oral dose more 
clearly identifies preferential effeds in ventral striatum, and this regional 
specificity is supported by both manually drawn ROI and statistically 
generated clusters. 
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There was substantial individual variability in the ability of d-
amphetamine to decrease [l1C]raclopride BP. This variability in 
extracellular DA in ventral striatum was associated with variability in self-
reported drug-induced drug wanting. To our knowledge, previous 
neuroimaging researchers have not assessed the association between DA 
release and drug wanting. In comparison, PET and fMRI studies suggest 
that both cue and drug-induced activation of the ventral striatum and 
interconnected limbic regions correlates with drug craving in cocaine 
dependent subjects (Grant, London et al. 1996; Breiter, Gollub et al. 1997; 
Childress, Mozley et al. 1999; Kilts, Schweitzer et al. 2001). Moreover, 
accumulating findings in the animal literature also suggest a close 
association between mesolimbic DA transmission and interest in addictive 
drugs (Marinelli and White 2000). Midbrain DA cell firing rates (Schultz 
1998) and extracellular DA levels in nucleus accumbens (Gratton 1996) 
increase as animaIs approach rewards. Low to moderate doses of DA 
agonists increase drug-seeking behavior (Stewart 1984; Robinson and 
Berridge 1993). A larger DA response to acute stimulant drug 
administration predicts more rapid acquisition of drug self-administration 
(Zocchi, Orsini et al. 1998). 
The magnitude of amphetamine-induced increases in extracellular 
DA in ventral striatum also correlated with the personality trait of novelty 
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seeking. Evidence of an association between TPQ novelty seeking and 
pharmaconeuroendocrine indices of DA neurotransmission has been 
reported (Gerra, Zaimovic et al. 2000). Since individuals at elevated risk 
for substance abuse have elevated Novelty Seeking scores (Howard, 
Kivlahan et al. 1997i Gabel, Stallings et al. 1999), this vulnerability might 
be related, in part, to an increased DA response to abused drugs. Novelty 
seeking, like risk for substance abuse, decreases with age (Jones and 
Meredith 1996). 
Novelty seeking scores significantly predicted VAS drug wanting 
on the amphetamine but not placebo test day. One possibility is that 
amphetamine elicits a DA-mediated appetitive state that increases drug 
wanting. Susceptibility to drug-induced drug wanting might be related to 
a neurobiological trait predisposing to larger DA responses to stimulant 
drugs and to a personality trait of high novelty seeking. Animal studies 
suggest that novelty seeking behavior predicts the nucleus accumbens DA 
response to cocaine (Hooks, Jones et aL 1991) and propensity to self-
administer amphetamine (Piazza, Deminiere et al. 1989). 
Amphetamine-induced DA release did not correlate with self-
reported mood-elevation or overt stimulant effects of the drug. Sorne 
evidence suggests that psychostimulant and mood-elevating drug effects 
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might be more closely related to increases in norepinephrine (Rothman, 
Baumann et al. 2001) and serotonin (Aronson, Black et al. 1995) than DA 
transmission. Previously reported correlations between euphorigenic and 
DA releasing effects of intravenous amphetamine (Laruelle, Abi-Dargham 
et al. 1995); (Drevets, Gautier et al. 2001) might be related to the ability of 
higher doses to release all three monoamines (Kuczenski and Segal 1989). 
The present study does not preclude a relation between DA and affect, 
though. Other evidence supports such an association (Murphy, Brodie et 
al. 1971; Depue and Iacono 1989). One possibility is that DA influences 
mood via its regulation of motivational states. The present study suggests 
that mesolimbie DA transmission might be more closely related to the 
appetitive component of emotion than providing a sufficient substrate of 
euphorie mood, pey se. 
The neuroanatomieal pathways innervating ventral vs. dorsal 
striatum are well-described (Lynd-Balta and Haber 1994; Haber and 
McFarland 1999). In primates, the ventral striatum is interconnected with 
the limbic system and receives DA projections primarily from the dorsal 
tier of the midbrain tegmentum. Additional input to the ventral striatum 
cornes primarily from limbie structures including amygdala, anterior 
cingulate and the medial and orbitofrontal cortex; these systems are 
thought to play important roles in associating behavior with reward, 
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attention to affectively relevant stimuli, and the initiation and inhibition of 
responses to rewards and punishments. In comparison, DA projections to 
the dorsal caudate-putamen come primarily from the ventral tier of 
midbrain DA cell bodies. Descending cortical inputs come primarily from 
sensory-motor cortices and the dorsolateral prefrontal cortex. 
In the present study, d-amphetamine did not significantly decrease 
[l1C]raclopride BP in the dorsal caudate or putamen; however, substantial 
individual variability was apparent and the changes correlated positively 
and significantly with each other. These changes did not, however, 
correlate with changes in ventral striatum or with drug-induced drug 
wanting or novelty seeking. These observations are consistent with the 
evidence that DA release in dorsal vs. ventral striatum is differentially 
regulated, and suggest further that DA release in human striatal sub-
compartments has different behavioral significance. 
The conclusions suggested by the present study should be 
interpreted in light of the following considerations. The sample size is 
modest (n=8) though within the norms for assessing effects of 
pharmacological challenges within subjects. The identified correlations 
would not have withstood Bonferroni corrections, but they were 
replicated in ventral striatum as identified by two methods, parametric 
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mapping and manually drawn ROI. Second, as typically seen, only half of 
the subjects indicated that they wanted more of the drug (Uhlenhuth, 
Johanson et al. 1981). However, it was this individual variability that 
correlated with change in [l1C]raclopride BP. Third, the mechanisms 
mediating preferential increases in extracellular DA in the ventral 
striatum remain unclear. Sorne evidence, though, suggests that the effect 
might be related to slower DA release or uptake V max (Cas s, Gerhardt et al. 
1992; Wu, Reith et aL 2001). Fourth, recent studies have questioned the 
mechanisms by which DA agonists decrease labeled D2 ligand BP. The 
original model had proposed competition between the labeled ligand and 
endogenous DA for occupancy of the DA D2 receptors (Seeman, Guan et 
al. 1989) More recent work raises the possibility that increased synaptic 
DA levels might alter monomer to dimer ratios (Logan, Fowler et aL 
2001)and / or induce receptor internalization (Laruelle 2000). Benzamide 
ligands, though, bind to both monomers and dimers (Zawarynski, 
Tallerico et aL 1998), and may not cross the cell membrane thereby 
restricting their access to cell surface receptor sites (Laruelle 2000; Seeman 
and Kapur 2000). Moreover, combination PET-microdialysis studies 
conducted in the same animal indicate that decreases in benzamide ligand 
BP have a strong linear association with increases in dialysate DA 
concentrations (Endres, Kolachana et aL 1997; Laruelle, Iyer et aL 1997). 
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These observations suggest that decreases in [llC]raclopride BP in the 
same individual can be considered to reflect increases in extracellular DA. 
In conclusion, the small sample size emphasizes the need for 
caution but the present results suggest that DA transmission in sub-
compartments of human striatum is differentially affected by 
amphetamine and has different behavioral significance. First, a low oral 
dose of d-amphetamine increased extracellular DA with preferential 
effects in ventral striatum. Second, there was a close association between 
three variables, (i) the personality trait of novelty seeking, (ii) 
amphetamine-induced drug wanting, and (iii) individual susceptibility to 
amphetarnine-induced DA release in ventral striatum. Both novelty 
seeking and drug-induced drug wanting might be related to susceptibility 
to drug seeking behavior and be predictive of vulnerability to substance 
abuse. 
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Table 1 Subject charaderistics. 
Age 
Current alcohol use (drinks / week): 
Lifetime drug use (ever used, mean±SD) 
Stimulants 
Tranquilizers 
Hallucinogens 
Opiates 
THe 
Novelty Seeking 
Beck Depression Score 
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23.8±4.1 (range, 19 - 30 
1.97±1.4 (range, 0.25 - 5) 
5/8, 3.1±5.0 (range, 0-15) 
0/8 
5/8, 1.25±1.3 (range, 1-3) 
1/8, 0.12±0.4 (range, 0-1) 
7/8, 13.0±14.0 (range, 0-40) 
13.0±4.5 (range, 13 - 27) 
3.0±2.7 (range, 0 - 8) 
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Figure 1 One subject's [l1C]raclopride binding potential map (right striatum) for 
the first scan day transformed to Talairach space and overlaid on his MRI in Talairach 
space. Regions of interest drawn on the same subject's MRI (left striatum) in Talairach 
space. Red: Ventral Striatum / Nucleus Accumbens (z: 8 to 4), Blue: Putamen (z: 2 to 10), 
Green: Caudate (z: 2 to 15). 
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Table 2 Effect of d-amphetarnine (0.0, 0.3 mg/kg, p.o.) on Addiction Research 
Center Inventory (ARC!) Scores and Visual Analog Scales (max). Effects Assessed with 2-
Tailed Repeated Measures t-tests. 
Placebo Amphetamine 
(Mean ± SD) (Mean ± SD) p-value 
ARCI 4.6±4.2 11.8 ± 10.2 .02 
Visual Analog Scale 
Alert -1.5 ± 1.9 1.8± 2.2 .002 
Mind Racing 0.25 ± 1.2 2.4± 2.0 .003 
Energetic -1.2 ± 1.5 2.0 ± 1.7 .01 
Excited 0.0 ± 0.9 1.9 ± 1.7 .03 
Euphoria 0.0 ± 0.8 1.4 ± 1.8 .09 
Rush -0.1 ± 0.6 1.6 ± 2.6 .13 
Like Drug -0.2 ± 1.8 1.4 ± 3.0 .17 
High 0.2 ± 1.6 1.2 ± 2.1 .41 
Want Drug 0.6 ± 1.1 1.4± 2.5 .46 
Anxietu 0.2 ± 1.0 0.6 ± 1.4 .53 
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Table 3 [l1C]Raclopride binding potential values on test days with placebo or d-
amphetamine (0.3 mg/kg, p.o.). Newman-Keuls post hoc tests. 
Test Day 
Placebo 
d-Amphetamine 
Ventral Striatum 
1.44 ± 0.5t 
1.26 ± O.4#t 
#Different from placebo, p .05. 
* Different from ventral striatum, p .001. 
t Different from caudate, p .001. 
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Cau date 
1.97 ± 0.2* 
1.94 ± 0.2* 
Putamen 
2.45 ± 0.3*t 
2.45 ± 0.3*t 
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Figure 2 Statistically generated t-map of d-amphetamine-induced changes in 
[l1C]raclopride binding potential superimposed on average MRI. Right side on right. 
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Table 4 Pearson correlations with change in [l1C]rac1opride binding potential. 
ROI Want NS NS-l HA RD RD-2 
Drng 
t-Map 0.83** 0.43 0.79* 0.06 0.06 0.01 
Ventral 0.62t 0.75* 0.74* 0.16 0.03 0.28 
Striatum 
Cau date 0.14 0.13 0.08 0.25 0.13 0.24 
Putamen 0.19 0.09 0.09 0.34 0.07 0.14 
t P .10, * P .05, ** P .01. 'Want Drug': Self-reported drug wanting on the amphetamine 
administration test day. t-Map: statistically generated c1uster of change; NS: Novelty 
Seeking; NS-l: Exploratory-Excitability; HA: Harm Avoidance; RD: Reward Dependence; 
RD-2: Persistence 
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Figure 3 Correlations between d-amphetamine-induced increases in extracellular DA 
and Novelty Seeking and the Novelty Seeking subscale, Exploratory-Excitability. 
[l1C]Rac1opride BP values were extracted from two regions, the manually drawn region 
of interest in ventral striatum and the statistically generated parametric t-map, 
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Figure 4 Correlation between d-amphetamine- induced drug wanting and (left) 
d-amphetamine-induced DA release, and (right) TPQ Novelty Seeking-Exploratory 
Excitability scores. 
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PREFACE CHAPTER V 
The following section introduces the second manuscript (study 2) 
included in the present thesis. This manuscript entitled "Alcohol promo tes 
dopamine release in the human nucleus accumbens" has been published in 
Synapse 2003; 49(4): 226-31. 
A central concept in drug addiction research is that although drugs 
of abuse are chemically divergent with different initial molecular targets, 
their action in the brain must converge since addictions to most if not all 
drugs share strikingly similar features. The ability of addictive drugs to 
strongly activate DA neurotransmission in the limbic striatum is believed 
to be a key feature of this common path to addiction. In this regard, most 
drug commonly abused by humans have been shown to trigger a supra 
physiological increase in DA level in the nucleus accumbens. This event is 
(for the least) thought to initiate the process of addiction. Although 
neuroimaging studies from different groups have provided direct 
evidence that psychostimulants directly increase DA release in the 
striatum, evidence that this observation extends to drugs of abuse 
belonging to different pharmacological classes is still sparse - in fact 
results presented in the following manuscript provide the first evidence 
that alcohol, one of the most widely used and abuse drugs, promotes DA 
release in humans. 
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The general aim of the second study (study 2) inc1uded in the 
present the sis was to investigate DA release with neuroimaging, during 
the administration of an intoxicating dose of alcohol in moderate drinkers. 
In study 2 of this thesis we report that alcohol promotes DA release in 
humans. Specifie regional effects are strikingly similar to the effects of 
amphetamine reported in study 1, in that release appears to be 
preferential in the ventral striatum. A high heart-rate response to alcohol 
is believed to be a risk factor in the development of alcohol use. In line 
with the hypothesis that alcohol induced heart-rate increase represents a 
reinforcing state, which involves dopaminergic transmission, we report a 
positive relationship between DA release and this measure. In this study 
we also investigated individual differences in the responsiveness of the 
DA system to alcohol and found reactivity to alcohol was potentiated in 
those with high impulsivity trait. 
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Aicohoi promotes Dopamine release in the 
Human Nucleus Accumbens. 
Isabelle Boileau1 MSc, Jean-Marc Assaad2,4 PhD, Robert O. PihF PhD, 
Chawki Benkelfat:3 MD, Marco Leyton3 PhD, Mirko Diksic1 PhD, Richard 
E. Tremblay4 PhD, Alain Dagher1 MD. 
1: McConnell Brain Imaging Centre, Montreal Neurological Institute, 
McGill University, Montréal, QC, Canada. 
2: Department of Psychology, McGill University, Montréal, QC, Canada. 
3: Department of Psychiatry, McGill University, Montréal, QC, Canada. 
4: Research Unit on Children's Psychosocial Maladjustment, Université de 
Montréal, Montréal, QC, Canada. 
Key words: Alcohol, Dopamine, PET, [l1C]raclopride, Nucleus 
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ABSTRACT 
Microdialysis experiments in rodents indicate that ethanol promotes 
dopamine release predominantly in the nucleus accumbens, a 
phenomenon that is implicated in reinforcement by drugs of abuse. The 
aim of the present study was to test the hypothesis in humans that an oral 
dose of ethanol would lead to dopamine release in the ventral striatum, 
including the nucleus accumbens. Six healthy subjects underwent two 
[l1C]raclopride PET scans following either alcohol (lm1/kg) in orange 
juice or orange juice alone. Subjective mood changes, heart rate and blood-
alcohol levels were monitored throughout the procedure. Personality 
traits were evaluated using the Tridimensional personality questionnaire. 
PET images were co-registered with MRI and transformed into stereotaxic 
space. Statistical parametric maps of [l1C]raclopride binding potential 
change were generated. There was a significant reduction in 
[l1C]raclopride binding potential bilaterally in the ventral striatum / 
nucleus accumbens in the alcohol condition compared to the orange juice 
condition, indicative of increased extra-cellular dopamine. Moreover, the 
magnitude of the change in [l1C]rac1opride binding correlated with the 
alcohol-induced increase in heart rate, which is thought to be a marker of 
the psycho stimulant effects of the drug. The present study is the first 
report that, in humans, alcohol promotes dopamine release in the brain, 
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with a preferential effect in the ventral striatum. These findings support 
the hypothesis that mesolimbic dopamine activation is a common 
property of abused substances, possibly mediating their reinforcing 
effects. 
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INTRODUCTION 
Addiction is thought to result in large part from the reinforcing 
properties of drugs of abuse on brain reward systems, and in particular on 
mesolimbic dopamine (Wise and Rompre 1989; Koob, Sanna et al. 1998). 
Microdialysis studies in rats show that ethanol and other drugs of abuse, 
such as opiates, nicotine, amphetamine, and cocaine, acutely increase 
extracellular dopamine levels predominantly in the nucleus accumbens 
(NAc) (Di Chiara and Imperato 1988). The role of NAc dopamine in 
alcohol self-administration is further supported by reports of changes in 
consumption following alterations in mesolimbic dopamine 
neurotransmission (Rassnick, Krechman et al. 1993; Samson and Hodge 
1993; Nowak, McBride et al. 2000) ethanol self-administration into the 
ventral tegmental area (VTA) (Gatto, McBride et al. 1994) and alcohol 
withdrawal-induced reductions in both dopamine neuron firing and NAc 
extra-cellular dopamine concentration (Diana, Gessa et al. 1992; Rossetti, 
Hmaidan et al. 1992)that are reversed by ethanol administration (Weiss, 
Parsons et al. 1996) 
Alcohol is widely abused by humans; however no studies have 
directly investigated the implication of the dopamine system in mediating 
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sorne of its reinforcing effects. We now present, for the first time in 
humans, evidence that alcohol consumed orally promotes dopamine 
release specifically in the NAc. 
We measured dopamine release in response to a single-dose 
administration of alcohol using positron emission tomography (PET) and 
the dopamine receptor ligand [l1C]raclopride. We used a two-scan method 
based on combined PET microdialysis evidence in primates that the 
binding of benzamides such as [l1C]raclopride is sensitive and 
proportional to extra-cellular dopamine concentration in the striatum 
(Endres, Kolachana et al. 1997; Laruelle, Iyer et al. 1997). This approach 
has been used in humans to measure the dopamine response to 
psychostimulants (Carson, Breier et al. 1997; Schlaepfer, Pearlson et al. 
1997) (Volkow, Wang et al. 2001), and behavioural tasks (Koepp, Gunn et 
al. 1998). Two recent PET studies have also shown that dopamine release 
following amphetamine occurs mostly in the ventral striatum, and that the 
amount of dopamine released correlates with self-reported behavioural 
measures of euphoria or drug wanting (Drevets, Gautier et al. 2001; 
Ley ton, Boileau et al. 2002). 
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MATERIALS AND METHODS 
Seven healthy non-alcoholic, non-abstinent males, moderate 
drinkers (brief Michigan Alcoholism Screening Test; (Pokorny, Miller et al. 
1972) aged 22 (± 0.6) were recruited from an existent longitudinal cohort 
(Tremblay, Pihl et al. 1994) and included in the study if they had 
experienced the alcohol dose required for participation in this study at 
least twice in a laboratory setting. Data from one of the seven subjects had 
to be excluded due to excessive motion during the scan. AU subjects were 
free of active or past medical or psychiatric illness. Subjects fasted and 
abstained from caffeine or tobacco for a minimum of four hours before 
each test session. Five of the six subjects were non-smokers and one was a 
light smoker (1-2 cigarettes per day). They were also asked to refrain from 
taking drugs for seven days and alcohol for 24 hours prior to each 
experimental day. Before each scanning session, subjects underwent 
screening for drugs of abuse (Triage Panel for Drugs of Abuse, Biosite 
Diagnostics, San Diego, CA) including alcohol (Alcosensor III 
intoxicometer, Thomas Instruments, Montreal, QC). AlI subjects read and 
signed a consent form approved by the Research and Ethics Committee of 
the Montreal Neurological Institute. 
Subjects participated in two [l1C]raclopride PET scans after 
consumption of alcohol in orange juice or orange juice alone (Figure 2). 
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Subject were told about drink content at the beginning of the session, 
however, to reduce the possible effect of alcohol associated olfactory cue, 
particular attention was made to avoid subject' s contact with alcohol 
vapour before the beginning of consumption. PET data acquisition was 
performed at the same time of day (between 14:00 and 16:00) on separate 
days, one week apart, and counterbalanced for order of administration of 
alcohol (three out of six received alcohol on the first day, randomly 
chosen). Prior to scanning, a venous catheter was inserted in the subject' s 
left arm. Oral consumption of alcohol (lmlfkg of 95% USP alcohol over 15 
minutes) or alcohol-free mixture started 30 minutes prior to tracer 
injection. At the end of consumption, subjects were immediately 
positioned in the scanner and a 12-minute transmission scan was acquired 
using a 68Ge source for the purpose of attenuation correction. Following 
the transmission scan, and 15 minutes after the end of alcohol 
consumption, [l1C]radopride 10 mCi was injected as a bolus into the 
antecubital vein, after which PET dynamic acquisition (63 slices, 26 time 
frames of 60 minutes total duration) was performed. 
Subjects were scanned on the CTIjSiemens ECAT HR+ PET camera 
with lead septa removed, with intrinsic resolution 4.2 mm FWHM. Blood 
samples, for plasma alcohol measurements, were withdrawn from the 
venous cannula before the initiation of drinking, at tracer injection (15 
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minutes after finishing drinking), and every 15 minutes thereafter. 
Subjective effects of alcohol, assessed with the Subjective High 
Assessment Scale (SHAS; Schuckit and Smith 1997) and heart rate were 
measured prior to alcohol consumption and throughout the procedure. 
The SHAS is a visual analog sc ale that asses ses sensations such as feeling 
high, drunk, and drowsy. Prior to the first scan, an subjects completed the 
Tridimensional personality questionnaire (TPQ; Cloninger, Przybeck et al. 
1991). This test asses ses three dimensions of personality including novelty 
seeking (impulsive, excitable, exploratory temperament), whieh is thought 
to depend in significant part on activity in the dopamine pathways 
(Cloninger 1994). For the purpose of anatomical co-registration, subjects 
also underwent a 1x1x1mm anatomical T1-weighted MRI of the whole 
brain using a gradient echo pulse sequence (TR = 9.7 ms, TE = 4 ms, flip = 
12°, FOV = 250, matrix = 256 x 256). 
PET frames were summed across time, co-registered with the 
corresponding MRI (Woods, Mazziotta et al. 1993), and transformed into 
standardised stereotaxie space (Talairach and P 1988) by means of 
automated feature-matching to the MNI template (Collins, Neelin et al. 
1994). Voxelwise [l1C]raclopride binding potential (BP) was calculated 
using a simplified reference tissue method (Lammertsma and Hume 1996; 
Gunn, Lammertsma et al. 1997) to generate statistical parametrie images of 
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the change in binding (Aston, Gunn et al. 2000). BP values for each subject 
were extracted from regions of interest (ROI) manually drawn on the co-
registered MRI on the left and right dorsal caudate (De, drawn on 
transverse slices at Talairach-space z coordinate from +2 to +15 mm), 
dorsal putamen (DP, + 2 to + 10 mm), ventral putamen (-8 to -4 mm), NAc 
(-8 to -4 mm) and cerebellum, which was used as the reference region. BP 
values extracted from ROI during alcohol and control scans were analysed 
using a three-way ANOV A for dependent samples [Treatment x ROI x 
hemisphere]. Sphericity was assessed with the Mauchly test and, when 
indicated, corrections were made with Greenhouse-Geisser adjustments. 
When appropriate, Least Significant Difference t-tests, Bonferroni 
corrected, were applied to determine the significance of regional 
differences in BP between the alcohol and orange juice conditions. Heart 
rate during the ascending part of the blood alcohol curve was compared 
to a baseline taken just prior to the study session (Amax [15-30 min.]). 
Since one subject exhibited a change in heart rate during the test session 
with orange juice that was greater than 2 SD from the sample mean, 
magnitude of he art rate change was analysed with the non-parametric 
Wilcoxon matched pairs test. Maximum change in SHAS rating from 
baseline taken on the same day (A max [SHAS]) was used to evaluate the 
subjective effects of alcohol and control drinks. A t-test for paired samples 
was used to determine the difference between A max [SHAS] for the 
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alcohol condition and Il. max [SHAS] for the control. Stepwise linear 
regression analysis was used to examine whether percent change in ROI 
BP could be predicted by changes in heart rate, change in SHAS scores, or 
TPQ personality ratings. 
RESULTS 
Screening for drugs of abuse was positive for only one subject 
(THC and trace cocaine prior to both scan conditions). Therefore, two 
different analyses were carried out, one exclu ding the data from this 
subject. In both cases, receptor parametric mapping identified significant 
reductions in [llC]raclopride BP in bilateral ventral striatum in the alcohol 
compared to the alcohol-free condition (Figure 1). In the statistically 
generated t-map, [llC]raclopride BP values were 16.8±16.3% lower on the 
test day with alcohol, compared to orange juice (t(5)=2.54, p = 0.05). 
Analyses of [l1C]raclopride BP values in the a priori defined ROI 
supported the receptor parametric mapping analyses (Figure 3). A 
treatment x ROI x hemisphere ANOV A yielded a main effect of ROI (F (3, 
15) = 42.55, p<O.OOl, Greenhouse-Geisser corrected) and a treatment X ROI 
interaction (F (3, 15) = 3.21, p=0.05). Bonferroni corrected pairwise 
comparisons confirmed that alcohol significantly reduced BP in the NAc 
(p = 0.003) and ventral putamen (p = 0.001) but not in the DC (p = 0.98) or 
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DP (p = 0.84). The percent change in [llC]raclopride BP also varied with 
ROI (F(3,15)=13,50, P = 0.001). In both the nucleus accumbens (15.0±15.9%) 
and the ventral putamen (13.7±16.4%), the percent decreases in 
[llC]raclopride BP were greater than those seen in either the dorsal 
putamen (5.2±17.5%) or caudate nucleus (4.0±16.4%) (p < 0.01). 
The blood alcohol level reached a mean peak of 18.10 (±1.4) 
mmolfL (0.0833 gm %) at 30 minutes after drinking. During the expected 
ascending phase of the blood alcohol curve (15-30 minutes post drink) 
alcohol consumption resulted in small but consistent increases in heart 
rate (5.47 ± 6 beats/min; t(5)=1.85, p=0.12; 6/6 subjects higher during 
alcohol test, Wilcoxon matched pairs test, z = 2.20; P = 0.028) and self-
reported feelings of "high" and Il drunkenness" (paired t-test, Il max 
[SHAS] alcohol vs. Il max [SHAS] orange juice, p < 0.01). A stepwise 
linear regression showed that impulsiveness, one of the subscales on the 
novelty-seeking dimension of the TPQ, and heart rate increase recorded at 
30 minutes (Le. during the ascending phase of the blood alcohol curve) 
were the only predictors of BP change in the ventral striatum (r = .985; P = 
0.005). Neither the subjective intoxication measures nor the peak blood 
alcohol level correlated with the change in [llC]raclopride BP in any 
region. 
PAGE 153 
ISABELLE BOILEAU CHAPTER IV: ALCOHOL 
DISCUSSION 
The observed reduetion in [l1C]raclopride BP eonfined to the 
ventral part of the striatum is indicative of dopamine release specifieally 
in the NAe and ventral putamen in response to alcohol in humans. These 
results are similar to those of two other [l1C]raclopride PET studies, in 
which amphetamine was found to preferentially induce dopamine release 
in the ventral striatum in humans (Drevets, Gautier et al. 2001; Ley ton, 
Boileau et al. 2002). In animaIs, in-vivo microdialysis studies have also 
shown a propensity for alcohol to induce dopamine release in the ventral 
striatum. Di Chiara and Imperato (1988) found that ethanol at rewarding 
doses had an almost ten-fold greater effect on dopamine release in the 
NAe than in the dorsal eaudate. Moreover, low doses of ethanol produee a 
dose-dependent inerease in the firing rate of Al0 dopamine neurons in the 
ventral tegmental area, whieh project to the ventral striatum (Gessa, 
Muntoni et al. 1985). Activation of A9 dopamine neurons, which project to 
the dorsal striatum, only oeeurs at five-fold greater ethanol doses. It is 
unclear if results obtained in the present study reflect a purely 
pharmaeological response. It is well aecepted that drug associated eues 
also elicit DA cell firing (Carelli, Ijames et al. 2000) and autonomie 
reaetivity (Stormark, Laberg et al. 1995) that could be in part responsible 
for the enhanced synaptie DA. 
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The dorsal and ventral striatum can be separated functionally and 
anatomically (Moore and Bloom 1978; Haber, Fudge et al. 2000). Their 
dopamine innervations originate in different cell groups in the midbrain, 
and their cortical connections likely account for their different functional 
roles. The ventral striatum, including the NAc and ventral putamen, 
belong to the "limbic" cortico-striatal loop that includes the amygdala, 
hippocampus, orbito-frontal cortex and cingulate cortex, structures 
involved in emotional behaviour and reward processing. There is much 
evidence for specifie involvement of ventral striatal, or mesolimbic, 
dopamine in the reinforcing effects of addictive drugs (Wise and Rompre 
1989; Koob, Sanna et al. 1998). It is thought to mediate associative 
learning, whereby drug-related eues acquire incentive value (Di Chiara, 
Tanda et al. 1999). Conditioned place preference, a laboratory test of 
conditioned incentive learning, is abolished by lesions or dopamine 
blockade of the ventral but not dorsal striatum (Everitt, Morris et al. 1991); 
(White, Packard et al. 1991). Our finding of dopamine release confined to 
the ventral striatum after oral ingestion of an intoxicating dose of alcohol 
may therefore account at least in part for its addictive properties in 
humans. 
Ethanol most likely acts on dopamine neurons indirectly (Yim and 
Conzales 2000). It potentiates CABAA receptor function (Weiner, Zhang et 
PAGE 155 
ISABELLE BOILEAU CHAPTERIV:ALCOHOL 
al. 1994) to cause inhibition of GABAergic interneurons in the substantia 
nigra reticulata (Gessa, Muntoni et al. 1985), which leads to dishinbition 
and increased burst firing of dopamine neurons (Grace and Bunney 1985). 
As stated ab ove, AI0 neurons projecting to the ventral striatum appear to 
be more sensitive to these systemic effects of ethanol than A9 dopamine 
neurons projecting to the dorsal striatum (Gessa, Muntoni et al. 1985). 
Opioid peptides may also be involved in the dopamine releasing actions 
of ethanol (Acquas, Meloni et al. 1993; Benjamin, Grant et al. 
1993)Gonzales et aL, 1998). 
The level of dopaminergic responsiveness in the NAc has been 
proposed as a marker of individual vulnerability to drug addiction. 
Numerous studies in rats have linked the propensity to self-administer 
drugs to enhanced dopamine release in the NAc in response to 
psychostimulants or stress (Piazza, Maccari et al. 1991; Hooks, Colvin et 
al. 1992; Zocchi, Orsini et al. 1998; Barrot, Abrous et al. 2001). In light of 
these studies, our finding of a correlation between the change in 
[l1C]raclopride BP in response to alcohol and two variables, the alcohol-
induced increase in heart rate and the personality trait of impulsiveness, is 
interesting. 
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In humans, cardiac response has been hypothesized to be an index 
of the psychostimulant properties of alcohol and of dopamine activation 
(Conrod, Peterson et al. 2001)and therefore a marker of vulnerability to 
addiction. Our findings, although in a small number of subjects, lend 
support to this theory. Moreover, the personality trait of novelty-seeking, 
of which impulsiveness is one component, has also been linked to both 
dopamine function (Cloninger 1994) and to addictive propensity. High 
scores on the novelty-seeking scale of the TPQ predict later alcoholism 
(Cloninger, Sigvardsson et al. 1988) as weIl as relapse-rate in detoxified 
alcoholics (Meszaros, Lenzinger et al. 1999). Interestingly, in a previous 
PET study we found that amphetamine-induced dopamine release also 
targeted the NAc, and correlated with novelty-seeking scores (Ley ton, 
Boileau et al. 2002). 
In the current study, we found no correlation between alcohol-
induced NAc dopamine release and subjective measures of intoxication. 
Previously, we similarly found no correlation between amphetamine-
induced dopamine release and behavioural effects such as euphoria and 
excitation (Ley ton, Boileau et al. 2002). The association between a drug' s 
euphorigenic quality and dopamine release has not been established in 
humans; similarly, in rats the behavioural significance of increased DA 
remains a subject of debate. Our failure to find a correlation between 
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subjective effects and DA release likely reflects the fact that alcohol acts on 
multiple neurotransmitter systems. In particular, the SHAS mostly reflects 
the sedative effects of alcohol (Conrod, Peterson et al. 2001), which are 
probably not mediated by dopamine. 
In conclusion, we showed that alcohol consumed by mouth in 
intoxicating doses promotes dopamine release in the ventral striatum. The 
observed relationship between the magnitude of change in [l1C]radopride 
BP, personality and heart rate increase suggests that the paradigm we 
have developed could be used to investigate the factors that lead to 
vulnerability for alcohol dependence. 
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Figure 1 Statistical t-map of the change in [llC]rac1opride BP induced by an acute 
oral dose of a1cohol (1 ml/kg) in healthy volunteers (n=6). Colour c1usters superimposed 
on the average MRI from aU subjects depict a significant change in BP in the ventral 
striatum. 
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Figure 3 Mean [11C] raclopride BP in the alcohol and control (orange juice) 
conditions. The data are extracted from manually drawn ROI on each subject's MRI. 
Bonferroni corrected pairwise comparisons; Differences between alcohol and control, 
p<O.OOl. Error bars represent the standard error of the mean. 
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PREFACE CHAPTER VI 
The following section introduces the third manuscript (study 3) 
included in the present thesis. This manuscript entitled "Madeling 
Sensitizatian ta Stimulants in Humans: A [llC]raclapride / PET Study ln 
Healthy Valunteers." Is in press in Archives of General Psychiatry 2006. 
DA neurons are believed to undergo adaptive changes whieh are 
unmasked upon suspension of a chronic regimen of addicting drugs - one of 
these changes results in an increase psychostimulant-induced DA releasability 
i.e.: sensitization. While animal models have yielded an enormous amount of data 
in favor of the occurrence of behavioral and neurochemical sensitization after 
repeated administration of amphetamine, human studies have been surprisingly 
unsuccessful. In this regard PET studies of human cocaine abusers, which 
demonstrated a blunted DA response following the single dose administration of 
a psychostimulant have challenged the sensitization hypothesis (Volkow, Wang 
et al. 1997) 
In the following manuscript we used PET and [llC]rac1opride to test the 
specifie hypothesis that repeated amphetamine administration in healthy 
humans results in an increased DA release. Our results suggest that 
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neurochemical and behavioral sensitization to stimulants in humans can be 
achieved safely in the laboratory. In agreement with the prediction of 
sensitization, repeated amphetamine potentiated DA release in several sub-
regions of the striatum, including the ventral striatum and posterior dorsal 
putamen. Notably, sensitization enhanced the psychomotor / arousing effects of 
the drugs. Finally, our findings also indicate that individuals vary in their 
propensity to sensitize and this vulnerability could be predicted by trait novelty 
seeking. 
Volkow, N. D., G. J. Wang, et al. (1997). IIDecreased striatal dopaminergic 
responsiveness in detoxified cocaine-dependent subjects. 1I Nature 
386(6627): 830-3. 
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ABSTRACT 
Introduction: In animaIs, repeated exposure to stimulant drugs leads to an 
enhanced drug-induced psychomotor response and increased dopamine release. 
This phenomenon, known as sensitization, may confer vulnerability to drug 
addiction or drug-induced psychosis in humans. A similar phenomenon, 
referred to as endogenous sensitization, is also believed to play a role in the 
emergence of positive symptoms in patients with schizophrenia (Lieberman, 
Sheitman et al. 1997; Laruelle 2000). 
Aim of the study: To determine whether behavioral and neurochemical 
sensitization occur in healthy volunteers following limited exposure to 
amphetamine in the laboratory. 
Method: Ten healthy male human volunteers (age, 25.8 ± 1.8 years) received three 
single doses of amphetamine (0.3 mg/kg; by mou th) on days l, 3 and 5. Using 
positron emission tomography (PET) and [l1C]raclopride, we measured 
dopamine release in response to amphetamine on first exposure (day 1) and 14 
days and one year after the third exposure. 
Results: The initial dose of amphetamine caused dopamine release in the ventral 
striatum (a reduction of [l1C]raclopride binding). Amphetamine 14 and 365 days 
after the third dose resulted in a greater psychomotor response and increased 
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dopamine release (a greater reduction of [llC]rac1opride binding), relative to the 
initial dose. Furthermore, this sensitized response to amphetamine was 
manifested not only as greater dopamine release in the ventral striatum but as an 
extension of dopamine release to the dorsal caudate and putamen. Novelty 
seeking personality and impulsivity predicted the degree of sensitization of the 
response to amphetamine induced by repeated amphetamine. 
Conclusion: Sensitization to stimulants can be achieved in healthy humans in the 
laboratory. This phenomenon is associated with increased dopamine release and 
persists for at least one year. 
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INTRODUCTION 
Altered dopamine (DA) neurotransmission is believed to play a critical role 
in the pathophysiology of psycho sis and addiction (Robinson and Berridge 1993; 
Lieberman, Sheitman et al. 1997). The phenomenon of sensitization that occurs 
within the midbrain DA system when animaIs are repeatedly exposed to 
stimulant drugs or stress may help us understand how DA neurotransmission 
becomes dysregulated. Repeated intermittent exposure to stimulant drugs or 
stress results in heightened behavioral and neurochemical responses following 
re-exposure (Antelman, Eichler et al. 1980; Robinson, Jurson et al. 1988; Paulson 
and Robinson 1995). It is generally believed that, during the induction of 
sensitization, the repeated stimulation of DA receptors in the ventral tegmental 
are a triggers a cascade of molecular events and changes in neuronal plasticity 
that, in turn, foster augmented DA release (Nestler 2001). In experimental 
animaIs, behavioral sensitization is an enduring (Robinson and Becker 1986; 
Hyman and Malenka 2001), time (Paulson and Robinson 1995) and context 
(Anagnostaras, Schallert et al. 2002) dependent phenomenon, which is associated 
with a long-lasting increase in stimulant drug-induced dopaminergic 
neurotransmission in the striatum (Kalivas and Stewart 1991; Kalivas 1993; 
Paulson and Robinson 1995; Pierce and Kalivas 1997). Sensitization is reported to 
cross-react with stress (Antelman, Eichler et al. 1980) and is affected by 
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individual differences (Hooks, Jones et al. 1991). A high locomotor response to 
novel environments in rats is a predictor of the development of sensitization 
(Hooks, Jones et al. 1991). Although widely described in experimental rodents, 
sensitization has seldom been investigated in humans (Rothman, Corelick et al. 
1994; Strakowski, Sax et al. 1996; Sax and Strakowski 1998; Wachtel and de Wit 
1999; Richtand, Woods et al. 2001). Sensitization in humans is thought to confer 
vulnerability to drug addiction (Robinson and Berridge 1993; Robinson and 
Berridge 2001) and is invoked to account for psychosis recurrence in chronic 
methamphetamine users exposed to stimulant drugs or stress after long periods 
of drug-abstinence (Sato, Chen et al. 1983; Yui, Coto et al. 1997). In 
schizophrenia, endogenous sensitization might underlie the conversion to 
psycho sis in prodromal and remitting patients (Lieberman, Sheitman et al. 1997; 
Laruelle 2000), a hypothesis that has gained partial validity from radioligand 
PET imaging studies which have demonstrated exaggerated amphetamine 
stimulated dopamine release and symptomatic exacerbation in patients with 
schizophrenia (Laruelle, Abi-Dargham et al. 1996) (Breier, Su et al. 1997) (Abi-
Dargham, Cil et al. 1998). 
PET neuroimaging with the D2 receptor ligand [l1C]raclopride has been 
used to investigate striatal DA function non-invasively in humans. There is 
substantial evidence that an acute intra-synaptic rise in DA concentration 
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translates into a proportional redudion in the binding potential (BP) of 
[l1C]radopride (Laruelle 2000), and that decreasing catecholamine 
neurotransmission increases BP (Ley ton, Dagher et al. 2003). This imaging 
modality has been successfully used to demonstrate DA release in response to 
the administration of drugs of abuse in human subjects (Volkow, Wang et al. 
1994; Drevets, Gautier et al. 2001; Ley ton, Boileau et al. 2002). The mechanisms 
underlying the changes in BP in response to changes in synaptic DA 
concentrations are not fully elucidated. It is believed that rapid internalization of 
D2/3 receptors in the endosomal compartment in the face of an agonist challenge 
may explain decreased [l1C]raclopride binding (Laruelle 2000). 
The purpose of this study was to test and validate an experimental model of 
stimulant-induced sensitization of the effeds of amphetamine on striatal DA 
release in humans in the laboratory, using the PET / [l1C]raclopride technique. 
The specifie hypothesis was that amphetamine-stimulated DA release in the 
striatum is enhanced as a result of the repeated administration of oral d-
amphetamine. 
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METHOD 
Design Overview 
Subjects completed an anatomical MRI scan and six experimental sessions (Table 
1), receiving five oral doses of amphetamine (Dextroamphetamine sulfate, 0.3 
mg/kg, p.o.) in the same physical setting, at the same time of day. During the 
sensitization phase, subjects received three doses of amphetamine (0.3 mg/kg, 
p.o.) with approximately two days between each dose (1.95 ± 0.6). A test dose 
was then given two weeks (17.2±3.2 days) after the last sensitization dose. PET 
[l1C]radopride scans were conducted during (i) a drug-free session, (ii) the first 
exposure to amphetamine, and (iii) the test dose two weeks after sensitization. 
Seven of the 10 subjects returned for a final [l1C]radopride amphetamine scan 
following a 12-month latency (407±60 days). Amphetamine doses 2 and 3 were 
administered during sham scans on days 3.1 ± 0.3 and 5.8 ± 0.7 in the course of 
which subjects underwent aU aspects of the PET procedure except for the 
administration of radiotracer. Five of the subjects underwent the drug-free 
(control) session prior to receiving amphetamine; five had this session foUowing 
the test dose (day 31.9 ± 6.5). 
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Day Day Day Day 
1 year 
o or >22 1 3 5 
PET"" PET Sham Sham PET 
Nodrug AMP AMP AMP AMP 
Table 1 Experimental design. PET*: no-drug control scan performed in a 
counterbalanced order, either before (day 0, n=5) or after (day 22, n=5) the 
sensitization regimen. PET: amphetamine PET scan. Subjects received 
amphetamine (AMP: d-amphetamine, 0.3 mg/kg, p.o) one hour prior to being 
positioned on the PET couch. Behavioral and physiological data were gathered at 
15-minute intervals. Sham: Subjects received amphetamine one hour prior to 
being positioned on the PET couch; these sessions inc1uded all aspects of the PET 
procedure except tracer injection. 
Subjects 
Ten men (age, 25.8 ± 1.8 years) were recruited to participate in the sensitization 
study (approved by the Montreal Neurological Institute Research Ethics Board), 
seven of who returned for the follow-up scan one year later. AlI subjects scored 
above the normal population mean (13.7± 5.2) on the Novelty Seeking sc ale of 
the tridimensional personality questionnaire (TPQ) (Cloninger, Przybeck et al. 
1991)(mean score and SD: 20 ± 4) which measures individual differences in 
response to novelty along four subscales on a scale from 0 to 35 ([1] Exploratory-
Excitability vs. Stoic-Reserve, [2] Impulsiveness vs. Reflection, [3] Extravagance 
vs. Reserve, and [4] Disorderliness vs. Regimentation). Novelty Seeking subjects 
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were selected based on the hypothesis that trait Novelty Seeking is analogous in 
humans to the hyperactive motor response to a novel environment in 
rodents(Dellu, Piazza et al. 1996), which is a strong predictor of behavioral and 
neurochemieal sensitization(Hooks, Jones et al. 1991). Exclusion criteria were as 
follows: current or previous personal history of significant medical illness; 
personal or first-degree relative history of psychiatrie disorder, including, but not 
limited to schizophrenia, bipolar disorder and substance dependence (assessed 
using the Structured Clinical Interview for DSM-IV(Badiani, Browman et al. 
1995)); regular use of tobacco (> 5 cigarettes/ day); and positive urine toxicology 
for illicit drugs (Triage TM Panel for Drugs of Abuse, Biosite Diagnostics©, San 
Diego, CA, USA). 
PET acquisition protocol 
AIl subjects were asked to fast and abstain from caffeine or tobacco for a 
minimum of four hours prior to each experimental session. They underwent PET 
scans on a CTI/Siemens ECAT HR+ PET camera with lead septa removed (63 
slice-coverage, with a maximum resolution of 4.2 mm full width half maximum 
in the centre of the field of view). A catheter was inserted into the subject's 
antecubital vein for the bolus injection of tracer and blood drawing. Attenuation 
correction was performed via a lü-minute 68Ga transmission scan. Three of four 
PET acquisitions were performed following the administration of an oral dose of 
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0.3 mg/kg amphetamine ingested 60 minutes prior to the Lv. bolus injection of 
[l1C]raclopride (7 mCi), a drug-schedule previously shown by our group to 
reliably reduce [l1C]raclopride BP(Leyton, Boileau et al. 2002). Emission data 
were collected over 60 minutes in time frames of progressively longer duration. 
In addition, aIl subjects underwent high-resolution magnetie resonance imaging 
(MRI) on a Siemens 1.5 T Vision scanner for the purpose of anatomical co-
registration. 
Parametric Image generation and voxel-wise analysis 
PET images were reconstructed using a 6 mm full width half maximum Hanning 
filter. Individual dynamie radioactivity PET data were averaged along the time 
dimension, co-registered to the individual' s MRI, and transformed into 
standardized stereotaxie space(Evans, Marrett et al. 1992). The dynamic PET data 
were corrected for motion artifacts(Reilhac, Sechet et al. 2003). Parametric images 
were generated by computing [l1C]raclopride BP at each voxel using a simplified 
kinetic model that uses the cerebellum as a reference tissue devoid of DA D2/3 
receptors to describe the kinetics of the free and specifieally bound ligand(Gunn, 
Larnmertsma et al. 1997). The application of this kinetic mode! to[l1C]raclopride 
has been previously shown to be insensitive to changes in cerebral blood 
flow(Aston, Gunn et al. 2000). 
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Region of Interest Analysis and MRI Atlas-based Segmentation 
The MRI volumes were corrected for image intensity non-uniformity(Sled, 
Zijdenbos et al. 1998) and linearly and non-linearly transformed into 
standardized stereotaxic space(Talairach and P 1988), using automated feature-
matching to the Montreal Neurological Institute template(Collins, Neelin et al. 
1994). Automated MRI tissue-type classification and segmentation (Collins DL 
1995) were applied, to generate a binary representation of anatomical structures, 
including cau date, putamen and ventral striatum. Five bilateral areas from the 
segmented brains were selected for region of interest (ROI) analysis based on 
previous work (Mawlawi, Martinez et al. 2001; Martinez, Slifstein et al. 2003): 
ventral striatum (VS; limbic striatum), pre and post commissural dorsal caudate 
(DC; associative striatum), pre-commissural dorsal putamen (associative 
striatum), and post-commissural putamen (PDP; sensorimotor putamen). 
[llC]Raclopride BP values from each ROI were then extracted and corrected for 
partial volume effects(Aston, Cunningham et al. 2002) . 
Behavioral and physiological assessment of acute amphetamine effeds 
Mood and alertness were assessed at baseline and at 15-minute intervals 
throughout each experimental session, using visual analogue scales(Bond and 
Lader 1974) and the Bipolar Profile of Mood States(McNair, Lorr et al. 1992). The 
addiction research centre inventory (ARCI)(Haertzen, Hill et al. 1963) Benzedrine 
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Scale was administered at the end of every experimental session to measure the 
subjective effects of amphetamine. Physiological recordings including electro-
oculogram for eye-blink rate and heart rate were carried out in 3-minute blocks 
at baseline and at regular intervals after amphetamine (45, 75, 90, 120 minutes) 
(Fl000 system; Focused Technology, Ridgecrest, CA). Blood samples for cortisol, 
prolactin and plasma-amphetamine levels were drawn via the indwelling 
catheter at baseline, 45, 90 and 120-minutes post drug. Plasma cortisol and 
prolactin concentrations were measured by radioimmunoassay, using 
commercially available kits (Kodak Clinical Diagnostics Ltd., Amersham UK). 
Plasma amphetamine concentrations were analyzed with electron-capture gas 
chromatography, after extraction and derivatization of amphetamine(Asghar, 
Baker et al. 2001). 
Statistical Analysis 
t-Maps were generated(Aston, Gunn et al. 2000) to assess the contrasts between 
the drug-free control scan and amphetamine scans at doses 1, 4 and 5, as weIl as 
the profile of time-dependent changes in [l1C]raclopride BP as a function of 
repeated amphetamine administration (BP at dose 1 > BP at dose 4 > BP at dose 
5). Voxel significance was set at t ~ 4.2, corresponding to p < 0.05 corrected for 
multiple comparisons across the entire striatum based on random field 
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theory(Worsley, Marrett et aL 1996). BP values extracted from ROI during 
amphetamine (dose 1 and 4) and control scans were analyzed using a three-way 
ANOVA for dependent samples (treatment x ROI x hemisphere). Sphericity was 
assessed with the Mauchly test and, when indicated, corrections were made with 
Greenhouse-Geisser adjustments. When appropriate, Least Significant Difference 
t-tests, Bonferroni corrected, were applied to determine the significance of 
regional differences in BP between the amphetamine dose l, dose 4 and the 
drug-free baseline scans. A separate three-way ANOV A was conducted to assess 
difference between BP values extracted from ROI during amphetamine dose l, 4, 
5 (follow-up) and drug free-baseline for the 7 subjects who completed the follow-
up study (one year later). VAS and POMS rating, plasma levels of amphetamine, 
cortisol, prolactin and physiological measures (heart-rate and eye-blink rate) 
where analyzed using two-way ANOV A for dependent samples (treatment x 
time). When appropriate these analyses included Greenhouse-Geisser 
adjustments. Pearson' s product moment correlation was applied to 
[l1C]raclopride BP extracted from ROIs to assess whether the personality trait of 
Novelty Seeking could predict the extent of neurochemical sensitization 
([llC]raclopride BP at doses 4 and 5 minus [l1C]raclopride BP at dose 1) and 
whether the development of behavioral sensitization (behavioral response at 
doses 4 and 5 minus behavioral response at dose 1) correlated with the reduction 
in [llC]raclopride BP. Voxel-wise linear correlation maps were also generated to 
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test the relationship between sensitization-induced decreases in [l1C]raclopride 
BP and Novelty Seeking personality score. 
RESULTS 
Behavioral and physiologie al measures 
Subjective ratings: When compared to the first amphetamine administration 
(dose 1), re-exposure to a fourth amphetamine dose (dose 4) led to increased 
energy (POMS energetic: F(4, 36) = 4.36, P = 0.029; dose1 vs. dose 4: p = 0.056), 
alertness (VAS alert: F(4, 36) = 11.6, p< 0.0001; dose1 vs. dose 4: p = 0.048), 
clearheadedness (POMS clearheaded: F(4, 36) = 3.02, P = 0.054; dose1 vs. dose 4: 
p = 0.009) and positive mood (POMS agreeable: F(4, 36) = 3.679, P = 0.04; dose 1 
vs. dose 4: p = 0.002) (Figure 1). Conversely, re-exp os ure to the fourth or fifth 
dose of amphetamine did not significantly affect amphetamine-induced euphoria 
(POMS Elated, VAS High, Euphoria, Rush) anxiousness (VAS Anxious) or drug-
wanting (VAS Want-Drug), relative to first exposure. The "energy" response to 
amphetamine remained elevated after the one-year latency (POMS energetic: F(5, 
30) = 3.33, P = 0.056; dose1 vs. dose 5: one-tailed, p = 0.045). 
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Figure 1 Behavioral effects of amphetamine. POMS scores (peak change 
from baseline; mean ± SEM) recorded during the drug-free control condition and 
after 0.3 mg/Kg of oral amphetamine (doses l, 4 and 5). (*) Significantly 
increased compared to dose 1. 
Physiological measures: Acute amphetamine yielded a time-dependent increase 
in the rate of eye-blinks per minute at every session (main effect of time: F(4, 36) 
= 7.47, P = 0.005). Relative to the first dose (dose 1), re-exposure to acute-
amphetamine after the two-week latency period (dose 4), resulted in a small but 
significant increase in blinks per minute (1.1 ± 0.4 beats per minute) (main effect 
of session, F(4, 36) = 7.47, P = 0.001; dose1 vs. dose 4: p = 0.021) (Figure 2). This 
effect was still present upon amphetamine re-exposure one-year later although 
not statistically significant (Figure 2). Heart rate response to amphetamine was 
not significantly affected by pre-exposure to amphetamine (F(4, 32) = 1.250, P = 
0.31). 
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Figure 2 Eye-blink rate (blinks per minute change from baseline; l:! max ± 
SEM) during control and acute d-amphetamine conditions (doses 1, 4 and 5). (*) 
Significantly increased compared to dose 1. 
Neuroendocrine measures: Relative to the control drug-free condition, 
amphetamine resulted in a significantly higher cortisol concentration (F(l, 9) = 
7.799, P = 0.021), but not plasma prolactin levels (F(l, 9) = 1.199, P = 0.30). There 
were no differences in cortisol or prolactin levels between the different 
amphetamine sessions. 
Plasma amphetamine: The plasma amphetamine concentrations rose in aIl 
sessions equally (main effect of time: F(3, 15) = 64.91, P < 0.0001) with plasma 
levels peaking on average at 120 min (20.5 ± 3.7 ng Iml). There was no difference 
between sessions (main effect of session: F(3, 15) = 0.224, P = 0.734). 
Amphetamine plasma levels at one-year foIlow-up were not analyzed. 
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PET [l1C)raclopride 
Parametric Map t-statistical tests: Voxel-wise analysis over the whole brain, 
revealed significant (t ~ 4.2; P < 0.05) bilateral clusters of decreased 
[llC]raclopride BP in response to amphetamine doses 1, 4 and 5 relative to the 
drug-free control scan (Figure 3 a-b-c). The clusters appear smaller in height and 
extent in the (drug-free - dosel) t-map compared to the (drug-free - dose 4) or 
(drug-free - dose 5) t-maps, suggestive of increased DA release in response to 
doses 4 and 5. The region of statistically significant reduction in [llC]raclopride 
BP for dose 1 (relative to control) was confined to the ventral striatum and 
posterior dorsal putamen. However, with doses 4 and 5, there was progressive 
antero-dorsal extension of this region to include the dorsal parts of the caudate 
and anterior putamen. Figure 3d illustrates the trend towards decreased BP as a 
factor of repeated drug administration. 
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Figure 3 t-Statistical maps of [l1C]rac1opride BP change illustrating a 
decrease of [l1C]rac1opride BP following dose 1 (A), dose 4 (B) and dose 5 (C) 
amphetamine administrations (0.3 mg/kg p.o.), relative to the drug-free control 
condition (x: 28; y:2; z: 0). (D) General linear model with dose as a regressor 
illustrating the progressive decrease in [l1C]rac1opride BP as a factor of repeated 
amphetamine doses (x: 9; y:7; z: -6). Colored t-maps are overlaid on an average 
Tl MRI of all participants. 
Region of interest analysis: Two-way repeated measure ANOV A of 
[l1C]rac1opride BP, using ROI and session (drug-free, dose 1, dose 4) as factors, 
confirmed the t-map results (Figure 4 a-b). Both dose 1 and dose 4 of oral 
amphetamine, resulted in a decreased [l1C]rac1opride BP, relative to the drug-
free session, in two sub-compartments of the striatum (ROI x session interaction; 
F(4, 36) = 3.887, p=O.Ol). In bilateral VS and PDP, this effect corresponded to a 
significant decrease in the mean [l1C]rac1opride BP of respectively -17.7 ± 9 % in 
the VS (Bonferroni corrected for one-tailed planned comparison; p = 0.034) and -
7.3 ± 3 % in the PDP (p = 0.031), following dose 1 of amphetamine, and -28.4 ± 9 
% in the VS (p = 0.007) and -14.3 ± 3 % in the PDP (p = 0.001), following dose 4. 
The first dose of amphetamine did not significantly reduce (11C]rac1opride BP in 
the anterior and posterior DC or in the anterior DP. Amphetamine dose 4 
resulted in a greater [l1C]rac1opride BP reduction than dose 1 in VS and PDP, 
corresponding to an additional-12.1 ± 5 % (VS; P = 0.023) and -7 ± 3.5 % (PDP; p 
= 0.031) reduction of [l1C]rac1opride BP, but no difference in DC (-0.3 ± 2 %; p = 
0.99). At one-year follow-up (dose 5, n = 7), amphetamine further reduced 
[l1C]rac1opride BP relative to the drug-free session (-24.23 ± 12.5% in the VS, -7.84 
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± 4.5% in the De and -20.10 ± 4.8% in the PDP). This effect corresponded to 
significant BP decreases from dose 1 (ROI x session interaction; F(6, 36) = 2.483, P 
= 0.041) (-15.40 ± 5.4% in the VS, p = 0.02; -7.38 ± 5.2% in the De, p = 0.09; and -
13.97±5.3% in the PDP, p = 0.01) and from dose 4 (-9.09 ± 2.5% in the De and -
9.05 ± 3.2% in the PDP). 
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Figure 4 (A) Mean (and SEM) [llC]rac1opride BP in three sub-compartments 
of the striatum during the control drug-free scan (ctrl), and following 
amphetamine administration before (dose 1) and after repeated amphetamine 
(dose 4) (n = 10), and (B) at one-year follow-up (n=7). VS: ventrallimbic striatum; 
De: associative pre-commissural dorsal cau date; PDP: post-commissural dorsal 
putamen. (*) Significantly different from dose 1 (p<0.05), (t) significantly 
different from dose 4 (p<0.05). 
To investigate whether repeated exposure to amphetamine affected baseline 
(drug-free) [l1C]rac1opride BP, we compared the baseline striatal [l1C]rac1opride 
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BP of those subjects who underwent the drug-free scan before first exposure (n = 
5; mean striatal BP = 3.0 ± 0.2) to those who had it after the last exposure (dose 4) 
(n = 5; mean striatal BP = 2.9 ± 0.36) and found that there was no significant 
difference (t = 0.469, P = 0.65). 
Brain-behavior Relationships 
There were regionally specifie correlations between DA release and various 
behavioral responses that sensitized to repeated amphetamine. Amongst those, 
the increase in eye-blink rate (dose 4 - dose 1; PDP: r = -0.73, P = 0.015), energy 
(dose 4 - dose 1; PDP: r = -0.67, P = 0.03; dose 5 - dose 1; VS: r = -0.69, P = 0.04) 
and alertness (dose 5 - dose 1; VS: r = -0.75, P = 0.02) correlated with the 
reduction in [llC]raclopride BP (dose 4 - dose 1). Moreover, the magnitude of the 
reduction in [llC]raclopride BP in DC was proportional to Novelty Seeking trait 
scores (dose 5 - dose 1; DC: r = -0.73, P = 0.06) (Figure 5) and impulsiveness (dose 
5 - dose 1; DC: r = -0.85, P = 0.014). 
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20 
Figure 5 Relationship between novelty seeking personality and 
sensitization. a) Scatter plots and b) voxel-wise regression maps illustrating the 
relationship between Novelty Seeking personality trait and sensitization-
induced changes in [l1C]raclopride BP (% decreases from dose 1) measured 
during amphetamine doses 4 (x=13, y=15, z=7) and 5 (x=l1, y=15, z=15) 
COMMENTS 
Although widely described in experimental animaIs, sensitization of the 
effeds of amphetamines has sel dom been investigated in humans(Sax and 
Strakowski 1998; Richtand, Woods et al. 2001). Here, we report, using the 
[l1C]raclopride PET method, that repeated amphetamine administration in 
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humans led to persistent behavioral and neurochemical sensitization, 
characterized by increased psychomotor, energy, agreeableness and alertness 
responses upon re-exposure, together with a proportional increase in 
amphetamine-stimulated DA release, primarily observed in the limbic and 
sensorimotor striatum (PDP) and progressing to include the associative dorsal 
caudate (DC) at one-year follow-up. The dose 1 t-map and ROI analysis showing 
amphetamine-stimulated DA release confined to the ventral limbic (VS) and 
sensorimotor striatum (PDP) is consistent with previous reports (Ley ton, Boileau 
et al. 2002; Martinez, Slifstein et al. 2003). Moreover, the progressive increase in 
DA response over time, from the initial amphetamine scan to the 14-day and 
one-year follow-up studies is compatible with reports indicating that 
sensitization is a delayed and enduring phenomenon in rats, occurring after 
withdrawal periods of two weeks or more and persisting for up to one year 
(Robinson and Becker 1986; Paulson and Robinson 1995). Our results suggest a 
regional disparity in the temporal emergence of sensitization in humans, with 
the DC only showing evidence of DA response to amphetamine at the one-year 
time point. This may reflect a difference between the DA projections to ventral 
and dorsal striatal regions in their ability to display sensitization, as suggested by 
sorne animal experirnents(Paulson, Camp et al. 1991) (Porrino, Daunais et al. 
2004) (Porrino, Lyons et al. 2004). However an alternative explanation for the 
lack of effect observed within the DC after the short latency might be the 
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presence of threshold effects. Effects of amphetamine on [l1C]rac1opride BP 
being relatively modest in the DC(Drevets, Gautier et al. 2001; Ley ton, Boileau et 
al. 2002; Martinez, Slifstein et al. 2003), it may be that sensitization-related 
changes are also present but undetected in the DC after the 14-day drug-free 
period. 
Consistent with previous c1inical reports indicating that sensitization of 
certain effects resulting from repeated amphetamine (e.g. vigor) may co-exist 
with tolerance to other effects (e.g. I/liking")(Sax and Strakowski 1998; Richtand, 
Woods et al. 2001), repeated amphetamine increased the arousing effects of the 
drug (alertness, energy) but had liule or no influence on drug-induced high and 
euphoria. The increase in amphetamine-stimulated DA release correlated with the 
progressive enhancement of the psychostimulant effect of amphetamine (energy, 
alertness, eye-blink rate), in line with the hypothesis that DA mediates only sorne 
of the behavioral components of sensitization (Pauls on and Robinson 1995). 
The finding that behavioral sensitization may be achieved experimentally in 
healthy volunteers and that it is associated with an enduring enhancement of 
striatal dopamine release in response to acute amphetamine, rests upon the 
following methodological and conceptual considerations: (1) Did the drug 
sensitization regimen affect D2 receptor density (or affinity), hence modifying the 
D2 baseline set point over time? (2) Are stimulant-induced changes in 
[l1C]rac1opride BP stable over time and reproducible within-subject? (3) What is 
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the role of context or anticipation of drug effects, if any7 (4) How generalizable is 
this finding7 (5) Why is it that increased dopamine release in response to 
stimulant drugs has not been described in drug-dependent patients(Volkow, 
Wang et al. 1997)7 
(1) The validity of the proposed interpretation, that the change in 
[l1C]raclopride BP during the last two amphetamine scans (doses 4 and 5), 
reflects a change in the extent to which amphetamine stimulates striatal DA 
release, rests upon the assumption that baseline BP is unaffected by the 
sensitization-inducing drug regimen. [l1C]raclopride BP represents a ratio 
between the concentration of binding sites (Bmax) and the affinity of 
[l1C]raclopride for D2/3 receptors (Kd). A change in Bmax or Kd would render the 
study difficult to interpret. Although an abundant lite rature suggests that the 
development or expression of sensitization does not entai! major changes in DA 
D2 receptor density(Pierce and Kalivas 1997), reports of D3 over-expression 
(Guillin, Diaz et al. 2001) and changes in D2 receptor affinity have been made by 
sorne (Seeman, Tallerico et al. 2002), though not by others(Pierce and Kalivas 
1997). In this study, half of the subjects underwent the drug-free scan (baseline) 
at the end, rather than at the beginning of the stimulant-inducing sensitization 
regimen, in effect, testing for a possible influence of repeated amphetamine on 
DA receptor density; indeed, [l1C]raclopride BP measurements obtained prior to 
versus following sensitization, were not significantly different. This was further 
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confirmed in a separate group of healthy volunteers (n = 6) in whom drug-free 
[l1C]raclopride BP was measured prior to, and 14 days after receiving the same 
amphetamine regimen described above (three administrations of oral 
amphetamine over five days). The mean striatal BP was respectively 2.35 ± 0.15 
prior to, and 2.36 ± 0.23 following, repeated amphetamine (main effed of session: 
F(l, 5) = 0.005, P = 0.94). Voxel-wise analyses confirmed that baseline (drug-free) 
[l1C]raclopride BP was not significantly decreased by repeat amphetamine 
administration. 
(2) In the present study, [l1C]raclopride BP was measured at several time 
points over the course of one-year. The stability and reproducibility of this 
method have previously been demonstrated in test-retest studies: both long-term 
stability of baseline [l1C]raclopride BP (11 months)(Hietala, Nagren et al. 1999) 
and within-subject reproducibility of amphetamine-induced decrease in ligand 
binding ([123I]IBZM SPECT) (Kegeles, Zea-Ponce et al. 1999) have been 
demonstrated. 
(3) In the present design, aIl drug administrations took place in the PET 
environment, in order to facilitate the expression of behavioral 
sensitization(Crombag, Badiani et al. 2001). It is not known what proportion of 
the behavioral and neurochemical effeds described here are accounted for by 
responses to associative cues and anticipation. Indeed, DA release in anticipation 
of reward, has been shown both in humans during placebo administration and in 
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primates faced with cues that predict reward(Schultz, Dayan et al. 1997; de la 
Fuente-Fernandez, Phillips et al. 2002). Nonetheless, although the expression of 
sensitization can be modulated by context(Anagnostaras and Robinson 1996; 
Crombag, Badiani et al. 2001; Mead, Crombag et al. 2003), neuroadaptive 
changes thought to underlie neurochemical sensitization are known to occur in 
vitro(Robinson and Becker 1982; Vanderschuren, Schmidt et al. 1999) and 
independently of the drug-paired context (Battisti, Uretsky et al. 2000; Bradberry, 
Barrett-Larimore et al. 2000). Until further experiments specifically designed to 
test for conditioning are carried out, the possibility that this may have 
contributed to an enhanced response to stimulant cannot be entirely discarded. 
(4) In this study, an enhanced behavioral and neurochemical response to 
amphetamine as a result of sensitization was observed in healthy male 
volunteers, scoring high on Novelty Seeking. Whether this finding can be 
generalized to males scoring low on Novelty Seeking, females or more generally, 
other non-clinical or clinical (drug dependence, PTSD, ADHD) populations, 
besides schizophrenia, is unknown, though plausible. Interestingly, 
neurochemical sensitization correlated with Novelty Seeking, an observation 
consistent with results from animal experiments, supporting theories linking this 
personality trait to vulnerability for substance abuse (Cloninger, Przybeck et al. 
1991; Howard, Kivlahan et al. 1997): rodents with a high locomotor response to 
novel environments, when compared with low responders, show higher stress 
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and drug-induced firing in mesencephalic dopaminergic neurons, sensitize more 
readily to amphetamine, and show a higher propensity to self-administer drugs 
of abuse (Dellu, Piazza et al. 1996) (Deminiere, Piazza et al. 1989) (Piazza, 
Deminiere et al. 1989) (Hooks, Colvin et al. 1992). 
(5) A report that detoxified cocaine-dependent patients exhibited an 
apparent tolerance or blunting of striatal DA responsiveness (and self-reported 
high) to a challenge dose of methylphenidate, relative to healthy control s, is 
somewhat surprising (Volkow, Wang et al. 1997). Based on their findings of 
decreased DA D2 receptor levels in the striatum and decreased drug-induced DA 
release, Volkow and colleagues have argued that a malfunctioning dopamine 
system in chronic drug-users might be responsible for decreased sensitivity to 
non drug associated context and non drug reinforcers (Volkow, Fowler et al. 
2004). Indeed, this theory is supported by fMRI studies showing decreased 
activation in cocaine abusers compared with controls when exposed to salient 
non-drug stimuli (Garavan, Pankiewicz et al. 2000); conversely, those subjects 
demonstrate large increases in activity in prefrontal cortex and nucleus 
accumbens, when attending to drug-cues. Thus, it is possible that in those 
studies, the absence of explicit pairing of the (PET) environment with the drug 
might have inhibited the expression of sensitization. Another plausible 
explanation for the blunted DA response to methylphenidate in chronic cocaine 
users could be that the decreased baseline [llC]raclopride BP, interpreted as 
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decreased DA D2 receptor levels, in fact, reflects elevated dopamine levels at 
baseline. Specifically, relative to stimulant naïve subjects, chronic cocaine users 
might be exhibiting cross-sensitization(Pani, Porcella et al. 2000; Stewart 2000; 
Barr, Hofmann et al. 2002; Nikulina, Covington et al. 2004; Kikusui, Faccidomo et 
al. 2005) to the stress related to the novel PET environment, or alternatively, be 
anticipating drug-reward(Schultz, Dayan et al. 1997) (de la Fuente-Fernandez, 
Ruth et al. 2001), in either case, releasing more DA at baseline, hence, making it 
difficult to detect further reductions in [llC]raclopride BP. 
In conclusion, the results presented in this study demonstrate that 
sensitization, expressed in the form of persistent changes in brain DA 
neurochemistry, may occur in humans following repeated intermittent exposure 
to stimulants. This finding has important clinical and pathophysiological 
implications. First, sensitization-like phenomena are believed to be central to the 
development of drug-seeking behavior(Robinson and Berridge 1993; Robinson 
and Berridge 2001). Animal studies show that sensitization increases the 
motivation to self-administer stimulant drugs, possibly via a mechanism that 
involves DA (Vezina 2004). It is thought that enhanced DA response to drugs 
may act to increase the incentive value of the drug (Robinson and Berridge 1993; 
Robinson and Berridge 2001), a hypothesis supported in humans by PET studies 
showing that the DA response to amphetamine correlates with desire for the 
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drug(Leyton, Boileau et al. 2002; Oswald, Wong et al. 2005). Our finding of a 
relationship between sensitization and novelty seeking personality provides a 
partial mechanism whereby drug addiction could result from the coupling of an 
inherent vulnerability and repeated drug exposure (Deroche-Gamonet, Belin et 
al. 2004). 
Second, a phenomenon similar to sensitization induced by drugs may play 
a role in psycho sis (Lieberman, Sheitman et al. 1997; Yui, Goto et al. 1999; 
Crombag, Badiani et al. 2001). It is hypothesized that repeated exposure to 
dopaminergic stimulation, whether from drugs or stress, results in a persistent 
hyperdopaminergic state which, in the presence of other risk factors (e.g. genetic 
vulnerability, perinatal lesion, altered brain development, stressful life events), 
could lower the threshold for acute psychosis. This may also explain why 
clinically stable remitted patients with chronic relapsing disorders such as 
psychosis or addiction, relapse in response to environmental stressors or drugs 
of abuse (Yui, Goto et al. 1999). Third, psychostimulants, such as 
methylphenidate and amphetamine are commonly prescribed to children with 
Attention Deficit Hyperactivity Disorder (ADHD). Although longitudinal studies 
have yielded no conclusive evidence that the therapeutic use of methylphenidate 
is unsafe (Spencer, Biederman et al. 1996; Volkow and Insel 2003), in particular 
during the course of treatment in ADHD, the present findings emphasize the 
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need to further investigate the behavioral and neurobiological consequences of 
long-term treatment with stimulant drugs. 
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7.0. GENERAL DISCUSSION 
7.1. OVERVIEW 
Various imaging techniques can be used to study the effects of drug on the 
structure and function of the brain in living human. In this regard, PET, a 
functional imaging approach used to study the metabolism, physiology and 
neurochemical transmission in the brain, has yielded important empirical 
findings. Experiments reported in the present thesis focused on chemical (Le., 
neurotransmitter) alterations following acute and repeated drug consumption. 
Specifically, we investigated the activation of DA D2/3 receptors in the functional 
subdivisions of the human striatum after alcohol (study 2), and after acute (study 
1) and repeated amphetamine administration (sensitization) (study 3). D2/3 
receptor availability (BP) was measured with PET and Lv. bolus [l1C]radopride 
in healthy volunteers under control conditions and after the administration of 
amphetamine (0.3 mg/kg) or alcohol (1 ml/kg) by mouth. Main findings showed 
that 1) both amphetamine and alcohol administration reduced D2/3 receptor 
availability in limbic (VS) and sensorimotor (PDP) regions but not in the 
associative regions (DC, PDC, DP). 2) Repeated administration of amphetamine 
yielded even greater BP reduction in the VS and this effect also expanded to the 
associative regions (DC, DP). Results of region-of interest analysis were 
confirmed by voxel-based analysis. 3) Amphetamine or alcohol-related drug-
wanting and cardiac response but not self-reported euphoria, high, drug-liking 
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were associated with changes in regional BP during acute challenges. These later 
subjective measures (euphoria, high, drug-liking) however consistently predicted 
BP changes at subsequent doses suggesting that anticipation of drug-reward 
(conditioning) may modulate DA response to later exposure. In addition inter-
individual variability in response might represent vulnerability markers since we 
found that personality trait novelty seeking predicted drug-induced BP changes. 
In the following sections we will firstly address 1) methodological 
considerations relevant to the interpretation of radioligand displacement 
secondary to acute a repeated drug challenges. We will then discuss points that 
were raised by our main findings; 2) How can we explain that the magnitude of 
effect seen secondary to alcohol is equal to that seen after amphetamine? 3) What 
is the relevance of the higher sensitivity of the ventral striatum over the dorsal 
striatum, 4) can the reduction in plC]raclopride BP be attributed to anticipation 
or conditioning? 5) What is the clinical relevance of sensitization? 
7.2. METHODOLOGICAL CONSIDERATIONS 
As described in chapter III, changes in the binding ability of the 
radioligand [l1C]raclopride (BP) are used as a quantitative index of synaptic DA 
release to indicate alterations in neurotransmitter concentration in the striatum in 
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response to pharmacological or cognitive challenges (for review (Laruelle 2000). 
This method is being extensively applied in neuroscience and psychiatrie 
research, however it does not provide a direct measurement of endogenous DA 
levels. The simplest framework for interpreting radioligand displacement studies 
is the competition paradigm. This theoretical model assumes that the exogenous 
radioligand compete with DA for the same DA receptor site. In this regard, the 
standard and well-replicated finding is that changes in [llC]rac1opride BP are 
dependent on endogenous transmitter levels, i.e.: DA-elevating challenges 
proportionally diminish [llC]rac1opride BP (see chapter III). Furthermore in line 
with the characteristic of a "true competition" model for reversible ligands, 
depleting DA stores by pre-treating with reserpine or a-methyl-paratyrosine, 
increases [llC]rac1opride BP by increasing the affinity of the receptor (l/Kd) but 
not receptor density (for example, through receptor upregulation) (Bmax) 
(Ginovart, Farde et al. 1997; Laruelle, D'Souza et al. 1997). The interaction 
between binding of benzamide radioligands and DA is, as others have described, 
far more complex than a true competition (Laruelle 2000; Ginovart 2005). Indeed, 
sorne reservations have been expressed about the significance of the 
[llC]rac1opride BP method on the basis of a variety of technical points whieh are 
summarized from a critieal review published by Laruelle (Laruelle 2000). 1) One 
point of controversy regarding the validity of the occupancy model emerges 
from the observation that the principle seems to apply solely to benzamide 
compounds but not to butyrophenone such as spiperone. 2) Another observation 
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that is inconsistent with the theoretical framework is the temporal discrepancy 
between microdialysis assessment of DA levels and changes in [l1C]radopride 
BP. Specifically, whereas microdialysis reports that DA dissipates within two 
hours of amphetamine administration, [l1C]radopride binding is still reduced for 
up to six hours after an equivalent dose (Cardenas, Houle et al. 2004). 3) A 
finding that directly refutes the validity of a simple competition explanation 
cornes from both ex vivo and in vivo findings that amphetamine treatment seem to 
affect Bmax (Sun, Ginovart et al. 2003; Ginovart, Wilson et al. 2004). Thus 
suggesting the involvement of non-competitive mechanisms. 
This being said it is likely that other factors actively contribute to 
[l1C]radopride BP changes. Severa! proposaIs have been formulated in view of 
reconciling these discrepancies and to thoroughly characterize this commonly 
used index of DA release. Briefly, whereas the occupancy model posits that all 
receptors should be equally accessible to the ligand, the two-state model proposes 
the existence of a receptor state which is reserved for the agoni st (Battaglia and 
Titeler 1982; George, Watanabe et al. 1985). Specifically, two inter-convertible 
D2/3 receptor configuration exist, a high affinity state (G-protein-coupled; 
representing < 50% of D2/3 receptors) and low affinity state (uncoupled with G-
proteins; representing ... 50% of D2/3 receptors); unlike antagonist that bind non-
selectively to receptors in both states, agonist receptors ligands form a tight 
selective bond orny with DA receptors in the high affinity state. This property 
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would result in the non-competitive occupation of the receptor by DA thus 
occlu ding the binding of [l1C]raclopride and reducing Bmax (Seeman, Guan et al. 
1989). For this reason, it has been suggested that one solution to resolve the flaws 
of the occupancy model and to obtain a more potent displacement, would be to 
use the advantage of full agonist ligands (for example: propyl-
hexahydronaphtho-oxazin; PHNO and NPA) in which binding is theoretically 
expected to be "complete" (i.e.: 100% susceptible to competition by endogenous 
DA) (Cumming, Wong et al. 2002; Cumming, Gillings et al. 2003; Narendran, 
Hwang et al. 2004; Wilson, McCormick et al. 2005). Another interpretation to 
account for the inconsistencies in the initial model is that DA, upon receptor 
binding (to an allosteric site) causes a change in the biochemical conformation of 
the receptors which would influence apparent receptor density (allosteric model) 
(Ginovart, Wilson et al. 2004). The internalization model described in chapter III is 
yet another view - and probably the most accepted mechanism described to 
account for results that contradict the occupancy model. This mechanism 
suggests that in face of a pharmacological event that triggers massive DA release, 
the rate of endocytosis is increased dramatically, receptors are therefore 
redistributed to the cytosol in a compartment inaccessible to membrane-(quasi) 
impermeant antagonist radioligands (Laruelle 2000) (Figure 1). This could explain 
changes in Bmax resulting from DA-elevating challenge and also explain the 
inconsistencies between ligands of different lipophillicity. 
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Figure 1 Schematic of the internalization of receptors. Loss of surface 
receptor number through endocytosis which occurs secondary to agonist 
treatment is a mechanism believed to explain changes in [l1C]radopride binding. 
The mechanism of non-competitive interaction might have sorne 
important implication when interpreting results, particularly those derived from 
dinical population in which receptor trafficking / internalization dysregulation 
has been reported (Bergson, Levenson et al. 2003); in the context of this thesis, 
sorne assumptions are necessary. The measurement of [l1C]radopride BP is 
related to the total amount of neurotransmitter and when compared with a 
baseline scan, [l1C]radopride BP measured during a pharmacological challenge 
reflects sorne sort of average alteration in the DA concentration over the course 
of the PET scan i.e.: PET measurements of [l1C]radopride BP are valid estimates 
of DA release in humans. Based on published findings we can also make the 
assumption that tracer BP has a good within-subject reproducibility and 
reliability since both amphetamine-induced decrease [123I]IBZM BP and baseline 
[l1C]radopride BP were shown to be stable in a test/ retest paradigm (Volkow, 
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Fowler et al. 1993; Kegeles, Zea-Ponce et al. 1999). We can also assume that the 
changes in regional cerebral blood flow (in regions of interest and reference 
regions) secondary to amphetamine or alcohol do not significantly affect the 
distribution volume of the ligand. Both experimentally and simulation studies 
explicitly looked at the impact of changing blood flow and found that the 
outcome measure (BP) was unaffected by physiologically possible changes in 
blood flow (Logan, Volkow et al. 1994). 
As noted above, although [llC]rac1opride BP has a good within-subject 
reproducibility, remaining stable across (short) testing time, one issue that we 
were concerned with was whether this measure would be aHected by the 
repeated amphetamine regimen. We addressed this issues in the discussion 
inc1uded in chapter IV; if repeated amphetamine causes a variations in Bmax or kd, 
the consequence would be a change in BP that may not reflect the same DA 
release accurately and could corrupt straightforward interpretations of 
differences in DA release between conditions. We therefore tested a group of 
subjects (n = 6) during a baseline scan prior to an after a repeated amphetamine 
regimen and found that baseline [llC]radopride BP (the ratio of Bmax over kd) was 
unaffected by the amphetamine pre-treatment. In light of the two-state model one 
might argue that these results do not discard the possibility that the repeated 
amphetamine treatment increased the proportion of D2/3 in high affinity state. 
An increase in D2/3 configured in high affinity state would lead to a greater 
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apparent reduction in [llC]rac1opride BP during a DA-elevating challenge. This 
idea has been supported by an ex vivo Scatchard analysis showing that in 
sensitized animaIs, the addition of guanine nuc1eotide (which converts the high-
affinity state to low-affinity state) unmasks a 4-fold increase in D2/3 receptors in 
the high affinity state (Seeman, Tallerico et al. 2002). In vivo studies using an 
agoni st tracer such as PHNO or NP A would be valuable in teasing apart the 
contribution of possible changes in D2/3 receptors affinity state from the 
dopaminergic response to sensitization. 
7.3. THE QUESTION OF EQUAL MAGNITUDE 
In the present dissertation we report that alcohol promotes a change in 
[llC]rac1opride BP in the VS (-13%) of equal magnitude to the changes in 
[llC]rac1opride BP induced by a low dose of amphetamine (-10% in the VS 
relative to a placebo and -17% relative to a drug-free condition). This adding to 
the general perplexing observation that DA elevating challenges 
(pharmacological and cognitive) measured in vivo with PET result in changes in 
[llC]rac1opride BP situated in the area of 15% (see chapter III). This observation 
however contrasts with microdialysis results which have shown that 
amphetamine is a much more potent DA-releasing agent. Specifically 
microdialysis studies which measure both synaptic and extra synaptic 
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concentration of neurotransmitter, have shown that amphetamine increases DA 
by a factor of ten in the VS whereas DA release secondary to alcohol is observed 
to be, in contrast, relatively weak representing approximately 1/4 of this effect 
(Di Chiara and Imperato 1988). 
There are at least a few likely reasons to explain this discrepant finding. 
One of the reasons that have been evoked resides in a methodologicallimitation 
that is assumed to involve a ceiling effect occurring in binding studies in vivo. The 
ceiling effect entails that massive changes in DA release, as those triggered by 
amphetamine, do not reduce [llC]raclopride binding by more than 50% (Laruelle 
2000). The factors contributing to this phenomenon have been hypothesized to be 
due to the limited number of receptors on which changes can be assessed. The 
occupancy model daims that competition between DA and [l1C]raclopride is 
unlikely to be measured at extra synaptic site (Abi-Dargham, Martinez et al. 
2000) mainly because synaptic DA receptors are not densely concentrated there 
and because extrasynaptic DA levels are low due to the very efficient DA 
reuptake system (Jones, Gainetdinov et al. 1998). In this case, both alcohol which 
increases DA mainly though phasic DA release and amphetamine which 
provokes increases in DA concentration via reverse transport through the DAT 
(in synaptic and extrasynaptic space) could be as potent in displacing 
[l1C]raclopride from synaptic sites. The low efficiency of DA, being an agonist, 
in occupying low affinity state receptors (50% of receptors are in high affinity 
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state) is aiso a factor contributing to the narrow window for measuring change. 
Lastly the portion of the receptor pool already occupied by DA in the baseline 
state (10%) also reduces the opportunity for displacement (Laruelle 2000). Under 
this model [llC]raclopride binding would be susceptible to competition by 
endogenous DA on a small portion of receptors: those in high affinity state, 
located in the synapse and which are not occupied at baseline by DA i.e.: 44% 
(40/90) of receptors. In baboons, the increase in DA extracellular concentration 
following 1 mg/kg of amphetamine is believed to represent close to the maximal 
release that can be elicited in the braini at this dose the displacement is 
approximately equal to the receptor population that is in fact susceptible to 
competition by endogenous DA (i.e.: 40% )(Laruelle, Iyer et al. 1997) (Figure 2). 
One conclusion is that changes in amphetamine induced DA rnight be greater 
however the method is not sensitive enough to detect those changes. 
[llC]raclopride BP merely measures relatively different amounts of 
neurotransmitter released and cannot distinguish between kinetically different 
neurotransrnitter perturbations. One might think that the failure to find a 
magnitude difference between alcohol and amphetarnine' s ability to displace 
[llC]raclopride is partly due to differences in timing and duration of the drugs 
i.e.: a difference in the pharmacokinetic of the drugs. Indeed it is recognized that 
the initial fast uptake of the drug into brain rather then its steady-state presence 
is key to its reinforcing effects (Seeman and Madras 1998). The finding that DA 
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changes induced by intravenously (peak brain uptake occurring about 10 min) 
and orally (peak brain uptake occurring about 60-90 min) -administered 
methylphenidate were comparable (-20%) suggests that pharmacokinetics of the 
drug could not explain equal magnitude (Volkow, Fowler et al. 2004) . 
•• 
.. HIGH 
.. Low l 
50% 
Figure 2 Two-state model of D2/3 receptors affinity illustrating that D2/3 
receptors are divided into two states for agonists (high affinity and low affinity 
sites), with each site contributing to 50% of the population. Under baseline 
conditions (prior to the challenge), 10% of the sites are occupied by DA, and not 
available to [llC]raclopride. Adapted from (Laruelle 2000). 
7.4. WANTING OR LIKING? 
In the studies reported in the present thesis no direct associations were 
observed between the subjective positive effects of amphetamine, i.e.: euphoria, 
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drug-liking, and acute changes in [l1C]rac1opride BP. This contrasts with the 
work of others who have found that positive drug-induced mood was correlated 
with the supraphysiological changes in DA secondary to stimulant 
administration as measured by both DZ/3 receptor and DAT radioligand 
displacement (Drevets, Gautier et al. 2001) (Martinez, Slifstein et aL 2003) 
(Volkow, Wang et aL 1997). Our failure to find a relationship between drug-
induced euphoria and changes in DA could in part be due to the different route 
of administration that was used in our studies. Whereas others have used mainly 
intravenous administration, subjects in our studies received the drug by mouth. 
In line with the views of Robinson and Berridge, we interpret our results as 
evidence that DA release secondary to drug reinforcement attributes incentive 
salience to cues associated with reward (Robinson and Berridge 2001) (see 
chapter I). Repeated administration of amphetamine le ad to neurochemical and 
behavioral sensitization (see chapter VI), however in this paradigm we did not 
find that sensitization increased behavioral intention to use the drug, namely: 
drug-wanting. This finding is difficult to interpret. Unfortunately, the manner in 
which drug-wanting is measured in our studies, i.e.: by verbal self-report, is not 
optimal and might lack the precision to capture change. Furthermore, sorne have 
suggested that drug-wanting might exist even in the absence of awareness 
(Robinson and Berridge 1993). According to this perspective verbal assessments 
would be slightly inadequate measures and should be complement with 
behavioral measures such as drug-seeking (through progressive ratio schedule 
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for example). In addition it is possible that our failure to find changes in this 
index simply reflects subjects bore dom in participating in a protocol that 
involves five sessions. 
7.5. DORSAL AND VENTRAL MATTERS 
We found that the acute effects of both alcohol and amphetamine on 
[l1C]raclopride BP were preferential in the ventral limbie striatum (VS) and 
sensorimotor striatum (PDP) but not in dorsal caudate (DC), and that after 
repeated doses of amphetamine the effect expanded to include the De. In the 
context of DA activation by psychostimulants (and drugs of abuse in general), 
both PET and mierodialysis studies report a higher sensitivity of the ventral 
striatum (nucleus accumbens) over the dorsal striatum (Di Chiara and Imperato 
1988; Drevets, Gautier et al. 2001; Martinez, Slifstein et al. 2003). This 
anatomically selective pharmacodynamie effect has prompted the view that 
preferential ventral dopaminergic activation is one the main mechanisms of the 
reinforcing effects of psychostimulants (Di Chiara 2002). 
The reason for this heterogeneous response is unclear. On one hand, 
several pre and postsynaptic factors have been suggested to contribute to this 
effect. The observation that amphetamine may induce larger DA release in the 
ventral striatum compared with the caudate-putamen might reflect features of 
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striatal and midbrain microscopie organization, Le.: the distribution of receptor 
proteins and up-take sites for example. In this regard, it has been shown by both 
post mortem studies in humans (Piggott, Marshall et al. 1999; Hurd, Suzuki et al. 
2001) and PET studies investigating pig as weIl as monkey brains (Rosa-Neto, 
Doudet et al. 2004) that there is a decreasing posterior to anterior gradient for D2 
receptors in the striatum. However D3 receptors (which raclopride also bind to) 
are predominately distributed in the limbic striatum. Relative to the D2 receptors, 
the D3 have been shown to have a much higher affinity for the agonist (Sokoloff, 
Ciros et al. 1992). The higher density of high affinity D3 receptors in the VS may 
result in a higher potency for [l1C]raclopride displacement. In addition, midbrain 
ventral tier neurons, which project to dorsal parts of the striatum, express higher 
levels of mRNA for D2 autoreceptors (Haber, Ryoo et al. 1995). This finding 
suggests a greater inhibition of DA neurons firing and release onto dorsal 
striatum. DAT are more densely distributed in the ventral caudate than in the 
putamen (Piggott, Marshall et al. 1999). This organization suggests an increased 
reuptake activity in the associative caudate. Although, since DAT blockade is the 
initial pharmacological effect of amphetamine it is difficult to estimate if a 
greater DAT density also increases the sites of action for amphetamine and in 
turn synaptic DA concentration. 
On the other hand, the anatomically heterogeneous response could be in 
part related to methodological issues discussed earlier (see above). Specifically it 
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might be that dorsal and ventral striatum are differently affected by the ceiling 
effect. For example it is possible that synaptic vs extrasynaptic receptors or 
receptors in different configuration states (high affinity vs low affinity) are 
distributed unequally between ventral and dorsal structures (Martinez, Slifstein 
et al. 2003) (Laruelle 2000). 
As described in chapter l, the striatum, is a heterogeneous structure that 
includes sever al anatomie subdivisions whieh have been functionally subdivided 
based on their connections (see chapter 1) into limbic areas, involved in drive and 
motivation, associative areas, involved in cognition and sensorimotor areas involved 
in locomotion (Joel and Weiner 2000). PET [l1C]raclopride studies have now 
shown that distinct striatal compartments display a differential sensitivity to 
amphetamine. Specifically a greater effect is shown in the vs and PDP with no 
effect in the De. Mierodialysis studies do not systematically investigate the 
difference between De and PDP, and therefore do not provide any reports of this 
specifie effect. The pattern of change induced by DA-elevating drugs is believed 
to result from the non-reciprocal pattern of connection between these structures 
and the midbrain. Specifically, DA mediated information progresses from the VS 
limbie, to De cognitive, to PDP sensorimotor areas in a feed-forward type 
inhibition (Martinez, Slifstein et al. 2003). Briefly increased DA release in the VS 
would lead to an inhibition of SNc through ascending VS GABAergie 
connections. This would in turn reduce DA release in the De and the inhibitory 
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influence of DC on SNr. Cells of the SNr projecting to the PDP would thus be 
desinhibited, resulting in a larger DA release in the PDP (Martinez, Slifstein et al. 
2003) (Figure 3). 
Figure 3 Schematic of the nonreciprocal striatonigrostriatal subcircuits, 
which provides a hypothetical model for the preferential effect of amphetamine 
in the VS and PDP. VT A: ventral tegmental; SNe: substantia nigra compacta, 
SNr: substantia nigra reticulata; Pre DCA: anterior dorsal caudatei Pre DPU: 
anterior dorsal putamen; Post CA: posterior dorsal caudate; Post PU: posterior 
dorsal putamen. The limbic loop is in red, the associative loop is in green and the 
sensorimotor loop is in blue. Ascending arrows represent DA projections from 
the midbrain descending arrows represent GABA projections from the striatum. 
Adapted from (Martinez, Slifstein et al. 2003) (Haber, Fudge et al. 2000). 
In the present dissertation we report that the pattern of regional changes 
in BP induced by acute amphetamine was modified after repeated doses. The 
topography of the response shifted such that the DC was involved at the one-
PAGE 219 
ISABELLE BOILEAU CHAPTER VII: GENERAL DISCUSSION 
year time point but not after a short latency period (14 days). Suggesting that 
changes in the functional activity of the DA system occupy larger portions of 
dorsal and ventral striatum with increasing exposure. This finding did not result 
from spill-over signal from other regions, since correction for partial volume 
magnified the difference. This regional disparity in the temporal emergence of 
sensitization may reflect a difference between the DA projections to ventral and 
dorsal striatal regions in their ability to display sensitization. Indeed, it has also 
been suggested that acute and sensitized behavioral responses to 
psychostimulant drugs involve activation of distinct neuronal circuits (Paulson 
and Robinson 1995; Vanderschuren and Kalivas 2000) and activate different 
populations of striatal neurons (Canales and Graybiel 2000). Specifically, it has 
been shown that initial exposure to drug involves mainly the limbic ventral 
striatum, an are a that mediates motivational and affective functions, and as drug 
exposure is repeated the effect progressively spread dorsally to include most 
aspects of the dorsal striatum which mediate sensorimotor and cognitive 
functions (Porrino, Daunais et al. 2004; Porrino, Lyons et al. 2004). The 
mechanism involved in this reorganization and the nature of this adaptation 
remain to be clarified. It has been suggested however that the nigrostriatal 
circuits (includes the dorsal striatum) is involved in habit formation (White 
1996). An alternative explanation for the lack of effect observed within the DC 
after the short latency might be the presence of threshold effects. As discussed 
above, the effects of amphetamine on [l1C]raclopride BP are relatively modest in 
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the De it may be that sensitization-related changes are also present after the 14-
day drug-free period but undetected in the De. 
7.6. DOES EXPECTATION MODULATE DOPAMINE RELEASE? 
It is weIl known that contextual stimuli associated with stimulant drug 
administration acquire the ability to elicit conditioned psychomotor activation 
similar to that produced by the drugs themselves and become potent 
determinants of their effect. The DA system has been implicated in conditioning 
and reward prediction in both human and non-human primates (Schultz, Dayan 
et al. 1997) (de la Fuente-Fernandez, Phillips et al. 2002). It is possible those non-
pharmacological variables, i.e.: drug-expectation, response to the PET 
environment, might have shaped the subject' s responses to the drug. Indeed it 
has been shown that subjects self-rate response to drugs as more positive and 
have an increased metabolic reactivity to the drug when they are expecting to 
receive the drug (Wang, Volkow et al. 1999). Similarly animal studies have 
shown that response to drugs is larger when animal self-administer drugs in a 
drug-paired context (DuvaucheIle, Ikegami et al. 2000). Perception of imminent 
drug consumption could in part explain the relatively large magnitude of 
[l1C]raclopride BP change during our alcohol vs orange juice paradigm when 
compared to the amphetamine vs placebo paradigm (see chapter IV & V). 
Similarly it can also partIy explain the magnitude difference between the two 
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acute amphetamine studies presented in this thesis (see chapter IV & VI). 
Specifically, relative to study 3 which was not placebo-controlled, study 1 
yielded a weaker magnitude of change in [l1C]raclopride BP (-17% and -10% 
respectively). In support of the role of anticipation in modulating subsequent 
drug response we found that positive response to drugs during the initial drug 
exposure (see chapter VI) predicted [l1C]raclopride BP response at following 
exposure (Figure 4). In as much as rewarding effects of a drug are a predictor of 
subsequent use (Davidson, Finch et al. 1993) the se data lend support to the view 
that response of the DA system to initial drug exposure may constitute a risk 
factor for addiction . 
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Figure 4 a) Scatter plots and b) vox el-wise regression maps illustrating the 
relationship between self-rated positive effects of amphetamine (euphoria) during 
initial dose and changes in [llC]radopride BP at subsequent exposure (dose 4 
and dose 5). 
In a recent study (n = 5; still in progress) healthy volunteers underwent 
the sensitization-inducing regimen described in chapter VI with the difference that 
the last challenge was with a placebo pill rather than with amphetamine. Results 
showed that the substitution of amphetamine by a placebo pill in the drug-
paired context increased DA release in the VS to the same extend as an acute 
challenge of amphetamine (Boileau, Dagher et al. 2005) (Figure 5). This result 
allowed us to estimate that approximately 42% of the effect of sensitization on 
[llC]radopride BP (12% of the 29% observed) reported in study 3 could be 
accounted for by response to associative contextual eues, placebo effect, 
sensitization to drug associated eues (associative sensitization) or to aIl of these 
factors combined. This suggesting that sensitization is powerfully modulated by 
context and conditioning. 
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Figure 5 t-Map overlaid average MRI illustrating placebo induced changes 
in [l1C]raclopride relative to a control condition (no-pill). In this experiment, 5 
healthy male volunteers received three doses of amphetamine (0.3 mg/kg, by 
mouth) in the same test environment (PET unit) on three separate days (every 
other day). Two weeks later, the amphetamine was substituted for a placebo pilI. 
7.7. IS NOVELTY SEEKING A RISK FACTOR FOR ADDICTION? 
A plethora of vulnerability factors for drug-abuse have been identified in 
humans, including genetic, social (economic, familial), and personality indices. In 
this regard, novelty-seeking (NS) personality trait has not only been described as 
etiologically significant in addiction but it is believed that differences in this 
personality style reflect individual variation in mesolimbic DA 
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activity(Cloninger 1987). Individuals who scored high on Cloninger's 
Tridimensional Personality Questionaire (TPQ) NS scale (Cloninger, Przybeck et 
al. 1991) (see chapter III) are described as having a temperament related to 
impulsivity, investigatory behaviour and sensitivity to novelty (Eysenck 1953; 
Cloninger 1987; Jaffe and Archer 1987; Zuckerman and Kuhlman 2000). 
Furthermore they have been identified as more likely to be diagnosed with 
alcohol and drug dependence disorders (Cloninger, Sigvardsson et al. 1988). In 
support of this, a wealth of evidence has linked this measure with risk for drug 
misuse, relapse-rate in detoxified alcoholics and with sensitivity to reward 
(Meszaros, Lenzinger et al. 1999). 
It is weIl know that DA function in laboratory animaIs modulates the 
predisposition to drug self-administration (Piazza, Deminiere et al. 1989). 
Although a considerable effort has been proffered in an attempt to understand 
the neurobiological basis of inter-individual responses to drugs in humans 
(specifically DA-related hormone levels, monoamine oxidase levels and D2/3 
receptor expression), evidence of neurobiological markers differentiating high 
and low responders is not entirely consistent (Koob 2003). One methodological 
approach, which greatly profits from the advent of PET technology, involves 
identifying putative vulnerability characteristics (for example personality style) 
that predict sensitivity of the DA system to the psychomotor stimulant (or 
rewarding) effects of drugs. With this in mind, one of the aims of this dissertation 
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was to investigate the relationship between DA transmission through 
radioligand-displacement studies and personality trait NS in otherwise healthy, 
"risk-free" individuals (assed through personal and family history of DSMIV 
axis 1 disorder). We found that subjects who scored high on the NS TPQ scale 
released more DA in the VS upon exposure to both amphetamine and a1cohol 
(see chapter IV and V). They also seemed to be more susceptible to sensitize to a 
repeated amphetamine regimen or perhaps, more sensitive to environmental 
cues that predicted the administration of the drug since re-exposure to 
amphetamine after a drug-free latency, triggered a greater magnitude of DA 
release (see chapter VI). Furthermore these individuals demonstrated that the 
effect of the drug was likely reinforcing as they readily reported increased "drug-
wanting" during acute administration of amphetamine (see chapter IV). Taken 
together these findings corroborate the relevance of using trait NS to predict 
DAergic response to drugs. The next relevant question then is whether these 
individuals are at higher risk for drug abuse? 
NS have a distinct disposition to engage in behaviour motivated by 
positive incentive and are more sensitive to salient meaningful stimuli (Depue 
and Collins 1999). From an evolutionary perspective, a strong exploratory drive 
provides adaptive skills. It increases opportunities to achieve goal, novel 
resources, social cooperation and assertiveness. In as much as novelty-seeking 
refleds risk-taking, then by definition it carries with it sorne potential for 
PAGE 226 
ISABELLE BOILEAU CHAPTER VII: GENERAL DISCUSSION 
negative outcome - drug abuse being one of them. Though sorne argue that 
occasional drug experimentation is an "appropriate", normative, and perhaps 
adaptive developmental process (Shedler and Block 1990). One conclusion is that 
NS might have a higher primary appetitive motivation or sensitivity to salience 
by virtue of DA transmission, however, in the absence of other risk factors 
(emotional distress, bad coping styles, low self-esteem, poor parental bonding, 
socioeconomic status, genetic predisposition), this trait has been shown to be a 
poor predictor of response to the reinforcing-effects of amphetamine (Corr and 
Kumari 2000). In this regard, one factor that has been postulated to play a key 
role at rendering a brain more susceptible to disruption by drugs is a low level of 
D2/3 receptors (Volkow, Fowler et al. 2004). Specifically, drug addicted 
individuals have been shown to have a markedly disrupted DA system 
(decreased D2/3 receptors level) coupled with a diminished motivation and 
salience attribution to natural reinforcers (Volkow, Chang et al. 2001) (Figure 6). 
Under this hypothesis, it is believed that endogenous or (chronic) drug-induced 
diminished D2/3 receptor expression puts individuals at greater risk for seeking 
drug stimulation in order to compensate for the anhedonia related to DA-
deficiency. 
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Figure 6 PET [l1C]raclopride measurements of DA DZ/3 receptor availability 
obtained in detoxified cocaine users and healthy control. The reduction in signal 
in (BP) in cocaine users is presumed to represent a reduced number of DZ/3 
receptors. Adapted from (Volkow, Fowler et al. 2004). 
Furthermore, it has been shown by the same group that non-addicted 
healthy individuals with a high striatal receptor density self-rate 
methylphenidate effects as negative (Volkow, Fowler et al. 2004). This suggesting 
that a high level of DZ/3 receptors can in fact act as a protective factor. 
Interestingly, studies in non-human primates have shown that a high level of 
DZ/3 receptors is associated with social dominance (Morgan, Grant et al. 2002). A 
correlation analysis including all subjects participating in the studies reported in 
the present thesis (n = 24) revealed that there was an association between the 
personality style exploratory-extraversion (NS1) and the density of DZ/3 in the 
striatum (r = 0.54; P < 0.05) (Figure 7). This does not mean that people with 
exploratory skills and high social dominance cannot become addicted. Rather 
more drugs might be needed to alter pre-existing brain chemistry (high DZ/3), 
decreasing DZ/3 expression and triggering DA deficiency and craving. 
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Figure 7 Scatter plots illustrating the relationship between explora tory-
extraversion personality (NS1) and [l1C]raclopride measurement of baseline D2/3 
receptor density in a the right ventral striatum (rVS). 
7.8. IS THERE EVIDENCE OF STIMULANT SENSITIZATION IN 
CHRONIC DRUG USERS? 
Investigations from different laboratories have been unable to 
demonstrate psychostimulant hypersensitivity expressed in self-reported mood, 
cardiovascular, neuroendocrine (prolactin and cortisol) or DA release responses 
in chronic drug us ers re-exposed to cocaine, methylphenidate or amphetamine. 
Rothman and colleagues have in fact failed to observer augmented responses 
(behavioural, physiological or neuroendocine) to cocaine (25 mg i.v. and 96 mg 
i.n.) in habituaI cocaine us ers after both a single dose administration (40 mg IV) 
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or 4 consecutive intranasal doses of cocaine (Rothman, Gorelick et al. 1994; 
Rothman, Henningfield et al. 1996). Additionally PET studies of stimulant-
induced DA release using the neuroligand [llC]rac1opride have not shown 
neurochemical sensitization but rather blunting of striatal DA responsiveness in 
detoxified cocaine-dependent subjects and in a1cohol abusers (reduction in 
[l1C]rac1opride BP) relative to healthy control following administration of the 
DAT blocking agent methylphenidate (Martinez, Gil et al. 2005) (Volkow, Wang 
et al. 1997). In line with this, animal models of drug addiction have shown that 
mesolimbic DA transmission appears to be drastically reduced in its tonic 
activity (for a review see, (Melis, Spiga et al. 2005) (Di Chiara 2002). Other lines of 
studies have found that despite its reduced activity, the system remains hyper 
responsive to eues that predict drug. Specifically, it has been found that 
perceived drug availability (expectation) in detoxified cocaine abusers amplified 
the effects of psychostimulants, as well as viewing a video of drug paraphernalia 
increases activity in the OFC (Garavan, Pankiewicz et al. 2000) (Grant, London et 
al. 1996; Sell, Morris et al. 2000; Volkow, Fowler et al. 2004). The OFC is though 
to be involved in a circuit that encodes the motivational and emotional value of 
the drug. Dysfunction of the OFC related circuit, namely reduced basal 
metabolism in chronic drug-users is believed to contribute to the compulsive 
drug self-administration in addicted subjects (Volkow, Fowler et al. 1991). These 
and other results have been integrated in a model suggesting that in addiction, 
DA hypofunctioning increases the thresholds required for environmental events 
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to activate DA cells and in contrast this system remains hypersensitive to cues 
associated with drugs; thus conferring long-lasting vulnerability (Melis, Spiga et 
al. 2005). 
At this point the source of this discrepancy remains unclear, and more 
human imaging studies are necessary to understand the neurochemical 
correlates of chronic abuse in humans. Specifically it would be interesting to 
investigate, in chronic drug users, DA response to the repeated amphetamine 
regimen described in chapter III. This would allow estimating if environmental 
cues associated with drug administration (PET environment) would magnify the 
effect of the drug, thus unmasking sensitization. 
7.9. DOES SENSITIZATION HAVE A ROLE IN PSYCHOSIS AND 
SUBSTANCE ABUSE CO-MORBIDITY? 
The association between psychosis and drug abuse is unquestionable. On 
one hand, a number of epidemiological studies of schizophrenia have 
documented that the use of drugs increasing DA transmission, for example 
psychostimulants such as amphetamine and cocaine, but also cannabis (Stefanis, 
Delespaul et al. 2004; Henquet, Krabbendam et al. 2005), increase the likelihood 
of developing psychosis. The psychomimetic effect of certain drugs has in fact 
been an argument in favor of the DA hypothesis of psychosis (Carlsson 1995). 
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On the other hand, there also happens to be an alarmingly high rate of substance 
abuse in patients suffering from schizophrenia: 26.5% of individuals with 
schizophrenia use or have used psychostimulants (methamphetamine, cocaine) 
in their lifetime, 70 to 90% smoke tobacco, 12 to 42% use or have used cannabis 
(for review (Murray and Fearon 1999). Furthermore, a retrospective report on 
cases of psychosis found that approximately one third (33-37%) of patients 
abused drugs prior to presentation to services (Hambrecht and Hafner 1996; 
Cantwell, Brewin et al. 1999). In summary, patients with schizophrenia engage in 
substance abuse to a greater extent than the general population. The nature of 
this association is a much-debated topic. Several factors have been proposed to 
interact in this association. One widely held explanation for substance use in 
schizophrenia includes the view that both disorders share a common etiology 
(genetic, neurodevelopmental) with common vulnerability factors (social, 
personality trait, biobehavioral, cognitive) and common premorbid signs 
(depression, anxiety, antisocial behavior) - and this is why both disorders are 
susceptible to drugs-use or attempt to self-medicate. Based on the idea of a 
common neuropathology, it has also been suggested that sensitization of the 
DAergic system could be a relevant vulnerability factor in the association 
between drug-abuse and schizophrenia. For example, progressive endogenous 
sensitization in schizophrenia, may initially lead to increased motivation to use 
drug, which would in turn elicit the onset of psychotic symptoms. Similarly, in 
individuals susceptible to drug-abuse, initial exposure to drugs might le ad to 
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sensitization to the reinforcing properties of drugs and to the overwhelming 
compulsion to take drugs. Findings reported in the present dissertation reiterates 
the importance of conducting investigations aimed at looking at the central role 
of DA in both these disorders; this in view of developing pharmacotherapy, 
directed at the underlying pathologies linking addiction and mental illness. 
7.10. IS THERE STIMULANT SENSITIZATION IN ADHD? 
Five to ten percent of the school-age population, more than 1.5 million 
children in the United-States, eighty percent of them boys, are now medicated to 
treat ADHD (Wolraich, Hannah et al. 1996). Psycho stimulants such as 
methylphenidate and d-amphetamine are the most efficacious treatment for 
ADHD (Santosh and Taylor 2000); they have a beneficial effect on behaviour and 
intellectual performance in school as well as social interactions with family and 
peers, and they reduce drop-out rate, substance use disorder, and antisocial 
behaviour apparently without producing long-term side effects (Solanto 2000). 
The hypothesis that dopaminergic mechanisms may play an important role in 
the pathophysiology of ADHD arises primarily from the c1inical efficacy of the 
mixed DAT and norepinephrine transporter blocker methylphenidate. 
Converging evidence from neurocognitive investigations of ADHD deficits using 
DA related-tasks (for review see (Castellanos and Tannock 2002; Seidman, Doyle 
et al. 2004), from molecular genetics (for review, (Bobb, Castellanos et al. 2005) 
PAGE 233 
ISABELLE BOILEAU CHAPTER VII: GENERAL DISCUSSION 
and from both functional (Ernst, Zametkin et al. 1999; Rosa Neto, Lou et al. 2002; 
Ernst, Kimes et al. 2003; Lou, Rosa et al. 2004; Jucaite, Fernell et al. 2005; Volkow, 
Wang et al. 2005) and structural brain imaging studies (neuroanatomical 
volumetries of the frontal cortex and striatal strucutres) (Giedd, Blumenthal et al. 
2001; Seidman, Valera et al. 2004), strongly point towards a DA dysfunction in 
ADHD. Recent studies using PET and [l1C]radopride have reported that 
adolescents with a current diagnosis of ADHD have an increased D2/3 
availability at baseline, possibly reflecting low resting synaptic DA. This measure 
of ligand binding was found related to baseline impulsivity and inattention and 
to positive treatment response to methylphenidate (Rosa Neto, Lou et al. 2002; 
Lou, Rosa et al. 2004). This suggesting that psychostimulant medication might 
correct decreased DA neurotransmission in ADHD thereby reducing inattention 
and impulsivity. 
Given the extent of prescribed use of methylphenidate (Ritalin), the 
question of stimulant sensitivity in humans has been raised through longitudinal 
prospective studies of children who are diagnosed with Attention Deficit 
Hyperactivity Disorder (ADHD) and are treated daily with methylphenidate (or 
amphetamine). Most research looking at the development of sensitization in 
cases of ADHD has focused on assessing methylphenidate' s potential to alter an 
individual's risk for drug addiction, this based on the fact that methylphenidate 
and amphetamine are known to interact with the dopaminergic system. Based on 
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animal findings of (cross-stimulant) sensitization, one would predict that 
methylphenidate exposure might increase sensitivity to the reinforcing effects of 
drugs. Sorne, but not aIl retrospective human data have supported this 
hypothesis. Elevated drug use in adults with prior ADHD diagnosis has been 
reported (Weiss and Hechtman 1979; Barkley, Fischer et al. 2003). As weIl, a high 
percentage of treatment-seeking cocaine abusers have been reported to have 
prior ADHD diagnosis (Cocores, Davies et al. 1987). Findings from other 
randomized trial studies have however contradicted the notion that stimulant 
treatment in childhood leads to substance use or abuse in later life (Mannuzza, 
Klein et al. 2003). Data examining other potential long-term behavioural 
consequences of early methylphenidate administration have shown that relative 
to vehicle-treated control animaIs, rats treated with methylphenidate during 
early-life (childhood) were significantly less responsive to natural rewards 
(sucrose, novelty-induced activity, and sex) and more sensitive to stressful 
aversive situations (increased anxiety-like behaviours and plasma levels of 
corticosterone) (Bolanos, Barrot et al. 2003; Carlezon, Mague et al. 2003). 
To date, there are no studies directly looking at potential DA transmission 
changes (sensitization) that might result from methylphenidate treatment in 
ADHD. Neurobiological characterization of DA transmission in ADHD would be 
useful to determine neurochemical indexes of vulnerability to sensitization. 
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7.10. CONCLUDING REMARKS 
In closing, the main findings of the present dissertation, drawn from 
modern clinical neuroimaging techniques, lend support to converging evidence 
in animaIs that drugs of abuse (amphetamine and alcohol) act through 
mechanisms involving the brain neurotransmitter DA. Specifically we have 
found that the acute administration of alcohol and amphetamine increases DA in 
the limbic and sensorimotor striatum. With repeated use this increase is 
potentiated or sensitized presumably through a presynaptic mechanism that 
facilita tes release. The activation of the human ventral striatal dopaminergic 
system by acute amphetamine and alcohol correlated better with subjective 
ratings of drug-wanting, self-rated energy, alertness and with cardiac 
acceleration than with subjective affective reactions (drug-liking, euphoria). 
Behavioral sensitization also seems to selectively activate psychomotor activity 
and arousal and not subjective pleasure. Interestingly, we did find that subjective 
pleasure influenced DA neurotransmission since ratings of drug liking predicted 
the magnitude of DA release when the subject was re-exposed to amphetamine 
in the same drug-context. These observed correlations re-state the view that other 
functions than that of assigning hedonic value can be attributed to dopaminergic 
transmission in the mesolimbic pathway. Specifically our findings support the 
idea that VS DA appears to participate in the brain circuitry that regulates 
motivational arousal and detection of future potential drug-reward (salience). 
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The key issue remains: does the DA system and sensitization become less 
important when people become addicted, as the habit is learnt? lndeed, once 
addiction is established, drug self-administration remains relatively preserved 
despite manipulations of mesolimbic DA system. Addiction is a complex process 
and not surprisingly, it depends on a variety of factors and on neural adaptations 
within a widespread circuit. Drug dependence and addiction can be partIy 
understood as graduaI adaptations of the brain to chronic drug exposure. 
Specifically, in the early stage of addiction, sensitization would initially lead to a 
motivational conditioned response of the brain to drugs and to the subsequent 
maintenance of recreational drug taking. Repeated use of addictive drugs would 
then progressively induce a neural reorganization in the circuit responsible for 
addiction. In this regard, molecular neuroadaptations induced by chronic 
administration of drugs have been shown to occur downstream of DA receptors 
in the nucleus accumbens and elsewhere, possibly triggered by a drive to 
homeostasis. Several neural factors are increasingly seen as important for 
understanding the switch from motivated drug use (misuse) to addiction and 
craving i.e.: the switch to loss of control over drug-intake. A network of cellular 
adaptations leading to increased excitability of glutamate projections from the 
prefrontal, orbitofrontal and cingulate cortices to the vs (nucleus accumbens) has 
been identified as a potential mediator of the overwhelming desire to take drugs. 
Functional imaging evidence supports to this view by demonstrating that that 
detoxified drug-addicted individuals have a malfunctioning prefrontal cortex: 
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hypo-function under resting condition would presumably contribute to both 
reduced salience of non-drug stimuli and reduced decision-making ability and 
hyper-function during cu es that predict drug availability presumably drive 
craving and relapse. This glutamate-dependent form of synaptic plasticity is 
believed to be initiated by chronic drug-induced adaptations in Dl receptor 
signalling, which triggers compensatory changes in glutamate receptor function 
(facilitating LTP), and ultimately contributes to inappropriate plasticity. 
Unregulated DA release after repeated exposure to amphetamine (sensitization 
and withdrawal) may therefore play a role in this maladaptive glutamatergic 
plasticity and in the ensuing compulsive nature of addiction. To summarize 
sensitization might have a role in the initial stage of sensitization by maintaining 
interest in the drug and, through cellular adaptation, sensitization might 
gradually facilitate the neural reorganization necessary to complete the complex 
portrait of addiction. Many questions remain. For one, is the deficit in prefrontal 
glutamatergic transmission and in impulse control a cause or a consequence of 
addiction? Indeed, there may be a co-morbidity of drug-taking behaviour with 
impulsiveness because of genetic or developmental factors. Alternatively, drug 
taking could pro duce neural or neurotoxic side effect in the cortex, which 
facilitate sensitization. Combining magnetic resonance spectroscopy (to detect 
and quantify glutamate / glutamine tissue based content) with PET and novel 
DA ligands such as PhNO would be an interesting tool to get a better 
understanding of neural system changes that occur in the course of sensitization. 
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Research directed toward finding compounds that counteract the specifie 
changes that drug use causes in the brain can profit from understanding the 
mechanisms of sensitization. 
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POSITRON EMISSION TOMOGRAPHY (PET) AND 
MAGNETIC RESONANCE IMAGING (MRI) CONSENT FORM 
MONTREAL NEUROLOGICAL INSTITUTE & HOSPITAL 
McConnell Brain Imaging Centre, Departments of Nuclear Medicine & Neuroradiology 
MCGILL UNIVERSITY 
Department of Psychiatry 
Title of Project: PET / (11C]Raclopride Studies of Extracellular 
Dopamine: Effects of d-Amphetamine 
Principal Investigators: 
Co-Investigator: 
Marco Ley ton, Ph.D. 
Alain Dagher, M.D. 
Chawki Benkelfat, M.D. 
It is of the utmost importance for the subject that this questionnaire be fi1led out by a physician 
and the subject, as well the investigator. 
1. REASON FOR THE STUDY 
We are interested in how brain chemicals (especially a chemical called dopamine) 
are used by the brain. Abnormalities in dopamine function have been implicated in a 
large number of illnesses, inc1uding Parkinson's Disease, schizophrenia, and drug 
addiction. The objective of this study is to devise a new method of measuring the 
release of dopamine by brain cells. Dopamine release will be affected by the 
administration of the medication, dextroamphetamine (0.30 mg/kg, given orally). 
2. PROCEDURES 
Your participation in this study will involve three sessions of about three and a half 
hours each, and one session of about one hour. The flfSt session will be an interview, 
the second two will be for the Positron Emission Tomography (PET) scans, and the 
final session for a Magnetic Resonance Imaging (MRl) scan. 
a) Interview 
On the first day, each potential subject will be interviewed by a research 
psychologist (Dr. Ley ton) and will be asked about personal and family histories 
of depression and other psychological disorders. After this initial assessment, an 
those who will be participating in the study will have times scheduled for the 
two PET scans and one MRI scan. 
b) Positron Emission Tomography Procedures (pET Scan) 
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1) The day before each PET scan, everyone will eat low protein meals and 
snacks. These will be delivered to every subject. 
2) On the PET scan days, aIl participants will come to Montreal Neurological 
Institute at 12:00 no on, not having eaten or drunk anything except for 
water since the previous day. First they will fill in various paper and 
pencil tests to measure mood. Then they will have a blood sample taken to 
measure blood amino acid levels. The volume of blood taken will be 10 ml 
(2 teaspoons). 
3) Immediately prior to the scan, a fine needle-catheter will be inserted into a vein in 
one arm for administration of a small amount of a radioactive substance: 10 mCi of 
llC-Iabeled rac10pride (halflife of20 minutes). 
4) You will be asked to lie on a couch in the scanner. 
5) We estimate that each scan will take about two hours, during which time you will be 
requested to lie still on the couch in the scanner. 
6) AlI procedures during the PET scan will be carried out by a qualified nuc1ear 
medicine technician, and supervised by a qualified nuc1ear medicine physician. 
7) Shortly before one of the PET studies, you will be asked to take a placebo whereas 
before the other PET scan you will be asked to take a medication called 
dextroamphetamine. This is a drug used to treat narcolepsy, attention deficit 
disorder, and depression. It acts by stimulating the release of dopamine from brain 
cells. You will receive a dose of dextroamphetamine of 0.30 mg/kg, and both it and 
the placebo will be given orally. 
c) Magnetic Resonance Imaging 
Procedures (MRI Scan) 
You will be asked to lie on a couch that will be moved into a cylindrical opening 
where pictures of your head will be taken during a period of 30 to 40 minutes. The 
MRI machine will be quite noisy during the scan. To reduce the noise, you will be 
given earplugs. 
3. CONTRAINDICATION 
a) For PET Scan 
The following are contraindications for this procedure. 
1) Under 18 years old 
2) Previous radiation doses received within the past year (over 5 mSv) 
b) For MRI Scan 
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The following are contraindications for this procedure. 
1) Pacemaker 
2) Aneurysm Clip 
3) HeartlVascular Clip 
4) Prosthetic Valve 
5) Metal Prosthesis 
c) For Receiving Dextroamphetamine 
The following are contraindications for this procedure. 
1) A history ofheart or lung disease. 
2) A history of psychiatric illness 
4. ADV ANTAGES OF THE PROPOSED STUDIES 
Both PET and MRI studies are tests, not treatments. It is hoped that the information obtained will 
help our understanding of the function of the human brain. This may, in the long term, help the 
diagnosis and treatment of neurological disorders. 
5. DISADV ANTAGES OF THE PROPOSED STUDIES 
a) PET 
(i) Sorne discomfort may be caused by insertion of the fine needle-catheter into the 
vein, as well as immobility on the couch. 
(ü) The main Risk of participating in this study is exposure to radiation from the short-lived 
tracer substances injected into your body: llC-Raclopride (two times 10 mCi) will result in 
less than 5 mSv of radiation to the whole body. This level of radiation dose is about twice 
that which you receive annually from natural background radiation (0.9 - 2.2 mSv) in 
various regions of North America. This is also 25% of the annual dose limit allowed for 
those who work in a high radiation environment, such as nuclear medicine technicians. The 
degree of Risk associated with exposure to an additional 5 mSv of radiation is thought to be 
very low. This amount of additional radiation increases the risk of fatal cancer by about 2 in 
10,000 during a lifetime, whereas the current overall risk of fatal cancer is about 2,300 in 
10,000. Similar risks, equivalent to those from the dose you are receiving, are associated 
with: 
a) smoking 2 packs of cigarettes during a lifetime. 
b) driving 2,000 miles by car (Montreal to Calgary). 
c) flying 20,000 to 60,000 miles by air. 
d) living 100 days in New York or Boston 
Additional information available upon request 
b) MRI 
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(cancer, heart disease) 
(accident) 
(accident) 
(air pollution) 
During this study, you will be exposed to a strong magnetic field. No long-term negative side-
effects have been observed from this type of study. As mentioned above, the MR is very noisy and 
you will be given earplugs to reduce this effect. 
c) Dextroamphetamine 
Side-effects of this drug include palpitations, mildly elevated blood pressure, restlessness, headache 
and dizziness. In sorne cases, anxiety, euphoria, or agitation may occur. It may also cause psychosis 
but this is very rare at the dose you will receive. AH of these effects are transient, and wear off after 
3 hours. Participants will be asked to remain for observation during these 3 hours. If an adverse 
response were to develop, the participant would be treated by the one of the study's physicians as 
deemed necessary. 
6. EFFECTS OF PARTICIPATION IN THIS STUDY ON YOUR TREATMENT 
Positron emission tomography or magnetic resonance imaging do not interfere with any treatment 
or other diagnostic tests. 
7. CONFIDENTIAL NATURE OF TIDS STUDY 
The results ofthe testing will be kept confidential. No personal information will be released to third 
parties without your written approval. Your name, date of birth, address and telephone number may 
have to be forwarded to the Atomic Energy Control Board of Canada upon their request. 
8. INCIDENTAL FINDINGS 
Any incidental fmdings regarding your own health will be communicated to you and/or to your 
physician at your request. 
9. DISCONTINUATION OF THE STUDY BY THE INVESTIGATOR 
At any time during the testing, the investigators have the right to terminate the study for purely 
scientific reasons. 
10. COMPENSATION 
Upon completion ofboth MRI and PET studies you will receive $100.00 as compensation for your 
time and inconvenience. If studies have to be terminated for scientific reasons, compensation will 
be adjusted according to the fraction of the studies completed. 
11. SUBJECT'S STATEMENT CONCERNING WITHDRA WAL FROM THE STUDY 
l understand that my participation in this research project is voluntary and l may withdraw at any 
time, including during the procedure, without prejudice to myself. 
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Montreal Neurological Hospital 
MAGNETIC RESONANCE 
Patient Name: _________ _ 
Medicare #: _________ _ 
QUESTIONNAIRE AND CONSENT FORM 
It is of the ultimate importance for the patient safety that this questionnaire is filled out by 
the physician and the patient, and attached to the request for service. 
1. Previous surgery (type and date) ___________________ _ 
2. Does the subject have any of the following? 
YES NO 
Cardiac pacemaker 
Surgi cal clip on an aneurysm or other vessel 
Surgical clip or valve on the heart 
Prostheses (please specify type and location) 
Implants (please specify type and location) 
Metal or metallic fragments in any part of the body 
(please specify) _________ _ 
3. Is the subject pregnant? 
Is the subject currently taking prescription medication? 
AH of my questions regarding this exam have been satisfactorily answered. 1 hereby give 
consent to Magnetic Resonance examination. 
Signature of Patient 
Date 
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Signature of Physician 
SUBJECT'S DECLARATION OF CONSENT 
1, _________________ -', have read the above description with one 
of the above investigators, ______________ ' 
1 fully understand the procedures, advantages and disadvantages of the study which have been 
explained to me. 1 freely and voluntarily consent to participate in this study. 
1 hereby certify that 1 have not participated in a PET investigation anywhere before. 
Further, 1 understand that 1 may seek information about each test either before or after it is given, 
that 1 am free to withdraw from the testing at any time if 1 desire, and that my personal information 
will be kept confidential. 
SIGNATURE _____ _ 
SUBJECT 
SIGNATURE _____ _ 
INVESTIGATOR 
SIGNATURE _____ _ 
WITNESS 
SIGNATURE _____ _ 
PHYSICIAN 
DATE CONTACT NO. 
DATE CONTACT NO. 
DATE CONTACT NO. 
DATE CONTACT NO. 
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TOMOGRAPHIE PAR ÉMISSION DE POSITONS (TEP) ET IMAGERIE PAR 
RÉSONANCE MAGNÉTIQUE (IRM) - FORMULAIRE DE CONSENTEMENT 
INSTITUT ET HÔ PIT AL NEUROLOGIQUES DE MONTRÉAL 
Centre McConnell d'imagerie cérébrale, 
départements de médecine nucléaire et de neuroradiologie 
Titre du projet: La libération de dopamine par l'alcool. 
Chercheurs : 
1. MOTIF DE L'ÉTUDE 
Alain Dagher MD, Jean-Marc Assaad, Robert Pihl PhD, 
Chawki Benkelfat MD, Marco Ley ton PhD. 
L'objet de l'étude est de mesurer la libération transitoire de la dopamine dans le cerveau. La 
dopamine, molécule produite naturellement dans le cerveau, facillite la transmission de l'influx 
nerveux entre les cellules. Il a été démontré que la dopamine est impliquée dans le contrôle des 
activitées motrices, dans la régulation des émotions et dans les procéssus d'attention. La 
libération de dopamine a lieu au cours de situations plaisantes. La maladie de Parkinson, la 
schizophrénie et les problèmes de dépendance aux drogues ont été associés à un 
dysfonctionnement du système dopaminergique. Nous nous intéressons donc la libération de 
dopamine dans le cerveau humain après la consommation d'alcool. Nous voulons aussi voir s'il y 
à un lien entre le pouls et la libération de dopamine. 
2. PROCÉDURES 
Pour participer à cette étude, vous devrez nous consacrer trois sessions. Les deux dernières 
seront réservées à la tomographie par émission de positons (TEP), et dureront à peu près quatre 
heures chaque, et la première à la séance d'imagerie par résonance magnétique. L'étude TEP 
consistera de deux scans, d'une durée de 60 minutes chaque. Immédiatement avant chaque scan 
TEP on vous donnera soit du jus d'orange, soit du jus d'orange et de l'alcool. Le dose d'alcool 
sera identique à celle que vous avez reçu durant l'étude préliminaire. Pendant la durée de l'étude 
votre pouls sera mesuré automatiquement, ainsi que votre taux d'alcool sanguin. Vous devrez 
rester sur les lieux sous observation jusqu'à ce que votre taux d'alcool soit inférieur à 0.04%. 
a) Tomographie par émission de positons 
Procédures (étude TEP) 
1) Vous serez peut-être invité( e) à ne rien manger ou boire sauf de l'eau pendant les trois heures qui 
précèdent le début de cette étude. 
2) Un cathéter à aiguille fine sera introduit dans une veine de votre bras pour l'administration de 
petites quantités (à préciser) d'une substance radioactive à vie courte: lle-raclopride, 10 
millicuries chaque injection (demi-vie du lle : 20 minutes). 
3) Vous serez pesé, et on vous installera des électrodes afin d'enregistrer votre pouls. Une première 
mesure de votre taux d'alcool sanguin sera prise à l'aide d'un intoxocomètre. 
4) On vous demandera ensuite de boire sur une période de 15 minutes trois consommation contenant 
soit du jus d'orange, soit du jus d'orange et de l'alcool. 
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5) Vous serez invité( e) à vous allonger sur la couchette de la caméra TEP. 
6) La durée de cette étude est d'environ deux heures pendant lesquelles vous devez rester immobile 
sur la couchette de la caméra. 
7) Toutes les modalités de l'étude TEP seront exécutées par un technicien qualifié en médecine 
nucléaire, sous la surveillance d'un médecin qualifié en médecine nucléaire. 
8) Après le scan vous resterez dans l'unité jusqu'a ce que les effets de l'alcool aient diminué au 
point où vous pourrez quitter les lieux. 
b) Imagerie par résonance magnétique 
Procédures (étude IRM) 
Vous serez invité(e) à vous allonger sur la table de l'appareil que l'on fera glisser dans une 
ouverture cylindrique pour prendre des images de votre tête pendant 30 à 40 minutes. La 
machine IRM fait beaucoup de bruit durant cette opération. Pour atténuer ce bruit, on vous 
donnera des bouchons pour vos oreilles. Vous pourrez communiquer avec le technicien par 
microphone pendant le scan. 
c) Administration d'alcool 
Avant l'un des deux scans TEP vous pourrez recevoir une quantité d'alcool pour élever votre taux 
d'alcool au dessus de la limite légale au Québec (0.08% d'alcool dans le sang). Ainsi on vous 
demandera de ne pas conduire pour vous rendre aux lieux d'expérimentation. Votre rhytme 
cardiaque sera enregistré constamment pendant l'étude. Votre niveau d'alcool sera mesuré trois 
fois à l'aide de prise de sang et deux fois par intoxicomètre (i.e. : par expiration) 
3. CONTRE-INDICATIONS 
a) Contre-indications à l'étude TEP 
l) Grossesse ou allaitement 
2) Être âgé(e) de moins de 18 ans 
3) Exposition à des doses radioactives dans les 12 derniers mois (plus de 5 mSv). 
b) Contre-indications à l'étude IRM 
1) Stimulateur cardiaque 
2) Clip d'anévrisme 
3) Clip cardiaque ou vasculaire 
4) Valve prothétique 
5) Prothèses métalliques 
6) (}rossesse 
7) Claustrophobie aigüe 
4. AVANTAGES DES ÉTUDES PROPOSÉES 
La tomographie par émission de positons et l'imagerie par résonance magnétique sont des 
examens, pas des traitements. Nous espérons que les renseignements glanés nous aideront à 
mieux comprendre le fonctionnement du cerveau humain. Cela pourrait à long terme contribuer 
au diagnostic et au traitement de certains troubles neurologiques. 
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5. INCONVÉNIENTS DES ÉTUDES PROPOSÉES 
TEP 
1) Il se peut que vous ressentiez un léger inconfort au moment où le cathéter à aiguille fine 
sera introduit dans la veine, et à rester immobile sur la couchette. 
2) Le RISQUE principal de votre participation à cette étude est une exposition aux 
radiations des traceurs à vie courte qui seront injectés dans votre organisme ou que vous 
devrez inhaler. La substance radioactive administrée exposera votre organisme à une 
dose maximale de 5 mSv. Cette dose équivaut li peu prés au double des radiations 
auxquelles vous êtes exposé( e) annuellement dans le cadre des rayonnements naturels 
(0,9 - 2,2 mSv) dans les diverses régions d'Amérique du Nord. Elle équivaut également à 
25 % de la dose annuelle moyenne autorisée pour les personnes qui travaillent dans un 
milieu à fortes radiations, notamment les techniciens en médecine nucléaire. Le niveau 
de RISQUE qui se rattache à une exposition à 5 mSv supplémentaires est jugé très faible. 
Cette quantité de rayonnement augmente les risques de cancer d'environ 2 pour 10 000 
durant votre vie, alors que le risque global de contracter un cancer fatal est d'environ 
2 300 pour 10 000. Pour donner une idée de ce niveau de risque, voilà à quoi il 
correspond; 
IRM 
a) fumer 2 paquets de cigarettes durant sa vie (cancer, maladie cardiaque) 
b) parcourir 2000 milles en voiture (accident) 
c) parcourir 20000 à 60 000 milles en avion (accident) 
d) vivre 100 jours à New York ou à Boston (pollution atmosphérique) 
* Renseignements supplémentaires sur demande 
Pendant l'examen IRM, vous serez exposé( e) à un champ magnétique puissant. Aucun effet 
secondaire à long terme n'a été observé à l'issue de ce type d'étude. Comme nous l'avons indiqué 
ci-dessus, la machine est très bruyante et on vous donnera des bouchons pour atténuer le bruit. 
6. EFFETS DE VOTRE PARTICIPATION SUR VOTRE TRAITEMENT 
La tomographie par émission de positons et l'imagerie par résonance magnétique ne nuisent à 
aucun autre traitement ou test diagnostique. 
7. CARACTÈRE CONFIDENTIEL DE L'ÉTUDE 
Les résultats de cette étude resteront confidentiels. Aucune donnée vous concernant ne sera 
transmise à un tiers sans votre autorisation écrite. Vos nom, date de naissance, adresse et numéro 
de téléphone pourront être transmis à la Commission de contrôle de l'énergie atomique du 
Canada, si cette dernière en fait la demande. 
8. CONSTATATIONS FORTUITES 
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Toute constatation fortuite sur votre santé sera portée à votre connaissance ou à celle de votre 
médecin, si vous en faites la demande. 
9. INTERRUPTION DE L'ÉTUDE PAR LE CHERCHEUR 
Le chercheur a le droit de mettre fin à cette étude à tout moment, pour des raisons purement 
scientifiques. 
10. COMPENSATION 
À l'achèvement des études IRM et TEP, vous toucherez $150 à titre de dédommagement. 
Advenant qu'il faille mettre fin à ces études pour une raison scientifique, votre compensation sera 
fonction de la fraction des études terminées. 
11. DÉCLARATION DES SUJETS QUI SOUHAITENT SE DÉSISTER 
Il est entendu que votre participation à ce projet de recherche est purement volontaire et que vous 
pouvez vous en désister à tout moment, y compris durant son déroulement, sans que cela soit 
préjudiciable à vous-même ou à votre traitement. Si vous désirez annuler l'étude après avoir reçu 
l'alcool, vous devrez tout de même rester dans l'unité jusqu'à ce que votre taux d'alcool soit 
inférieur à 0.04%. 
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QUESTIONNAIRE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE 
1. Chirurgie antérieure (type et date) ______________________ _ 
2. Le sujet porte-t-ill'un ou plusieurs des éléments suivants? 
Stimulateur cardiaque 
Clip d'anévrisme ou clip sur un autre vaisseau 
Clip chirurgical ou valve cardiaque 
Prothèses (veuillez préciser type et site) 
Implants (veuillez préciser type et site) 
Métal ou fragments métalliques dans le corps 
(veuillez préciser) 
3. Le sujet est-elle enceinte? 
Le sujet prend-il des médicaments sur ordonnance? 
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OUI NON 
ISABELLE BOILEAU 
DÉCLARA nON DE CONSENTEMENT DU SUJET 
Je soussigné(e) ___________ ai pris connaissance de ce qui précède en présence 
de l'un des chercheurs suivants, __________ _ 
J'ai parfaitement compris les procédures, les avantages et les inconvénients de cette étude. Je 
consens volontairement et librement à y participer. 
Je certifie par la présente que je n'ai jamais participé à une étude TEP auparavant. 
Il est par ailleurs entendu que je peux demander des renseignements à propos de chaque examen 
avant ou après son déroulement, que je suis libre de me désister de ce protocole à tout moment si 
je le souhaite et que toute donnée me concernant restera confidentielle. 
SIGNATURE ______________ _ 
SUJET DATE N CONTACT 
SIGNATURE ______________ _ 
CHERCHEUR DATE N CONTACT 
SIGNATURE ______ --.-______ _ 
TÉMOIN DATE N CONTACT 
SIGNATURE 
MÉDECIN DATE N CONTACT 
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ISABELLE BOILEAU 
POSITRON EMISSION TOMOGRAPHY (PET) 
MAGNETIC RESONANCE IMAGING (MRI) CONSENT FORM 
MONTREAL NEUROLOGICAL INSTITUTE & HOSPITAL 
McConnell Brain Imaging Center, Departments of Nuclear Medicine & Neuroradiology 
Title of Project: Sensitization to Psychomotor Stimulants: A PET study with 11C-
Raclopride. 
Investigators: Dr Alain Dagher, M.D. Dr Benkelfat, M.D., Marco Ley ton, Ph.D., Mirko 
Diksic, Ph.D., Isabelle Boileau. 
1. REASON FOR THE STUDY 
The purpose of this study is to identify the chemical mechanisms in the brain that 
lead to the development of sensitization to drugs. Sensitization, sometimes called 
reverse tolerance, is an enhanced behavioural response to drugs like cocaine or 
amphetamine that occurs after repeated exposure. Studies done in animaIs suggest 
that sensitization to drugs results from changes within a brain chemical system 
called the dopamine (DA) neurotransmitter system. Dopamine is naturally 
produced by the brain. It facilita tes transmission between nerve cells and has been 
implicated in motor control, in the regulation of emotions and in processes related to 
learning and attention. Dysfunctions in DA neurotransmission are associated with 
disorders such as schizophrenia and drug addiction. It is believed that sensitization 
might be related to these problems. In the following (2) studies we are Iooking at 
short and long term (12-months) dopamine changes in the brain in response to four 
or five doses of dextroamphetamine (0.3 mg/kg given orally). This drug is widely 
prescribed for the treatment of attention deficit disorder and can be safely given to 
healthy humans. 
2. PROCEDURES 
Participants will take part in one of the two studies described below. Both of these 
studies include 6 (approximately 3-hour long) experimental sessions taking place on 
separate days at the Montreal Neurological Institute PET unit (MNI) and / or Allan 
memorial Institute department of psychiatry (AMI) (Figure 1). In either study, you 
will receive four low doses of amphetamine by mouth (0.30 mg/kg per session), 
given every few days, over approximately three weeks. If you are participating in 
Study1 you will also be asked to come back to the lab 12 months Iater at which time 
you would receive a 5th dose of amphetamine. 
The amphetamine given in Study1 will be administered while participants lie inside 
of the PET camera. For comparison purposes, one PET scan will be conducted 
without amphetamine. If you are available to come back 12 months Iater, a final PET 
scan will be conducted then also. Two of the sessions in Study 1 will be "pretend 
scans"; that is, the procedure will be identical but you will not actually receive the 
PET tracer injection. Study2 is quite similar to Study 1. It will also involve PET scans, 
but the amphetamine will be given on separate da ys in a different room. 
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For aU sessions of both studies, electrodes will be placed on your skin and we will 
record heart activity, eye-blink rate and other physiological measures. Blood samples 
will be drawn every 15 minutes from an intravenous line, and mood will be assessed 
by questionnaires. For both studies you will also participate in two other sessions: 
the first will be an interview (see a) and the second will be reserved for a Magnetic 
Resonance Imaging (MRI) study that lasts about one hour (see c). Hence the studies 
are composed of 8 sessions (6 of which are illustrated in the following figure. The 
interview takes place before these 6 days and the MRI will be scheduled at your 
convenience. 
1 and 2. 
Day 1 Day 3 Day 5 Day 21 12 months 
llC- 11 c- 11C- 11 C-
No scan No scan 
rac10pride rac10pride rac10pride rac10pride 
80.3 80.3 
No drug 80.3 mg/kg 
mg/kg mg/kg 
8 0.3 mg/kg 80.3 mg/kg 
MNI MNI MNI MNI MNI MNI 
Day 0 Day 1 Day 3 Day 5 Day 21 Day 22 
11 c- No scan No scan No scan 11C- No scan 
rac10pride rac10pride 
80.3 80.3 
Nodrug 80.3 mg/kg 
mg/kg mg/kg 
No drug 80.3 mg/kg 
MNI AMI AMI AMI MNI AMI 
a) Interview 
On the first day, you will be interviewed about personal and family histories of 
psychological disorders, you will complete a personality assessment, blood will be 
drawn for routine blood analysis and an EKG (to monitor your heart) will be done. 
After this initial assessment, if you are eligible to participate in the study you will have 
times scheduled for the PET and MRI scans. 
b) Positron Emission Tomography Procedures (PET Study) 
1) You will be asked to avoid excessive fluid intake. 
2) On your arrivaI at the MNI PET unit you will be asked to fill in questionnaires. 
3) On three days in Studyl, you will receive an oral dose of amphetamine one hour 
prior to the injection of ll-C raclopride. In Study 2, the PET scans will always be 
conducted without amphetamine. 
4) Prior to scanning, a fine needle-catheter will be inserted into an arm vein for the 
administration of smaU amounts of a radioactive substance. In your instance, 
this will be Raclopride which is labeled with the short-lived radioactive atom 11 -
C (physical half-life = 20 minutes). The total dose administered to you will be 
less than 7 millicuries per scan. On the "pretend" scan days, the catheter will also 
be inserted but the raclopride tracer will not be injected PET images will not be 
collected. 
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5) Blood will be drawn for hormonal measurements via the catheter in your arm 
vein. The total amount of blood will be 28ml (2 tbsp) 7 ml per sample (1 tsp). 
6) Electrodes will be placed on your skin in order to record your heart rate and 
muscle tone. 
7) The length of the study is approximately two hours (60 minutes preparation + 60 
minutes of PET scanning). During this time you will be requested to lie still on 
the couch in the scanner. 
8) AH procedures during the PET study will be carried out by a qualified nuclear 
medicine technician, and supervised by a qualified nuclear medicine physician. 
c) Magnetic Resonance Imaging 
Procedures (MRI Study) 
You will be asked to lie on a couch that will be moved into a cylindrical opening where 
pictures of your head will be taken during a period of 30 to 40 minutes. The MRI 
machine will be quite noisy during the scan. To reduce the noise, you will be given 
earplugs. You will be able to communicate with the technician during the procedure. 
3. CONTRAINDICATION 
a) For PET Study 
1) Pregnancy or Breast Feeding 
2) Under 18 years old 
3) Previous radiation doses received within the pa st year (over 5 mSv / 25 mCi) 
b) For MRI Study 
1) Pacemaker 
2) Aneurysm Clip 
3) Heart/Vascular Clip 
4) Prosthetic Valve 
5) Metal Prosthesis 
6) Claustrophobia 
c) Dextroamphetamine 
1) Heart problems. 
2) High Blood Pressure. 
3) History of drug abuse. 
4) Glaucoma. 
4. ADV ANTAGES OF THE PROPOSED STUDIES 
The PET study is not a treatment. It is hoped that the information obtained will help our 
understanding of the function of the human brain. This may, in the long term, help the 
diagnosis and treatment of neurological disorders. 
5. DISADV ANTAGES OF THE PROPOSED STUDIES 
a) PET 
Sorne discomfort may be caused by insertion of the fine needle-catheter into the vein, as 
weH as immobility on the couch. The main RISK of participating in this study is 
exposure to radiation from the short-lived tracer substance injected in your body or 
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inhaled. The administered radioactive material will expose your body to a maximal 
dose of 5 mSv. This level of radiation dose is about twice that which you receive 
annually from natural background radiation (0.9 - 2.2. mSv) in various regions of North 
America. It is also 25% of the current average annual dose limits allowed for those who 
work in a high radiation environment, such as nuclear medicine technicians. The degree 
of RISK associated with exposure to an additional 5 mSv of radiation is thought to be 
very low. This amount of additional radiation may increase the risk of fatal cancer by 
about 2 in 10,000 during a lifetime, while the current overall risk of fatal cancer is about 
2,300 in 10,000. Similar risks, equivalent to those from the dose you are receiving, are 
associated with: 
• Smoking 2 packs of cigarettes during a lifetime (cancer, heart disease) 
• driving 2,000 miles by car (accident) 
• flying 20,000 to 60,000 miles by air (accident) 
• living 100 days in New York or Boston (air pollution) 
*Additional information available upon request. 
b) MRI 
During this study, you will be exposed to a strong magnetic field. No long-term 
negative si de effects have been observed from this type of study. As mentioned above, 
the MR is very noisy and you will be given earplugs to reduce this effect. 
c) Dexedrine, dextroamphetamine 
d-Amphetamine is currently in clinical use in Canada for the management of attention 
deficit hyperactivity disorder (ADHD) and sleep-disorder (narcolepsy). Side-effects of 
this drug include palpitations, mildly elevated blood pressure, restlessness, headache 
and dizziness. In sorne cases, anxiety, euphoria or agitation may occur. Sustained high 
doses of amphetamine (>100mg / day) can lead to dependence or cause psychosis but 
this is very rare at the dose you will receive. The long term effects of sensitization are 
not known. All of these effects are transient and wear off after three hours. Participants 
will be asked to remain in the McConnell Brain Imaging Center of the Montreal 
Neurological Institute for observation during these three hours. If an adverse response 
were to develop, the participant would be treated by one of the study' s physicians as 
deemednecessary. 
6. EFFECTS OF PARTICIPATION IN THIS STUDY ON YOUR 
TREATMENT 
Positron emission tomography imaging does not interfere with any treatment or other 
diagnostic tests. 
7. CONFIDENTIAL NATURE OF THIS STUDY 
The results of the testing will be kept confidential. No personal information will be 
released to third parties without your written approval. Your name, date of birth, 
address and telephone number may have to be forwarded to the Canadian Nuclear 
Safety Commission, upon request. 
8. INCIDENTAL FINDINGS 
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Research scans are not subject to clinical review. However, any incidental findings will 
be communicated to you and, upon your request, to your physician. 
9. DISCONTINUATION OF THE STUDY BY THE INVESTIGATOR 
At any time during the testing, the investigators have the right to terminate the study for 
any reason. 
10. COMPENSATION 
Upon completion of both MRI and PET studies you will receive, as compensation for 
your time and inconvenience: Studyl, 230.00$, for the first part of the study (7 sessions) 
and 80.00$ for the follow-up study (12 months later); Study2, 260.00$. If studies have to 
be terminated for any reason, compensation will be adjusted according to the fraction of 
the studies completed. 
11. SUBJECT'S STATEMENT CONCERNING WITHDRAWAL FROM 
THESTUDY 
1 understand that my participation in this research project is voluntary and 1 may 
withdraw at any time, including during the procedure, without prejudice to myself or 
my treatment. 
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IT IS ESSENTIAL FOR THE SUB}ECT THAT THIS QUESTIONNAIRE BE 
FILLED OUT BY A PHYSICIAN, THE SUB}ECT AS WELL AS THE 
INVESTIGATOR. 
QUESTIONNAIRE FOR MAGNETIC RESONANCE IMAGING 
1. Previous surgery (type and date) 
1. Does the subject have any of the following? 
(a) Cardiac pacemaker 
(b) Surgical clip on an aneurysm or other vessel 
(c) Surgical clip or valve on the heart 
(d) Prostheses (please specify type and location) 
(e) Implants (please specify type and location) 
(f) Metal or metallic fragments in any part of the body (please 
specify) 
2. Is the subject pregnant? 
3. Is the subject currently taking prescription medication? 
PAGE 277 
ISABELLE BOILEAU 
POSITRON EMISSION TOMOGRAPHY (PET) 
MAGNETIC RESONANCE IMAGING (MRI) CONSENT FORM 
MONTREAL NEUROLOGICAL INSTITUTE & HOSPITAL 
McConnell Brain Imaging Center, Departments of Nuclear Medicine & Neuroradiology 
Title of Project: Sensitization to Psychomotor Stimulants: A PET study with llC-
Raclopride. 
Investigators: Dr Alain Dagher, M.D. Dr Benkelfat, M.D., Marco Ley ton, Ph.D., Mirko 
Diksic, Ph.D., Isabelle Boileau 
IT IS ESSENTIAL FOR THE SUBJECT THAT THIS DECLARATION OF CONSENT BE 
FILLED OUT BY A PHYSICIAN, THE SUBJECT AS WELL AS THE INVESTIGATOR. 
SUBJECT'S DECLARATION OF CONSENT 
l, ________________ -', have read the above description with 
one 
of the above investigators, ____________ _ 
1 fully understand the procedures, advantages and disadvantages of the study, which 
have been explained to me. 1 freely and voluntarily consent to participate in this study. 
Further, 1 understand that 1 may seek information about each test either before or after it 
is given, that 1 am free to withdraw from the testing at any time if 1 desire, and that my 
personal information will be kept confidential. 
SIGNATURE 
SUBJECT DATE CONTACT NO. 
SIGNATURE 
INVESTIGATOR DATE CONTACT NO. 
SIGNATURE _____ _ 
WITNESS DATE CONTACT NO. 
SIGNATURE _____ _ 
PHYSICIAN DATE CONTACT NO. 
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